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THE ROLE OF SEPT9_V1 IN BREAST CANCER: INSIGHTS INTO THE DEVELOPMENT OF PRO-
ONCOGENIC PHENOTYPES AND GENOMIC INSTABILITY 
by 
Esther A. Peterson 
Chair: Elizabeth M. Petty 
  
Breast cancer is a complex heterogeneous disease stemming from alterations in the 
function and/or expression of multiple oncogenes and tumor suppressor genes.  SEPT9, a 
member of a family of genes encoding cytoskeletal GTPases important in cell division, encodes 
multiple SEPT9 splicing isoforms, SEPT9_v1-SEPT9_v7.  SEPT9 maps to a region of allelic 
imbalance in breast cancers and SEPT9 isoforms are differentially expressed in breast cancer. 
One isoform, SEPT9_v1, is over-expressed in more than 50% of breast cancer cell lines and 
primary breast cancer samples, suggesting an important role in tumorigenesis.   
 To examine the role of SEPT9_v1 in mammary tumorigenesis, we established expression 
models in immortalized human mammary epithelial cells (IHMECs) and analyzed SEPT9_v1 
expression in a human breast cancer tumor microarray with clinicopathological variables.  High 
SEPT9_v1 was observed with more than 50% of hormone receptor positive tumors.  Retroviral 
expression of SEPT9_v1 in IHEMCs resulted in the development of pro-oncogenic phenotypes 
such as increased cell proliferation, decreased apoptosis, enhanced motility and invasiveness, 
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epithelial to mesenchymal transition and increased aneuploidy.  Conversely, ablation of 
SEPT9_v1 in breast cancer cells reduced proliferation and decreased motility and invasiveness.   
 To explore the impact of SEPT9_v1 on genomic stability, IHMEC models expressing 
SEPT9_v1 were analyzed for mitotic spindle checkpoint function, chromosome segregation and 
cytokinesis.  SEPT9_v1 promoted both mitotic spindle defects and cytokinesis failure.  SEPT9_v1 
was found to interact with two major components of the mitotic spindle, -tubulin and -
tubulin, promoting -tubulin filament formation defects and centrosome amplification.  In 
addition, transient expression of SEPT9_v1 was sufficient to drive chromosome instability 
independent of increased cell proliferation.  Subsequently, we found that SEPT9_v1 could 
increase cellular proliferation rates in IHMEC lines by interacting with the c-jun-N-terminal 
kinase (JNK).  High SEPT9_v1 expression stabilized JNK and increased the transcriptional 
activation of target genes important in cell cycle progression such as cyclin D1.   
 Finally, in an effort to identify novel interacting partners of SEPT9 isoforms, we 
identified the newest member of the human septin family, SEPT14, by yeast two-hybrid analysis.  
SEPT14 is localized to stress fibers, is not expressed in cancer cell lines and has expression 
limited to testicular tissues. 
 Together, these novel findings indicate that SEPT9_v1 has oncogenic potential in 
mammary cells and may be a biomarker for disease aggressiveness.  SEPT9_v1 impacts genomic 
instability by affecting mitotic spindle function, chromosome segregation and cytokinesis.  Its 
interaction with the JNK signaling pathway is relevant to understanding its diverse roles in cell 
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cycle regulation.  This study provides novel insights into the mechanisms by which SEPT9_v1 
expression may lead to the disruption of cellular processes important in breast cancer 









    









DECIPHERING THE COMPLEX WORLD OF SEPTINS:                                                                                         
THE HUMAN SEPT9 LOCUS IN SICKNESS AND IN HEALTH 
 
Introduction 
 Forty years ago, septin’s pioneer researchers may have never imagined that their 
discovery of four novel yeast genes would open the door to a biologically complex world of 
cytoskeletal GTPases relevant to human disease.  Septins were first characterized in 
Saccharomyces cerevisiae as a group of cytoskeletal GTP-binding proteins essential for proper 
cell division.  Genetic screening performed by Hartwell and colleagues for budding yeast 
mutants lead to the discovery of the first septin genes, CDC3, CDC10, CDC11, CDC12, in which 
temperature sensitive mutations caused defects in budding morphology and cell cycle arrest (1).  
These genes were further characterized in Saccharomyces pombe in which mutations led to 
cytokinesis defects during mitotis.  Subsequently, septins have been found to be highly 
conserved in all eukaryotes except plants, with an extensive pattern of alternative splicing as a 
common feature.  Recently, phylogenetic and evolutionary analysis for septins of metazoans 
demonstrated that all septin proteins could be clustered into four subgroups.  It has been 
proposed that the emergence of these four subgroups occurred prior to the divergence of 
vertebrates and invertebrates and that septin expansion in number was due to duplication of 
pre-existing genes (2).  Over the past 40 years, septin research has grown impressively, from 
four genes identified in budding yeast to 14 members identified in humans to date.  The variety 
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of existing septin isoforms and the diversity of their biological functions in eukaryotic cells are 
both intriguing and exciting.  Many questions remain related to their multiple normal functions 
in cells and their implicated roles in the development of human diseases.  Contributions to 
septin biology over the last few years include the first crystal structure of septin oligomers, 
septin protein interactions, expression profiles, associations with well known signaling pathways 
and involvement in human disease.  These observations have set the stage for more exciting 
experimental strategies to further understand the role of septins in health and disease. 
Human septin family conserved domains 
The four human septin subgroups are characterized by sequence homology and domain 
composition (Fig 1.1 and Fig 1.2).  All human septins share a highly conserved central region that 
contains a polybasic domain and the GTP-binding domain.  The N- and C-terminal regions vary in 
length and amino acid composition.  They contain a proline-rich domain and an -helical coiled-
coil domain, respectively.  The relevance of the difference in the N- and C- termini of septins and 
their isoforms is not completely understood, but these variations may play a role in their unique 
cellular localizations, protein interactions and biological functions (Fig 1.2).  The specific 
functions of these domains remain to be fully elucidated, but recent studies have begun to 
reveal information about the possible roles of these domains, as described later in this chapter.  
Several members of the human septin family also contain the less well studied proline-rich 
domain near the N terminal region.  Even though there are no specific studies dedicated to 
understand the functional role of the proline-rich domain of septins, one can suggest that this 
domain may be essential for protein-protein interactions, including interaction with proteins 
containing SH3 domains, based on other proteins containing these domain (3, 4).  Preceding the 
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Fig 1.1: General structure of septins 
N- and C- termini  vary between Septin family members and their isoforms.  Some septins 
contain a proline rich domain in their amino terminus that is involved in protein interaction. 
The C- terminus of some septins consists of a coiled-coil domain predicted to contain an -
helix.  The polybasic domain is responsible for the association of septins with the plasma 
membrane.  The central GTP-binding domain contains conserved motifs G1 (GxxxxGK[S/T]), 
G3 (DxxG) and G4 (xKxD) and is implicated in the formation of septin heteroligomers and 






Fig 1.2: Phylogenetic tree of the human septin family 
A dendrogram tree illustrates the phylogenetic relationship of the human septin family 
members as determined by Clustal W analysis (modified from Peterson E.A., et al. (2008) 




responsible for the association of septins with cellular membranes.  Studies of the polybasic 
domain of SEPT4 have shown that this domain binds to phosphoinositol phosphates (5).  The 
polybasic domain might mediate the targeting of septins to membrane domains relevant for 
their role as diffusion barriers in yeast and mammalian cells.  The Wittinghofer team studied the 
human septin complex composed of SEPT2, SEPT6 and SEPT7 and found that these three septins 
form a hexameric complex of two copies of each septin through a GTP/GDP bound interface, 
which is also crucial for the GTPase activity (6, 7).  Future studies of these domains are necessary 
for comprehensive insight into septins intricate functional roles in mammalian cells.  
 Septins are widely subjected to functionally significant post-translational modifications.  
For example, sumoylation of yeast septins in G2/M-arrested cells is well described and the 
ubiquitin-protein ligase (E3) Siz1p is required for yeast septin sumoylation (8).  Sumoylation of 
mammalian septins has not been reported.  However, mammalian septins contain multiple 
phosphorylation sites and they can be phosphorylated by Ser/Thr kinases in post-mitotic 
neurons (9-11) and by Aurora-B kinase in mitotic cells (12).  This suggests that sumoylation 
and/or phosphorylation of septins might modulate conformational changes that can alter their 
functional role. 
Functional role of septins 
Despite the mechanistic differences between budding yeast and dividing animal cells 
(13), several orthologs of yeast septins were identified in Caenorhabditis elegans (unc-59 and 
unc-61), Drosophila melanogaster (pnut) and mammals (Nedd5 and H5) (14-17).  Similar to yeast 
septins, animal septins can form polymeric actin-associated filaments, hydrolyze GTP and 
produce multinucleated cells when mutated (18, 19).  Septins can form microfilaments by 
interacting with each other or with cytoskeletal and filamentous proteins such as actin, myosin 
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and tubulin, indicative of their functional roles in cytokinesis during contractile ring 
formation, cell morphology changes and dynamic scaffolds (14, 20-24).  Mammalian 
septins have many interacting partners (Table 1.1) and form complexes between family 
members to create filaments important in different cellular functions.  The diverse 
functional roles of mammalian septins are intrinsically related to their physical 
interactions, which might explain how one septin can have multiple functions in different 
tissues and at different times during cell cycle and development.     
In addition to their roles in cytokinesis, mammalian septins have been associated 
with other distinct cellular processes including vessicle trafficking, cell polarity, 
cytoskeletal dynamics, apoptosis, neurodegeneration and oncogenesis.  The diversity and 
complexity of these septin-associated functions is not well understood, but it is believed 
that a wide range of hetero-oligomeric septin complexes are major players in these 
cellular processes.  For example, SEPT4/ARTS, an alternative transcript of SEPT4, is 
translocated from the mitochondrion to the nucleus upon exposure to the apoptotic 
agent TGF-, possibly providing a mechanistic link between cell division and cell death 
(25-27).  Recent data indicate that several septins, including SEPT2, 4, 6 and 7, co-
precipitate with the mammalian sec6/8 complex, suggesting an association of septins 
with membrane dynamics and vesicle trafficking (28-31).  In addition, septins have been 
implicated in platelet function (SEPT4, 5 and 8) (32-35), cardiac myocyte development 
(36),  chromosome dynamics (SEPT2) (37), cell polarity, motility and microtubule 
dynamics (SEPT9 and others) (20, 22-24, 38).  In a very elegant study, Kremer et al. 
showed that a complex of septin proteins (SEPT2, 6 and 7) interacts with SOCS7, which is 
necessary to retain SOCS7 and NCK in the cytoplasm at a steady state to regulate actin 
organization and DNA  
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Table 1.1 Interacting partners and functional roles of mammalian septins 
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damage response.  The SOCS7/NCK complex accumulates in the nucleus to activate CHK2 and 
p53 mediated cell cycle arrest upon DNA damage. This action is potentiated by the depletion of 
the septin complex by siRNA.  The spatial distribution of NCK as mediated by septin complex is 
important in the reorganization of the actin cytoskeleton, cell polarity and the DNA damage 
response.  One can predict that in vivo the distribution of septins in the cytoplasm is an 
important mechanism that regulates the localization of many proteins and their site of action in 
the cell (39). 
 SEPT2 and SEPT11 are required for phagosome formation important for cell membrane 
dynamics (31).  SEPT2 is also required for epithelial cell polarity by associating with tubulin 
networks and facilitating vesicle transport by preventing polyGlu microtubule tracts from 
binding to MAP4 (38).  SEPT12 has been implicated in mammalian spermatogenesis (40, 41).  In 
addition, SEPT4 and SEPT7 serve as diagnostic markers for human male asthonozoospermia, 
since healthy individuals showed septin expression in the annuli of spermatozoa while infertile 
patients do not(42).  Ihara et al. demonstrated that expression of murine Sept4 is important for 
the cortical organization required for morphology and motility of the sperm flagellum (43).  
SEPT2 and SEPT11 are modulators of InlB-mediated invasion by Listeria monocytogenes.  SEPT2 
is essential for the entry of Listeria to the cells, but SEPT11 expression restricts the efficacy of 
Listeria invasion to the cells.  Overall, these findings demonstrate the diverse roles of septins 
despite their high structural conservation (44-46). 
Septins as microtubule associated proteins 
  Several studies suggest that septins might be involved in microtubule dynamics and 
chromosome segregation.  Two groups showed that mammalian SEPT2 and SEPT7 may form a 
mitotic scaffold for CENP-E and other effectors to coordinate chromosome segregation and 
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cytokinesis (37, 47).  Kremer et al. proposed a novel molecular function for septins in 
mammalian cells through the modulation of microtubule dynamics via an interaction with MAP4 
(22).  Looking specifically at SEPT9 isoforms, SEPT9_v1 (MSFA) was found to localize specifically 
with microtubules.  This localization was required for the completion of cytokinesis and it could 
be disrupted by nocodazole treatment (24).  Interaction of SEPT9_v1 with microtubule networks 
was found to be essential for septin filament formation (23).  We propose that there is a tight 
regulation between tubulin filaments, microtubules and septins filaments.  How this regulation 
is mediated and what other proteins are involved remains unclear.  Fluorescence microscopy 
and further characterization of protein interactions might give better insight into septin-tubulin 
interaction and its regulation chromosome segregation during mitosis.   
Septins and neurological disorders 
 Possible roles for septins in neurological disorders have emerged based on the brain-
specific expression of some septins (Table 1.2).  SEPT2/NEDD5, SEPT1/DIFF6 and SEPT4/H5 have 
been found to associate with Alzheimer-specific neurofibrillary tangles (5, 48).  The 
SEPT5/CDCREL-1 interaction with Parkin, a pathogenic protein in Parkinson’s disease (49, 50), 
provides evidence for the involvement of another subset of septins in neuronal development 
and disease.  SEPT4 has also been implicated in brain pathogenesis by its association with 
cytoplasmic inclusions in Parkinson’s disease and other synocleinopathies (51).  The SEPT3/5/7 
complex was identified in the mammalian brain and SEPT3 specifically is developmentally 
regulated and enriched in presynaptic nerve terminals, suggesting a role for these septins in 
neuronal biology (52, 53).  SEPT2 and SEPT8 are associated with neurotransmitter release due to 
their interaction with the glutamate transporter (Glast) and the synaptic vesicle protein 
synaptobrevin 2 (Vamp2), respectively (54, 55).  Other septin complexes have been associated 
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with myelin formation in the peripheral nervous system (56).  Recently, SEPT9 point mutations 
and a duplication within the gene have been identified in patients with the autosomal dominant 
neuropathy Hereditary Neuralgic Amyotrophy (HNA) (57-59), further supporting a role for 
septins in neurological disease.  The mechanism by which these mutations are pathogenic in 
HNA is still not fully elucidated, but McDade et al. showed that isoforms v4 and v4* have distinct 
5' ends encoded by exons where germline mutations of HNA are found.  The two mRNAs are 
translated with different efficiencies and cellular stress can alter this pattern (60).  These 
mutations dramatically enhance the translational efficiency of the v4 5'-UTR, leading to elevated 
SEPT9_v4 protein under hypoxic conditions (60).  These data provide mechanistic insight into 
the effect of HNA mutations on fine control of SEPT9_v4 protein and its regulation under 
physiologically relevant conditions.  The data are consistent with the episodic and stress-
induced nature of the clinical features of HNA (60).  
Septins in cancer 
  The first evidence that septins may contribute to neoplasia occurred with the discovery 
of septin SEPT5/CDCREL-1 as a carboxy-terminus fusion partner with mixed lineage leukemia 
(MLL) in an acute myeloid leukemia (AML) patient with a t(11;22)(q23;q11.2) translocation (61).  
Subsequently, SEPT9/MSF, SEPT6, SEPT2, and SEPT11 were also identified as fusion partners 
with MLL in human leukemic cells (62-65).  MLL, the human homolog of Drosophila trithorax, is a 
common translocation partner in leukemias with more than 80 rearrangements with 50 fusion 
partners identified (66).  The well-characterized MLL fusion products produce in-frame 
translated chimeric proteins associated with phenotypic disease variability such as leukemia 
type and prognostic outcome.  These carboxy partners, in addition to MLL, appear to be  





Table 1.2 Characteristics of the human septins loci and disease association 
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Other septins have also been implicated in other types of cancer including SEPT2, SEPT3, 
SEPT4, SEPT5 and SEPT9 (25, 68, 69).  In fact, SEPT4 acts as a tumor suppressor in leukemias and 
solid tumors.  The SEPT4 gene promotes apoptosis, and is lost in 70% of leukemia patients (26), 
in addition to being associated with inhibition of colorectal cancer tumorigenesis (70).  SEPT2 
phosphorylation by casein kinase 2 was found to be important for hepatoma carcinoma cell 
proliferation (71).  SEPT2 and SEPT3 were abundantly expressed in several brain tumors and 
brain tumor cell lines, suggesting that these family members are potential oncogenes (69).  
SEPT9 seems to be important not only in leukemias but also in solid tumor cancers (72-77). 
 Overall, these studies show that human septins are important in many cellular and 
molecular functions, as summarized in Fig 1.3.  It seems that their expression needs to be highly 
regulated and the dynamics with their interaction partners are crucial for their function as either 
scaffolds for cytoskeletal proteins or signaling GTPases.  Mutations or altered expression of 
these genes can arise by multiple mechanisms that are not well understood. Septins are 
strikingly associated with multiple human diseases, primarily cancers and neurological disorders 
(Table 1.2 and Fig 1.3).  This thesis is focused on the role of SEPT9 in normal cellular functions, 
and the importance of specific isoforms in mammary tumorigenesis.  
Human SEPT9 locus 
 Human SEPT9 became of great interest to the septin scientific community after it was 
mapped to chromosome 17q25, a region linked to breast and ovarian cancer, by positional 
cloning to a region of allelic imbalance in breast and ovarian cancers in our laboratory (74, 78-
80), suggesting that alterations of this novel septin gene may be important in breast and ovarian 
cancer.  Subsequently, it was shown that the SEPT9 locus gives rise to multiple alternative 
transcripts encoding at least seven annotated isoforms (SEPT9_v1-SEPT9_v7) (74).  The SEPT9 
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locus contains 13 exons and shows complex 5’ and 3’ alternative splicing.  The variable exons 1-3 
and 12-13 encode alternative translational start and stop sequences and are spliced on to a core 
of 8 coding exons (Fig 1.4) (74).  These isoforms maintain the general structure of septins with a 
highly conserved central region containing the polybasic domain and GTP-binding domain (Fig 
1.1).  They vary in the 5’- and 3’- untranslated regions (UTR) and at the N- and C- terminus of the 
protein.  Interestingly, the SEPT9_v4 and SEPT9_v4* isoforms encode for the exact same 
protein, but they differ at their 5’ UTRs, suggesting that these transcripts might be differentially 
regulated in time or tissue of expression (73, 76, 77).  SEPT9_v1 and SEPT9_v3, the longest 
transcripts, are highly similar except for 25 distinct amino acids at the N- terminus of SEPT9_v1.  
The biological reason for the presence of multiple SEPT9 transcripts is still not elucidated, but 
many studies, including expression analyses, show that these isoforms are differentially 
expressed and may have distinct functional roles in mammalian cells. 
 SEPT9 is widely expressed based on ubiquitous adult and fetal transcript expression, 
although individual isoforms may have tissue specific expression (74).  The cellular localization of 
SEPT9 isoforms is largely cytoplasmic in interphase cells, but the SEPT9_v1 isoform has a 
bipartite nuclear localization signal that may direct the shuttling of SEPT9_v1 between the 
nucleus and the cytoplasm.  In mitotic cells SEPT9 exhibits a punctuate staining pattern located 
between the separating chromosomes and at the cleavage furrow during telophase (24).  
SEPT9_v1 is localized to microtubule networks in interphase cells and in mitotic cells it is 
localized at the mitotic spindle and the bundle of microtubules at the midzone (23).  Both 
studies showed that when SEPT9 is ablated, cells become binucleated, suggesting a role for 





Fig 1.3: Human septins in health and disease 
Human septins are involved in multiple tissue and cellular phenotypes.  Alterations in 
their expression or gene mutations affect these phenotypes, which are mechanistically 










































  Fig 1.4: SEPT9 genomic structure 
Genomic structure of SEPT9 alternatively spliced transcripts and variants.  SEPT9 exhibits 5’ 
and 3’ alternative spliced and variable exons and is composed of 13 exons in total.  Gray 
boxes indicate common exons and colored boxes indicate variant-specific exons, all drawn 
to scale.  Transcriptional start sites are indicated by (*) and the end of each transcript by 
(**).  The variable exons (colored boxes) encode different translational start (arrow) and 




Since they were discovered, septins had been characterized as cytoskeletal GTPases important 
in cell division.  Mutations of this family of genes in yeast lead to budding defects, cell cycle 
arrest and cytokinesis defects.  In mammals, several septins (eg. SEPT2, SEPT5, SEPT7) also have 
been implicated in mitosis, specifically in chromosome segregation dynamics and cytokinesis 
(Table 1.1).  SEPT9 is not an exception.   Its localization to microtubules, the cleavage furrow and 
midbody at different stages in mitosis suggests a possible specific role of SEPT9 isoforms in 
chromosome segregation and/or completion of cell division by affecting the mitotic spindle 
assembly, disassembly or dynamics and the cytokinesis process (Fig 1.5).    
Intricate human SEPT9 nomenclature 
Ten years ago, the SEPT9 locus was called MLL septin-like fusion (MSF) due to the fact 
that it was identified as a fusion partner of MLL in leukemias (65).  In 2002, a committee of 
septin researchers developed an official nomenclature system for SEPT9 transcripts (81).  This 
new name was derived from the functional role of these genes in septae formation in yeast.  
Some research groups published with the old nomenclature while others used their own 
versions, making progress in SEPT9 research hard to reconcile.  New nomenclature was 
established by the National Center for Biotechnology Information (NCBI) and HUGO Gene 
Nomenclature Committee (HGNC), but it has not been universally accepted by the septin 
community.  These nomenclature changes are depicted in Table 1.3 by group and year.  
Throughout this study I will refer to the nomenclature used in current publications, which was 
established in 2005 by Scott et al. and endorsed at the 2009 International Septin Meeting (76).   
SEPT9 model of oncogenesis in solid tumors 
A compelling example of the role of septins in the oncogenesis of solid tumors was the 
identification of the MSF/SEPT9 murine ortholog Sint1/Sept9 at a provirus insertion site in SL3-3 
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Kalikin LM, et al. McIlhatton MA, et al. Macara IG., et al. Inagaki M., et al. Scott M., et al. NCBI HGNC NCBI Accession Numbers
2000 2001 2002 2004 2005 2008 2008
variant/isoform isoform transcript/protein
MSF-A epsilon SEPT9_v1 SEPT9a SEPT9_v1a SEPT9_v1/SEPT9a SEPT9_i1 NM_001113491/NP_001106963
- gamma - - SEPT9_v2a SEPT9_v2/SEPT9b SEPT9_i2 NM_001113493/NP_001106965
MSF alpha SEPT9 SEPT9b SEPT9_v3a SEPT9_v3/SEPT9c SEPT9_i3 NM_006640/NP_006631
- - - - - SEPT9_v4/SEPT9d SEPT9_i4 NM_001113495/NP_001106967
MSF-B zeta SEPT9_v2 SEPT9c SEPT9_v4*a SEPT9_v5/SEPT9ea SEPT9_i5 NM_001113492/NP_001106966
MSF-C beta SEPT9_v3 SEPT9c SEPT9_v4a SEPT9_v6/SEPT9ea SEPT9_i6 NM_001113494/NP_001106966
- delta SEPT9_v4 - SEPT9_v5a SEPT9_v7/SEPT9f SEPT9_i7 NM_001113496/NP_001106968




Table 1.3: SEPT9 nomenclature 
a SEPT9 variant 5 and 6 differ in their 5’ UTR but encode the same protein isoform.                                                                                    
*SEPT9_v1-5b-c variants differ at the 3’ UTR.  No well characterized.                                   
Current nomenclature in this thesis and peer reviewed publications  
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Fig. 1.5: SEPT9 functional role in mitosis 
Diagram showing the phases in mitosis in which SEPT9 expression is present.  SEPT9 is 
localized to the microtubules at the midzone during anaphase and at the cleavage furrow in 
telophase.  Its particular localization during mitosis suggests a role in chromosome 
segregation and cytokinesis. 
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MLV-induced lymphomas (82), which demonstrated that this septin locus is a site for oncogenic  
integration.  SEPT9 also maps to a region of allelic imbalance at chromosome 17q25.3 in breast 
cancer (74) and sporadic ovarian cancer (80).  There is differential expression of SEPT9 isoforms 
in tumors of various tissues (21, 77, 83, 84).  SEPT9 has been characterized as a candidate gene 
in head and neck squamous cell carcinomas by a genome-wide screen for methylated genes 
(85).  Circulating methylated SEPT9 DNA cDNA in plasma was recently identified as a valuable 
biomarker for minimally invasive detection of colorectal cancer.  This lead to the development 
of a new methylation (m)SEPT9 assay which may prove useful in clinical research for the 
detection of invasive colorectal cancer in patients (86, 87). 
Finally, an isoform of SEPT9, SEPT9_v1, might be important as a biomarker for 
therapeutic resistance of many cancers to microtubule disrupting agents.  SEPT9_v1 expression 
was strongly correlated with susceptibility of a wide range of cancer cells to drugs such as 
paclitaxel (88).  In general, cancer cells with high SEPT9_v1 expression were more resistant to 
these drugs (88).   
SEPT9 isoforms have been associated with signaling pathways relevant to oncogenesis.  
For example, SEPT9_v1 interacts with HIF1 preventing its ubiquitination and degradation, thus 
activating HIF downstream survival genes to promote tumor progression and angiogenesis in 
prostate cancer cells (72).  The SEPT9_v3 isoform binds SA-RhoGEF, functioning as a scaffold to 
keep it in an inactive state, thereby inhibiting SA-RhoGEF mediated Rho activation (89, 90).  This 
finding was crucial for the study of septins in cancer because it provided a direct link between 
septins and signaling proteins involved in cellular functions such as actin cytoskeletal 




SEPT9 is a novel cancer associated protein and a potential biomarker for diagnosis and 
chemotherapeutic response in some epithelial cancers.  SEPT9 was identified as candidate gene 
in a region of allelic imbalance in breast cancer cells.  Its expression is altered in many types of 
cancers including head and neck tumors, ovarian, prostate, colorectal, and breast cancers and it 
is over-expressed in a MMTV mouse model of mammary tumorigenesis (20, 72-76, 82, 86).  One 
of its alternative transcripts, SEPT9_v1, was found to be amplified and over-expressed in breast 
cancer cell lines and primary tumors.  These facts led to the hypothesis that high SEPT9_v1 
expression specifically promotes malignant transformation in mammary epithelial cells by 
promoting the development of pro-oncogenic phenotypes.  To test this hypothesis, the first aim 
of this work was to define the relevance of high SEPT9_v1 expression to breast cancer 
progression in an over-expression model using mammary epithelial cell cultures.  The findings 
from these experiments are presented in Chapter 2.  The second aim, described in Chapter 3, 
was to characterize the role of SEPT9_v1 expression in genomic stability and cell proliferation.  
Chapter 4 describes a novel interacting protein of SEPT9 isoforms and the newest member of 
the human septin family, SEPT14.  Chapter 5 is a concluding chapter that discusses the 
















HIGH SEPT9_v1 ECTOPIC EXPRESION PROMOTES PRO-ONCOGENIC PHENOTYPES IN 
MAMMARY EPITHELIAL CELLS 
 
Summary 
 Altered expression profiles of human septins have been observed in multiple cancers, 
including leukemias and solid tumors.  Almost all human septin genes demonstrate complex 
patterns of alternative splicing as well as 5’ and 3’ variations.  These variations give rise to 
multiple protein isoforms whose expression patterns may be temporal and tissue specific.  Upon 
positional cloning of the human SEPT9 locus, several alternative transcripts were identified that 
encode at least seven distinct confirmed isoforms that vary primarily in their N- and C- termini.  
Extensive microarray analyses of normal versus tumor tissue demonstrated differential 
expression of specific SEPT9 isoforms in tumors when compared to normal tissue.  By examining 
a panel of breast cancer cell lines and a panel of primary breast tumors with matched control 
tissues for expression of SEPT9 variants using a variety of methods (i.e. semi-quantitative RT-
PCR, Q-PCR, Western blotting and immunohistochemistry), we found altered expression in 
breast cancers as compared to normal mammary epithelial cells.  Of all the SEPT9 isoforms, 
SEPT9_v1 was found to be highly expressed in >50% of breast cancer cell lines tested.  SEPT9_v1 
also showed increased cytoplasmic staining in primary tumors as compared to matched control 
samples.  In addition, when analyzing SEPT9_v1 staining in breast cancer patient samples with 
clinicopathological variables, we found that high SEPT9_v1 staining correlated with grade and 
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hormone receptor-positive tumors.  Therefore, we established a SEPT9 high expression model in 
mammary epithelial cells by retroviral transduction of SEPT9 isoforms.  We found that high 
retroviral expression of SEPT9_v1 in immortalized human mammary epithelial cell lines 
(IHMECs) caused these cells to acquire common cellular phenotypes that are associated with 
malignant cells.  Additionally, knockdown of SEPT9_v1 expression in breast cancer cell lines 
(BCCs) caused a reduction in some malignant phenotypes such as growth kinetics, invasiveness 
and cell motility.  These analyses demonstrated that high SEPT9_v1 expression in mammary 
epithelial cells can promote the development of cellular phenotypes that are markers of cancer 





 Breast cancer results from genetic and environmental factors that lead to the 
accumulation of mutations in, or altered expression of, essential genes.  Cancer is a complex 
multistep process in which mutations and/or deregulation of major oncogenes and/or tumor 
suppressors with large effect in the cells (c-Myc, p53, BRCA1, etc...) dictate the path to 
oncogenesis (91).  In addition, oncogenesis can be affected by the contribution of genes with 
small effects that, in combination, will impact either cancer initiation and/or progression.  The 
last decade has been highlighted by the development of clinically useful predictive, diagnostic, 
prognostic and therapeutic options based on knowledge about some of these genetic changes.  
However, the diverse molecular pathways underlying this heterogeneous disease are complex 
and remain poorly understood.  In fact, a variety of comparative genomic and expression studies 
suggest that additional genes and novel pathways important in breast cancer initiation and/or 
progression remain to be characterized (92, 93).   
In recent years there has been an increasing interest in the association of a family of 
human genes called “septins” with human cancers.  Septin family members have been 
implicated in multiple cancers, from leukemias to solid tumors (94).  In fact, our laboratory 
previously discovered a novel breast cancer associated gene, MSF (MLL Septin-like Fusion), on 
chromosome 17q25 by positional cloning (74).  Due to its high level of homology to cytokinesis 
genes encoding a family of GTPases containing septins, it was later renamed SEPT9.  Its high 
homology to other evolutionarily conserved septins important in cell division and implicated in 
oncogenesis, as well as its localization to a discrete region of allelic imbalance (AI) on 
chromosome 17q25 in breast tumors, suggested that alterations of this novel septin gene 
maybe important in breast cancer (74). 
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Upon further analysis, the SEPT9 locus exhibited, as do many other members of the 
septin family, extensive alternative splicing with the majority of diversity in the 5’ and 3’ ends of 
the transcripts.  This resulted in the gene encoding at least 7 well-characterized isoforms, 
believed to be tissue-specific, spatially and/or temporally regulated (Fig 1.4; Chapter 1).   For 
example, SEPT9_v1, the longest isoform, has unique exons 1-2 (red boxes) as compared to the 
SEPT9_v3 transcript which has a unique exon 1 (green box) (Fig 2.1A). The additional exons (gray 
boxes) are shared between the two transcripts, including those exons encoding for the proline 
rich domain (PRD), polybasic domain (PB) and the GTP-binding domain.   SEPT9 isoforms also 
differ in amino acid composition at both the N-terminus and C-terminus.  These two isoforms, 
SEPT9_v1 and SEPT9_v3, which are the main focus of this thesis, are compared by translational 
start sites and domain composition in Fig. 2.1B.  These two isoforms, as the other SEPT9 
isoforms, shared the same domains at the central region including the PRD, PB and GTP-binding 
domain.  The difference between these two isoforms reside on their N-termini, SEPT9_v1 
contains 18 additional amino acids at position 1-18 followed by 7 amino acids that differ from 
SEPT9_v3.  These 25 specific amino acids were used as a peptide (Fig 2.1B) to design a polyclonal 
antibody specific for SEPT9_v1.  Another antibody that recognized a peptide shared between all 
the isoforms was designed and used in this work (Fig 2.1).  It is hypothesized that the differences 
in 5’ and 3’ untranslated (UTR) regions of these SEPT9 variants may be important for the 
regulation of expression of each variant at different cell stages and tissues.  For example, 
SEPT9_v5 (SEPT9_v4*) and SEPT9_v6 (SEPT9_v4) have different 5’ UTRs but encode for the same 
polypeptide, but are translated at different efficiencies between normal and tumor tissues (73, 
76, 77).  The differences in protein structure and amino acid content between SEPT9_v1 and 
SEPT9_v3, as well as between the other isoforms may dictate the specificity of their protein 
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Fig 2.1: Genomic and protein structure comparison between SEPT9_v1 and SEPT9_v3 
variants 
(A) Genomic structure of SEPT9_v1 and SEPT9_v3 transcripts.  Gray boxes indicate common 
exons and colored boxes indicate variant-specific exons, all drawn to scale.  SEPT9_v1 specific 
exons are depicted by red boxes and SEPT9_v3 specific exon by a green box.  Transcriptional 
start sites are indicated by (*) and the end of each transcript by (**).  The variable exons 
encode different translational start (arrow) and stop sequences () and are spliced into a 
core of common coding exons shared between variants (gray boxes).  (B) Schematic showing 
SEPT9_v1 (586 amino acids; 65.4 kDa) and SEPT9_v3 (568 amino acids; 63.6 kDa), which are 
used throughout the majority of the experiments.   Red and green boxes represent specific 
amino acids for each isoform as shown.  Shared domains are shown in colored boxes (PRD: 
proline rich domain, PB: polybasic domain, GTP-binding domain).  Dash lines delineated 
identical amino acids shared between the isoforms.  Boxed amino acids showed peptides 
used to produce SEPT9 antibodies in which (a) denotes the peptide used to produce a rabbit 
polyclonal SEPT9_v1-specific antibody and (b) denotes the peptide used to produce a rabbit 
polyclonal SEPT9-X antibody that recognized all the SEPT9 isoforms shown.  SEPT9_v1 
contains 18 additional amino acids at the N terminus that are not present in SEPT9_v3 and 
both isoforms differ in additional 7 subsequent amino acids, that makes a total of 25 specific 





No pathogenic SEPT9 mutations associated with cancer have been reported to date, 
thus SEPT9 may belong to a class of critical regulatory genes in which altered expression profiles 
may underpin its role in tumorigenesis (76, 77, 94).  In fact, many reported expression analyses 
of SEPT9 variants showed differential expression between different tissues, and most 
importantly altered expression in cancer tissues such as breast, ovarian and prostate among 
others (73, 76, 77, 85, 86, 88, 94, 95). Previous studies in our laboratory showed that SEPT9 was 
amplified and over-expressed in more than 50% of breast cancer cell lines by Southern blot and 
RT-PCR (Table 2.1).  Additional expression analyses of each specific SEPT9 isoform by RT-PCR, 
quantitative real time PCR, and Western blotting showed high expression of SEPT9_v1 in more 
than 60% of BCCs as compared to IHMECs (Table 2.1).  Preliminary immunohistochemistry 
analysis of primary breast tumors showed increased SEPT9_v1 cytoplasmic staining as compared 
to matched controls (Table 2.1).  Therefore, my primary goal was to determine the role of 
SEPT9_v1 expression in breast tumorigenesis. We hypothesized that high SEPT9_v1 retroviral 
expression promotes malignant transformation in immortalized human mammary epithelial 
cells by promoting the development of pro-oncogenic phenotypes.  To test this, we designed a 
high SEPT9 expression model in mammary epithelium by establishing several IHMECs and breast 
cancer cell lines with stable expression of two SEPT9 isoforms (SEPT9_v1 and_v3,) using 
retroviral transduction.   
Part of our goal is to characterize the specific role of SEPT9_v1 in mammary 
tumorigenesis as either a “large effect” or a “small effect” oncogene by testing its effect on 
essential processes in cells that collectively drive malignant growth.  Some phenotypes that are 
considered to be the hallmarks of cancer include: self–sufficiency in growth signals, insensitivity 
to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (96).  In addition, many solid tumors can be 
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characterized by anchorage-independent growth, loss of contact-contact inhibition, and 
genomic, chromosomal and microsatellite instability among other phenotypes.  Our retroviral 
expression model showed that SEPT9_v1 impacts malignant transformation and/or progression 
by promoting cells to acquire many of these pro-oncogenic phenotypes as measured by cell 












Material and Methods 
Cell lines 
HPV-immortalized mammary epithelial cell lines were developed and provided by S.P. 
Ethier (Karmanos Cancer Institute, Wayne State University, Detroit, MI).  MCF10A cells and 
additional BCCs and immortalized human mammary epithelial cell lines (IHMECs) were 
purchased from The American Type Culture Collection: The Global Bioresource Center™ and 
grown under recommended conditions. 
Immunohistochemistry 
To study SEPT9_v1 expression in primary breast cancers, 160 paraffin-embedded patient 
samples arrayed on a single high-density tissue microarray (TMA) were used for the analysis. 
Details on this TMA have been described previously (97).  Immunohistochemistry was 
performed with a custom polyclonal anti-SEPT9_v1 specific antibody at a 1:200 dilution on 
previously prepared slides of paraffin-embedded or frozen sections of human breast tissue using 
standard methods.  Primary antibody was detected following protocols described by the 
manufacturer (DAKO Cytomation, UK), with diaminobenzidine as a chromogen and with 
haematoxylin counterstain.  Optimization and validation of the immunostaining dilution 
conditions were performed on several paraffin slices made from BCCs cell pellets, which 
reflected different levels of SEPT9_v1 expression corresponding to the endogenous level of 
expression described by other methods in this paper.  Cells were visualized with an Olympus BX-
51 microscope with a 10x and 40x objective lens.  Samples were scored from 0 to 4 by a 
pathologist (C. Kleer) to indicate intensity where “0” represented no SEPT9_v1 staining and “+4” 
represented dark, intense staining.  
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Establishment of SEPT9’s stable lines 
Open reading frames of SEPT9_v1, SEPT9_v3 and SEPT9_v4 were cloned into the 
pLNCX2 and/or pLPCX retroviral vectors (BD Biosciences).  Constructs were transfected into 
PT67 packaging cell lines using Fugene 6® transfection reagent.  Supernatant containing viral 
particles were collected 48 hours after transfection.  MCF10A cell cultures were individually 
infected with virions produced for each construct using polybrene (hexadimethrine bromide).  
Positive selection was started with either geneticin (G418) and/or puromycin 48 hours after 
infection.  Polyclonal lines for each construct were established after 10 days under selection. 
Western blot 
Western blot analysis was performed as previously described (98) using 50.0 µg of 
whole cell lysates.  The following antibodies were used: a custom-made rabbit polyclonal anti-
SEPT9_v1 (N-terminal epitope: KKSYSGGTRTSSGRLRR, BioCarta, San Diego CA) at a 1:1000 
dilution, a rabbit polyclonal anti-SEPT9 kindly provided by W.S. Trimble (24) at a 1:1000 dilution 
(Fig 2.1B), mouse ascites anti-βActin at a 1:10,000 dilution, mouse anti-vimentin at a 1:1000 
dilution, goat anti-rabbit:HRP secondary antibody at a 1:10,000 and goat anti-mouse HRP also at 
a 1:10,000 dilution (or 1:20,000 when used with anti-βActin primary antibody).  Antibodies were 
purchased from Sigma, unless otherwise noted, and diluted in 5% milk, 3% BSA and 0.05% 
Tween-20 in 1x TBS.  The Super Signal West Pico Chemiluminescent kit (Pierce Biotechnology, 
Rockford, IL) was used for detection, prior to exposure to Kodak XAR-5 film.  Relative to the 
loading control, semi-quantitative protein expression level was determined by densitometry 




Cell proliferation assays 
Two methods were conducted to examine cell proliferation.  For one, cells were plated 
in triplicate at the same density and counted at different time points, according to their 
doubling time, over the course of several days.  For the other, cells were plated at the same 
density and cultured for 24 h in a 96-well microplate. WST-1 reagent was added and absorbance 
at 450 nm was measured after 3 hours of incubation following manufacturer’s instructions 
(Roche Molecular Systems). 
Apoptosis assay 
Subconfluent cultures of HPV4-12, MCF10A and transductants were treated with 10 µM 
camptothecin for 24 hours to induce apoptosis; untreated cells were used as controls.  AnnexinV 
antibody conjugated to Alexafluor488 was hybridized to the cells, which were then counted by 
flow cytometry, following the manufacturer’s instructions (Vybrant Apoptosis Assay #2, 
Molecular Probes, Invitrogen, Carlsbad, CA).  Propidium iodide was used as a counter-stain to 
distinguish between apoptotic cells and dead/necrotic cells. 
Mitotic Index 
HPV4-12, MCF10A, empty vector, and SEPT9 transductants were prepared as previously 
described (23) and stained with 0.54mg/ml Giemsa solution, and then destained in deionized 
water.  Cells were visualized using a Leica DAS model microscope, and 1000 cells were counted 
per sample in triplicate.  The mitotic index was calculated as the percentage of cells with 





Scrape motility assay 
SEPT9-overexpressing stable transductants and empty vector controls were grown to 
confluency on 6-well plates in triplicate.  The cell monolayer was scraped using a pipette tip and 
visualized for movement into the wound 22 hours later with the Leica inverted microscope 
(phase-contrast optics, 20x objective).  The open wound areas at the initial and end points for 
each motility assay were calculated using Image J (http://rsbweb.nih.gov/ij/).  The ratio between 
time 0 and 22 h later (0 h/22 h) represented the motility for each cell line through the wound. 
Matrigel invasion assay 
Transwell membranes coated with Matrigel were used to assay invasion in vitro.  A 
suspension of MCF10A cells stably transduced with SEPT9_v1, SEPT9_v3 or empty vector was 
added to 24-well BD BioCoat Matrigel invasion chambers at 5 x 10 4 cells/ml in triplicate (BD 
Biosciences Discovery Labware).  The invading cells were fixed and stained using the Protocol 
Hema stain set (Fisher Diagnostics).   
Foci formation assay 
Hs578T transductants and parental cells were plated in 100mm dishes at 80% 
confluence.  Medium was changed every three to four days over 30 days.  Cells were stained 
with methylene blue, and colonies were photographed.  
Immunofluorescence 
For immunofluorescence analysis, stable transductants and parental cell lines were 
grown on two-chambered glass slides and fixed with 4% paraformaldehyde for 40 min at room 
temperature.  Slides were then washed thrice in 1X PBS for 10 min, blocked for 1 h in blocking 
solution (5% dry milk, 1% BSA, and 0.025% Triton X-100 in 1X PBS)and incubated overnight at 
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4°C in polyclonal rabbit anti-SEPT9_v1 or anti-vimentin (Sigma-Aldrich Corp.) antibodies at a 
1:50 or 1:30 dilution, respectively, in blocking solution.  Phalloidin conjugated to Alexa Fluor 568 
was used to identify filamentous actin (F-actin).  Alexa Fluor 488 and Alexa Fluor 633 were used 
as secondary antibodies (Molecular Probes, Invitrogen) at a 1:500 dilution in blocking solution 
for 1 hour at room temperature. Slides were prepared using mounting solution Prolong Gold® 
antifade reagent with Dapi (4',6-diamidino-2-phenylindole) to visualize DNA.  Cells were 
visualized using an Olympus FV-500 confocal microscope (100X objective).   
Knockdown of SEPT9_v1 expression in BCCs  
Transient siRNA knockdown was used in MDA-MB-231 cells, a cell line primarily 
expressing the SEPT9_v1 isoform, following the manufacturer’s protocol.  Cells were plated in 
triplicate, at a density of 4.0 x 105 cells/well in a 6-well plate, and subsequently transfected with 
DharmaFECT2 and the MSF siRNA pool.  This pool of four siRNAs targets all SEPT9 isoforms 
(catalog number M-006373-02, Dharmacon Research, Inc. Lafayette, CO).  Target sequences for 
the four duplexes in the siRNA-SEPT9 (MSF) pool correspond to the following loci of the 
SEPT9_v1 transcript (accession number AF189713): 5’GGAGAUCACCAUCGUCAAA (546 bp to 564 
bp); 5’GGUAAAUCCACCUUAAUCA (1024 bp to 1042 bp); 5’GAGAAAGGCGUCCGGAUGA (1147 bp 
to 1165 bp); 5’CCAACGGCAUCGACGUGUA (1496 bp to 1514 bp).  Mock transfected and 
siCONTROL RISC-Free siRNA supplied by the manufacturer were used as negative controls.  
Functional studies were performed 72 hours post-transfection, which was the time point with 
the greatest decrease in expression. 
 Stable knockdown in BT-549 cells was achieved using the pRNA-H1.1/Retro vector with 
either a Sept9_v1-specific shRNA construct or a scrambled sequence shRNA cassette provided 
by the manufacturer as a negative control (GenScript Corporation, Scotch Plains, NJ).  The 
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SEPT9_v1 shRNA construct targeted the unique 5’UTR, spanning base pairs 15 through 33 (sense 
strand target sequence; 5’ GGCCCAGGATTAGCGCCCT 3’; Genbank accession number AF189713).  
Following sequence verification of the constructs, 5 µg of purified plasmid DNA were transfected 
into PT67 cells to produce viruses, which were then used to retrovirally transduce the BT-549 
target cell line.  Polyclonal stable cell lines were selected in hygromycin (40µg/ml) for one week. 
Statistics Analysis 
The ANOVA test was used to determine statistical significance when comparing 
quantitative phenotypic differences between parental, vector and SEPT9 transductants.  The 
Wilcoxon signed-rank test and the Student's t test were done to assess statistical significance 
when analyzing patient data from the TMA.  In some instances, Student's t test was used to 
confirm statistical significance between vector and SEPT9 transductants.  For all tests, statistical 
significance was defined as P =0.05.  Error bars in the graphs presented here represent the SE. 
Results 
High SEPT9_v1 expression correlates with clinicopathological variables 
SEPT9_v1 staining by immunohistochemistry was low in the mammary gland epithelial 
cells from normal primary breast tissue present in the tissue microarray whereas 50% of primary 
invasive breast cancer tumors showed medium to high expression (Fig 2.2).  We next wanted to 
determine if SEPT9_v1 expression correlated with clinical and pathologic patient variables.  
From 152 patient samples of invasive breast carcinoma present on the TMA, 152 were available 
to score for SEPT9_v1 staining and 136 had complete clinicopathologic data for statistical 
analysis. Patient samples were annotated for several clinicopathologic variables, including tumor 
size, ER status, PR status, HER2/neu expression, lymph node status, patient age and tumor 
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grade.  Because there is no published evidence as to a threshold of expression that is required 
for proper SEPT9_v1 function, we included all positively stained samples in our analysis. 
Interestingly, there was a trend toward higher SEPT9_v1 staining correlating with ER and PR 
positive tumors (P = 0.0006 and P=0.014, respectively; Wilcoxon rank test; Fig 2.3).  Surprisingly, 
a low SEPT9_v1 expression was associated with high grade tumors (grade 3) as compared to 
grade 2 (P=0.0286; ANOVA test Fig 2.3).  However, there was an increase in SEPT9_v1 
expression between grade 1 and grade 2 tumors.  
 
  
Fig 2.2: SEPT9_v1 immunohistochemistry of primary breast tumors of the breast cancer 
tissue microarray  
Set of representative examples of primary samples of normal (N) and breast cancer tumors 
(T) tissues stained by immunohistochemistry for the SEPT9_v1 isoform.  Note the low 
staining in normal mammary epithelial cells of the ducts (N1) but strong staining in the cells 






Fig. 2.3: High SEPT9_v1 correlates with estrogen receptor and progesterone receptor 
positive status breast cancer tumors 
Statistical analyses of clinicopathologic characteristics from 152 primary invasive breast 
carcinoma (TMA 64) samples indicate that higher SEPT9_v1 mean (Mean+SE)expression 
correlates strongly with estrogen positive (ER+) status and have a weaker association with 
progesteron positive (PR+) status.   Lower SEPT9_v1 mean expression was correlated with 
tumor grade 3 and high SEPT9_v1 expression with tumor grade 2.  P values were calculated 
using the Wilcoxon rank test, except for tumor grade (**) for which the P value was 
calculated using ANOVA. 
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High expression of SEPT9_v1 leads to acquisition of oncogenic phenotypes 
 To examine the role of increased expression of SEPT9 on cellular characteristics, we 
retrovirally transduced several cell lines that showed no or low endogenous SEPT9_v1 
expression, MCF10A, HPV 4-12 and Hs578t, with cDNA constructs of SEPT9 variants, SEPT9_v1 
and/or SEPT9_v3.  First we analyzed the effect of ectopic expression of SEPT9 isoforms on cell 
proliferation by manually counting cells at different time points and by the WST-1 proliferation 
assay.  High expression of SEPT9_v1 dramatically increased the proliferation rate of all the cell 
lines as compared to parental and vector controls (Fig 2.4B and Fig 2.6A).  In contrast, high 
expression of isoform SEPT9_v3 dramatically lowered the growth rate of MCF10A cells, 
suggesting a potential tumor-suppressive or dominant-negative function, which needs to be 
characterized in future studies (Fig 2.4B; left panel).  In addition, high expression of SEPT9_v1 
increased the mitotic index of HPV 4-12 and MCF10A as compared to controls, confirming the 
high proliferative state of SEPT9_v1 transductants (Fig 2.5). 
To determine if impaired apoptosis contributed to the increased growth rate, we 
assessed the percentage of apoptotic cells following camptothecin treatment to induce 
apoptosis.  HPV 4-12 cells were insensitive to camptothecin-induced apoptosis, likely due to 
impaired p53 function as a result of the HPV E6/E7 immortalization.  There was no significant 
difference in apoptotic response between the controls and SEPT9_v1-overexpressing cells for all 
cell lines without camptothecin treatment.  However, overexpression of SEPT9_v1 significantly 
decreased the percentage of apoptotic cells in the MCF10A line following exposure to 

















































































































Fig 2.4: SEPT9 retroviral expression model 
(A) Western blotting shows the over-expression of SEPT9_v1 and SEPT9_v3 following 
retroviral transduction in MCF10A (left), HPV 4-12 (middle), and Hs578t (right) cells 
compared with parental controls. Beta-actin was used as a loading control.  (B) Growth 
curves showed increased growth kinetics of the polyclonal SEPT9_v1 transductants 
compared to empty vector, parental and SEPT9_v3 transductants in the three cell lines.  

























Fig 2.5: SEPT9_v1 increases mitotic index of IHMECs 
SEPT9_v1 over-expression increased the mitotic index more than two-fold in HPV4-12 and 
more than seven-fold for MCF10A cells compared to the parental and empty vector controls.  
The percentage of mitotic cells in three independent experiments is shown (* denotes p < 




  Fig 2.6: SEPT9_v1 over-expression increases cell proliferation in IHMECs and decreases 
apoptotic response in MCF10A  
(A) This cell proliferation colorimetric assay showed that SEPT9_v1-over-expressing cells 
proliferated faster than the empty vector controls in IHMECs. Cells were treated for 3 h with 
the WST-1 substrate and absorbance was measured at 450 nm after 48 h for HPV4-12 and 24 
h for MCF10A (*p<0.05). (B)  SEPT9_v1 over-expression inhibits camptothecin-induced 
apoptosis in MCF10A cells compared with parental and empty vector controls. Cells were 
treated with 10 mM camptothecin for 24 h and the percentage of apoptotic cells was 
determined by flow cytometry using an Annexin V-Alexa Fluor 488–conjugated antibody. 
HPV4-12 cells were resistant to the induction, as the vector control showed no significant 
difference in the percentage of apoptosis between untreated and camptothecin-treated cells 
(*p < 0.05). 
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We also noted a cellular morphology change reminiscent of an epithelial to 
mesenchymal transition (EMT), which is characteristic of epithelial cancers, for cells with high 
expression of SEPT9_v1, and for some of the cells over-expressing SEPT9_v3 in MCF10A and 
Hs578t lines (Fig 2.7).  The control cells displayed the usual organized and cuboidal appearance 
of epithelial cells.  The cells ectopically expressing SEPT9_v1 became elongated, almost 
fibroblastic or mesenchymal in morphology.  This morphology change was confirmed by 
increased vimentin expression as described below in Fig 2.12.  In previous reports, similar 
morphology changes were associated with increased motility and invasiveness (99). 
As cancer progression is often characterized by the capabilities of tumor cells to invade 
surrounding tissue and metastasize to distant sites, we used the Matrigel model of a basement 
membrane to determine if the SEPT9-transductants acquired an invasiveness phenotype.  We 
found that ectopic expression of SEPT9_v1, but not SEPT9_v3, in MCF10A, HPV 4-12 and Hs578t 
cells significantly increased invasiveness as compared to controls (Fig 2.9A, B and D).  
Additionally, multiple polyclonal lines of MCF10A cells with high SEPT9_v1 showed increased 
invasion, indicating that the results were not due to a specific integration site or expression of a 
predominant clone (Fig 2.8 and 2.9C).  Using a scrape motility assay, we also found that high 
SEPT9_v1 expression increased motility in MCF10A and HPV4-12 cells compared to the other 
variants and controls used in this assay.  Additionally, the MCF10A polyclonal lines with high 
SEPT9_v1 expression were also tested and showed the same pattern (Fig 2.10A and B).    
Next, the ability of high SEPT9_v1 ectopic expression to promote a phenotype indicative 
of cellular transformation was tested by analysis of a focus formation assay.  Foci formation was 
not observed in the immortalized cell lines HPV 4-12 and MCF10A, indicating that ectopic 






Parental  SEPT9_v1 SEPT9_v3
MCF10A
Hs578t
Fig 2.7: High SEPT9_v1 expression promotes an epithelial to mesenchymal transition (EMT) 
Top: MCF10A SEPT9_v1 transductants showed a change in morphology from cuboidal 
organized epithelial cells, such as the parental control, to spindle-like elongated disorganized 
morphology resembling a fibroblastic or mesenchymal cell appearance. SEPT9_v3 did not 
have an effect when compared to controls. Bottom: Hs578t both SEPT9_v1 and SEPT9_v3 























































  Fig 2.8: SEPT9_v1 expression of multiple polyclonal populations of MCF10A cells over-
expressing SEPT9_v1 
(A)Quantitative real time PCR showing the relative expression of SEPT9_v1 retroviral 
construct against GAPDH loading control in vector and SEPT9_v1 transductants. The average 
relative expression of four independent polyclonal population of MCF10A for vector and 
SEPT9_v1 construct is depicted. SEPT9_v1 transductants shows approximately a 6-fold 
increase in SEPT9_v1 expression overall. (B) Western blot analysis showing over-expression 
of SEPT9_v1 in each independent polyclonal population.  These polyclonal lines were used in 
several of the subsequent experiments to eliminate the possibility that the results were due 
















































































Fig 2.9: High SEPT9_v1 expression increased invasiveness  
SEPT9_v1 over-expression promotes invasion in MCF10A (A) MCF10A multiple polyclonal 
transductants (B) HPV4-12 (C) and Hs578T (D) cells when compared with SEPT9_v3 
transductants, parental, and empty vector controls. A Transwell Matrigel invasion assay was 
done in the presence of a chemoattractant (“chemo”), such as serum. Cells were also plated 
without the presence of chemoattractants as controls.  Columns represent average number 









Fig 2.10: High SEPT9_v1 expression increased cellular motility 
(A) A wound was created in a confluent culture and wound closure was measured after 22 h 
as a measure of cellular motility.  SEPT9_v1 over-expression resulted in a 6- to 10-fold 
increase in motility compared with SEPT9_v3-over-expressing cells, empty vector, and 
parental cell line controls for both, HPV4-12 and MCF10A cells. The area of the wound was 
quantified using ImageQuant software, and the graphs depict the ratio of the area of three 
initial wounds to the area of the closed wounds.  Average of three experiments is depicted in 
the graphs; bars, SE. *P<0.001, ANOVA.  (B) Representative images of the MCF10A and HPV 








Hs578t   +SEPT9_v1                                    +SEPT9_v3 
Fig 2.11: High SEPT9_v1 increases foci formation  
 Over-expression of SEPT9_v1 in Hs578t cells induced foci formation as compared to 
parental and SEPT9_v3 isoform, after prolonged culture. Cells are stained with methylene 
blue and colonies were photographed. 
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Hs578t transduced with SEPT9_v1 showed enhanced foci formation when compared with 
SEPT9_v3 transductants and parental cells (Fig 2.11). 
High SEPT9_v1 co-localizes and increases vimentin expression in IHMECs 
The breast cancer cell line Hs578T is classified in the mesenchymal-like group and 
expresses high levels of vimentin, a cytoskeletal protein marker for mesenchymal cells that has 
been shown to increase cellular motility and invasiveness in MCF7 cells (100).  We hypothesized 
that this feature of Hs578T cells, in addition to the over-expression of SEPT9_v1, could 
contribute to the increased invasion and foci formation of the SEPT9_v1 transductants when 
compared to the IHMEC lines, which do not express high levels of vimentin.  Therefore, we 
studied the interaction between vimentin and SEPT9_v1 by immunoprecipitation.  We found co-
immunoprecipitation between vimentin and SEPT9_v1 only in Hs578T cells with high SEPT9_v1 
expression but not in HPV4-12 cells with high SEPT9_v1 expression or either parental cell line. 
This indicates that up-regulation of both vimentin and SEPT9_v1 were needed for their 
interaction (Fig. 2.12A).  In support of this, we also noted strong co-localization of SEPT9_v1 and 
vimentin by immunofluorescence when SEPT9_v1 was highly expressed (Fig. 2.12B panels j and 
t).  In addition, high expression of SEPT9_v1 in MCF10A and Hs578T cells increased vimentin 
expression as shown by immunofluorescence (Fig 2.12B, panels i and s versus panels d and n).  
This data further supports the epithelial to mesenchymal morphology change described above 
and is suggestive of coordination between vimentin and SEPT9_v1 for cellular transformation.    
Depletion of SEPT9_v1 in BCCs reverses oncogenic phenotypes 
 To test further our hypothesis that the SEPT9_v1 isoform contributes to tumorigenic 
phenotypes, we questioned whether lowering its expression would reverse these phenotypes in 
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Fig 2.12: SEPT9_v1 immunoprecipitates and co-localizes with vimentin and over-expression 
of SEPT9_v1 causes increased vimentin expression in MCF10A and Hs578T cell lines. 
(A) Vimentin co-immunoprecipitated with SEPT9_v1 in Hs578T cells, but not in HPV4-12 cells, 
only when both proteins were over-expressed (top blots versus bottom blots).  SEPT9_v1, 
alpha tubulin, and vimentin antibodies were used for immunoprecipitation and the samples 
were subsequently immunoblotted for SEPT9_v1.  Whole cell lysates from the parental cell 
lines were used for as shown in the blots in the top panel.  Whole cell lysates from cells 
transduced with the SEPT9_v1 construct were used for immunoprecipitation for the blots 
represented in the bottom half of the image.  (B) Immunofluorescence studies indicate that 
vimentin co-localizes with SEPT9_v1 in interphase cells, as indicated by the white areas 
where the green and magenta overlap, and more intense staining of vimentin is observed in 
SEPT9_v1-over-expressing cells, supporting the hypothesis of an epithelial to mesenchymal 
transition.  The DNA is stained with DAPI (panels a, f, k, and p), SEPT9_v1 is green (panels b, 
g, l, and q), vimentin staining is shown in purple (panels d, i, n, and s) and the merged images 
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Fig. 2.13:   siRNA and shRNA mediated knockdown of SEPT9_v1 in BCCs with high 
endogenous expression level results in the loss of tumorigenic cellular phenotypes.   
(A) Transient transfection of siRNA to deplete SEPT9_v1 in MDA-MB-231 (left) was assessed 
72h post-transfection by semi-quantitative duplex RT-PCR, which shows specific knockdown 
of SEPT9_v1 mRNA levels by > 80% compared to controls, relative to GAPDH. Bottom left, 
immunoblot to validate the specific knockdown of SEPT9_v1 protein.  Densitometry showed 
that >60% of SEPT9_v1 protein was lost 72 hours post-transfection, and knockdown persisted 
for six days, compared to the parental and mock control, relative to the β-actin.  Specific 
stable knockdown of SEPT9_v1 by shRNA in BT-549 cells (right) showed >80% depletion of 
SEPT9_v1 mRNA.  Bottom, results of Western blotting, which reveals that > 70% of SEPT9_v1 
protein is lost in the shRNA-expressing polyclonal cell population when compared to the 
parental cells and cells expressing a scrambled shRNA negative control, relative to the 
GAPDH.  (B) Depletion of the endogenous SEPT9_v1 isoform in BCCs impaired cell growth 
compared to the parental and negative controls (left, MDA-MB-231; right, BT-549). *, P<0.03; 
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Fig 2.14:  Depletion of SEPT9_v1 in BCCs reverses invasiveness and motility phenotypes 
(A) Both transient and prolonged, stable knockdown of SEPT9_v1 in BCCs resulted in a 
decrease in the number of invading cells compared to parental and mock controls, by two-
fold for MDA-MB-231 (right)  and by more than seven-fold for BT-549 cells (left).  *, P<0.008 
by ANOVA.  (B) SEPT9_v1 depletion causes a reduction in cell motility, in MDA-MB-231 (left) 
and BT-549 (right) cultures.  Cells with decreased SEPT9_v1 were not able to close the wound 
in the confluent culture, when compared to parental and negative controls, after 20 h.  The 
graphs show that SEPT9_v1 ablated cells have reduced motility by >3-fold in MDA-MB-231 
cells (left) and 6-fold in BT-549 cells (right).  Columns, mean ratio of the initial wound area to 
the final wound area, ±SEM, from triplicate experiments; bars, SE.  *, P<0.008, as determined 
by the ANOVA test for statistical significance. (C) Representative images of three motility 
assays for MDA-MB-231 (left) and BT-549 (right) are depicted.  A wound was created in a 




different approaches in two breast cancer cell lines.  First, we transiently transfected MDA-MB-
231 cells, which predominantly over-expressed SEPT9_v1 protein compared to other isoforms, 
with a pool of four siRNAs that targeted the SEPT9 locus.  Seventy-two hours post-transfection, 
there was an 80% decrease of SEPT9_v1 mRNA and a 60% decrease in SEPT9_v1 protein levels 
compared to the mock transfected and non-targeting (siControl) negative controls (Fig 2.13A, 
left panel).  Other SEPT9 isoforms were not affected (Fig 2.13A, left panel and data not shown).  
Also, we used a stable shRNA construct to permanently and specifically decrease SEPT9_v1 
expression in BT549 breast cancer cells by targeting the isoform-specific 5’ UTR.  This resulted in 
an 80% decrease in endogenous SEPT9_v1 mRNA expression and decreased protein expression 
by more than 70% compared to the parental and the scrambled shRNA controls (Fig 2.13, right 
panel). 
For both lines, cells with decreased SEPT9_v1 expression showed inhibited cellular 
proliferation (Fig 2.13B), decreased invasion in the presence of chemoattractant (Fig 2.14A) and 
impaired cellular motility (Fig 2.14B and 2.14C), when compared to mock transfected and non-
targeting/scrambled construct controls.  In MDA-MB-231 cells in which SEPT9_v1 expression is 
transiently decreased by SEPT9 locus siRNA, the growth curves indicated a significant difference 
between the SEPT9 knockdown cells and the control cells at day four (p=0.03; Student’s t test) 
while there is not a significant difference between the parental and the negative controls.  
However, at day eight, the difference in growth rates becomes less significant, likely due to a 
return of SEPT9_v1 expression since loss of expression was transient and increasing by day six, 
as indicated by the Western blot.  As expected, the results obtained with the stable knockdown 
were much more striking than the transiently depleted cells, likely due to a more efficient and 
isoform-specific knockdown of SEPT9_v1 in these cells.  These two strategies support the initial 




To further examine if altered SEPT9_v1 expression was relevant to the pathogenesis of 
breast cancer, we analyzed expression in an invasive breast cancer tissue microarray panel and 
developed SEPT9_v1 expression models in immortalized mammary epithelial cells.  Previously in 
our laboratory, we analyzed SEPT9_v1 expression in a patient-matched normal and primary 
breast cancer tissue panel and found that 70% of the primary breast cancer tissue samples 
showed high cytoplasmic SEPT9_v1 staining as compared to absent or low staining in matched 
normal control tissues (20).   In the present study, after analyzing SEPT9_v1 expression in a TMA 
of samples from patients with invasive breast carcinomas with clinicopathological variables, we 
found that high SEPT9_v1 expression correlated with ER+ and PR+ positive tumors.  This might 
suggest that high SEPT9_v1 expression is relevant in hormone receptor positive tumors which 
account for 65% to 75% of breast cancers (101).  Interestingly, SEPT9 expression was shown to 
be correlated to BRCA1 expression in a microarray study annotated in GEO (Gene Expression 
Omnibus) profiles.  Most BRCA-deficient tumors tend to be estrogen (ER-) receptor negative and 
progesterone (PR-) negative (102).  Hormone receptor positive tumors are responsive to 
hormone therapy such as tamoxifen, and the chance of patients to respond to therapy is 
generally 80% (101, 103, 104).  Further studies to tease out relationships between hormone 
receptor status, BRCA1 status and SEPT9_v1 expression will be extremely useful to characterize 
SEPT9_v1 as a potential biomarker in breast cancer initiation, aggressiveness and therapy.   
On the other hand, it is possible that SEPT9_v1 up-regulation is associated with cancer 
initiation.  For example, SEPT9_v1 could modulate the development of neoplastic lesions or DCIS 
during breast cancer progression. The majority of breast cancer tumors started by being 
estrogen and progesterone receptor positive, but as the tumor progress they tend to lose 
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expression of these receptors (105).  Future studies are crucial to determine if SEPT9_v1 will be 
an important biomarker for prognosis or treatment options, given that hormone-receptor 
positive tumors are better treated with tamoxifen while negative tumors are treated with 
conventional chemotherapeutic drugs, especially drugs that target cytoskeletal proteins 
important for cell division.  In fact, recent studies support the importance of SEPT9 isoforms as 
biomarkers for cancer prognosis and therapy.  For example, deVos et al. showed that circulating 
methylated SEPT9 DNA is a potential biomarker for colorectal cancer (86).  Also, Amir et al., 
showed that high SEPT9_v1 expression is associated with resistance of cancer cells to 
microtubule disrupting drug such as paclitaxel (88).  
 We hypothesized that high SEPT9_v1 expression would be correlated with high grade 
tumors.  It was surprising to find that while SEPT9_v1 expression did increase between grade 1 
and 2 tumors it decreased between grades 2 and 3 tumors.  One possible reason could be that 
SEPT9_v1 expression is high during the course of tumor growth which explains the increase in 
expression between grade 1 and 2.  Then, by an unknown mechanism or an overall increase in 
genomic instability, SEPT9_v1 expression is gradually lost during tumor progression which could 
explain the low expression in grade 3 tumors.  The fact that high SEPT9_v1 expression is not 
associated with lymph node status further supports the possibility that SEPT9_v1 expression 
may be important early in the pathogenesis of invasive breast cancer rather than metastatic 
disease.  Still, additional studies, including analysis of more patient samples, are needed to 
confirm these results and to have a better sense of how SEPT9_v1 is modulating tumor 
progression in breast cancer.  
We next hypothesized that increased expression of SEPT9 might contribute to malignant 
progression in mammary epithelial cells and wanted to examine if it contributed to the 
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development of invasive phenotypes.  This hypothesis was supported by reports of increased 
expression of SEPT9 in human and murine cancers (75, 77, 83, 94).  In addition SEPT9, as well as 
other human septins (i.e. SEPT5, SEPT6, SEPT11), are well-described MLL-fusion partners noted 
in acute leukemia cells (61-65, 106, 107).  This evidence suggested important roles for one or 
more SEPT9 variants in tumorigenesis, but no compelling data supporting a role for SEPT9 in 
breast cancer had been reported to date.  To test our hypothesis, we retrovirally transduced 
cDNA constructs of SEPT9 variants into IHMECs (HPV4-12 and MCF10A), which promoted the 
development of cellular phenotypes characteristic of malignant cells.  Specifically, ectopic 
expression of SEPT9_v1 induced increased growth kinetics, accelerated cell proliferation, 
enhanced invasiveness, promoted an epithelial to mesenchymal morphology change with 
increased vimentin expression and increased cell motility when compared to controls.  Similar 
results were seen, as well as enhanced foci formation, when SEPT9_v1 was ectopically 
expressed in a BBC line with low SEPT9-X and no SEPT9_v1 endogenous expression, Hs578T.  
Knockdown of SEPT9, and specifically to SEPT9_v1, in two cancer cell lines with high endogenous 
levels of SEPT9_v1 (MDA-MB231, BT-549) using RNAi techniques confirmed our hypothesis and 
substantiated our conclusions by rescuing tumorigenic phenotypes.  Still, a rescue experiment 
expressing a SEPT9_v1 construct resistant to siRNA will be important in the future to further 
support the specificity of SEPT9_v1 effects on the cells.  Together, our results provide 
compelling support that SEPT9_v1 may function as an oncoprotein in mammary epithelial cells 
to drive malignant progression.  The association with invasiveness, motility and a mesenchymal 
phenotype suggests that up-regulation of SEPT9_v1 may be functionally important in 
progression to invasive or metastatic phenotypes. 
The other abundant SEPT9 variant detected in our assays,  SEPT9_v4* (SEPT9_v5), was 
previously noted to be up-regulated in tumor cells and showed only mild evidences of cell 
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transformation, suggesting that it might be a manifestation of tumorigenesis rather than a 
significant functional contributor to malignant progression (19).  In addition, the observation 
that the SEPT9_v3 isoform dramatically decreased growth rates in MCF10A cells supports the 
idea that these isoforms of the same gene could be dynamically rearranged under the guidance 
of different signaling pathways to accomplish different intracellular functions.  This work, 
combined with the data presented here, indicates that the SEPT9_v1 isoform contributes to 
oncogenesis when the SEPT9 locus is amplified or deregulated.  However, further work to 
determine if the other SEPT9 isoforms are also involved in tumorigenesis, either as oncogenes or 
as tumor suppressors, will be necessary to clarify the role of this locus in breast cancer 
development. 
 To our knowledge, the effects of SEPT9_v1 on cell proliferation, motility and invasion in 
the context of cellular transformation have not been previously examined.  Our studies provide 
compelling evidence supporting an important functional role for SEPT9_v1 in mammary 
tumorigenesis.  Future efforts focused on mechanistic studies, to elucidate how specific SEPT9 
isoforms coordinate different cellular functions, and to determine what regulates expression of 
one variant over another, should provide additional novel insights to the functional roles of 
SEPT9 in health and disease.  In addition, further characterization of the SEPT9 variants in in vivo 
models should enhance our understanding of how cellular division and proliferation normally 
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SEPT9_v1 interactions with cytoskeletal proteins and JNK promote malignant progression 
Summary 
Septins are highly conserved cytoskeletal GTP-binding proteins implicated in numerous 
cellular processes from apoptosis to vesicle trafficking.  Importantly, they also have been 
associated with human cancers and neurological disorders.  We previously reported that high 
SEPT9_v1 expression in human mammary epithelial cell lines (HMECs) led to malignant cellular 
phenotypes (i.e. increased growth kinetics, invasiveness, motility, and aneuploidy), suggesting 
its role in oncogenesis. Our goal is to better understand how altered SEPT9_v1 expression may 
contribute to genomic instability and malignant progression. 
To determine if SEPT9_v1 expression disrupts normal mitotic spindle formation and 
chromosome segregation, we analyzed SEPT9_v1 expression by immunofluorescence.  SEPT9_v1 
also interacted with alpha-tubulin, where its expression disrupted normal tubulin filaments.  
SEPT9_v1 expressing cells demonstrated striking cytokinesis defects, chromosome segregation 
abnormalities, and centrosome amplification, suggesting more than one molecular mechanism 
contributing to the development of aneuploidy or chromosomal instability.  To determine if 
aneuploidy accelerated cell proliferation we examined flag-SEPT9_v1 transient expression in 
HMECs and found that increased cell proliferation may develop independently of aneuploidy.  
Further investigation of SEPT9_v1–associated molecular mechanisms underlying increased cell 
proliferation revealed that SEPT9_v1 stabilizes JNK, which can accelerate cell cycle progression. 
57 
 
While the roles of SEPT9 in malignant progression remain poorly understood, our work 
suggests that SEPT9_v1 may accelerate cell proliferation through the JNK signaling pathway and 




Genomic instability is a characteristic feature of carcinogenesis, especially in human 
tumors of epithelial origin, such as breast tumors.  Genomic instability is broadly classified into 
two categories: microsatellite instability (MIN) associated with mutations in DNA repair genes 
and chromosome instability (CIN), which is recognized by numerical or structural chromosomal 
abnormalities (108).  During normal mitosis the parent somatic cell divides to generate two 
daughter cells with a diploid number of chromosomes.  In carcinogenesis, many tumors exhibit 
abnormal chromosome segregation during mitosis, which can lead to loss or gain of one or more 
chromosomes, also known as aneuploidy (109).  These events have been associated with 
tumorigenesis by increasing the rate of chromosome mutations, including deletions and 
amplifications of critical genes involved in cell proliferation and/or survival (109).  The various 
possible mechanisms that lead to the development of aneuploidy are described below (Fig 3.1). 
Mechanisms of aneuploidy 
Mitotic spindle defects 
 Proper mitotic spindle assembly is crucial for the subsequent segregation of 
chromosomes during anaphase (110).  Mitotic spindle formation is orchestrated by the tight 
regulation of microtubule and microtubule organizing center (MTOC) proteins such as 
/tubulin, tubulin, and Aurora A kinase among others (110, 111).  Mammalian cells have 
one MTOC, or centrosome, during interphase, usually located near the nucleus, and generally 
associated closely with the Golgi apparatus (111, 112). The centrosome is made of a pair of 
centrioles (111, 112).  Microtubules are anchored with their "minus" ends in the centrosome, 
and because microtubules dissociate preferentially at this end, this anchoring has a stabilizing 
effect and MTOC-associated microtubules can grow very quickly (111, 112).  During cell division, 
the centrosome is duplicated and each one moves to opposite poles in preparation for mitosis.  
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At this point, microtubule organization and dynamics are extremely important for the 
localization of the condensed chromosomes at the metaphase plate and their proper 
segregation later on in anaphase. The disruption of proper centrosome synthesis and/or 
organization and microtubule dynamics could lead to defects in mitotic spindle assembly and 
unequal distribution of chromosomes (112, 113).  Chromosome mis-segregation may arise by 
lagging of chromosome movement, unipolar movement of chromosomes, multipolar spindles 
due to centrosome amplification, or the stabilization or destabilization of microtubules (109).    
Defective attachment of chromatids  
 Each sister chromatid needs to be properly attached to the microtubules at the 
kinetochore before the cell enters anaphase during mitosis.  In fact, cells have a complex and 
tightly regulated surveillance mechanism to ensure the proper attachment of each sister 
chromatid to microtubules called the spindle assembly checkpoint or mitotic checkpoint.  This 
checkpoint is controlled by several proteins that serve as checkpoint sensors and signal 
transducers, which include BUB1, BUB3, BUBR1, MAD1, MAD2, CENP-E and the APC/CDC20 
complex (113).  Defective chromatid attachment to microtubules and improper separation may 
result in non-disjunction in which both sister chromatids may go to one daughter cell leading to 
the complementary gain and loss of chromosomes, thereby giving rise to aneuploidy in the 
daughter cells (109, 113).     
Defective cytokinesis 
 Failure of cytokinesis may produce abnormal accumulation of chromosomes in a single 
cell, resulting in tetraploidy.  Cytokinesis in vertebrates is governed by different core proteins 
including septins, which were identified by various large-scale screens in at least two distantly 
related animals (114).  Loss or over-expression of these proteins may lead to cytokinesis failure, 
which may be visualized by the appearance of giant bi- or multinucleated  
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Fig 3.1: Mechanisms of aneuploidy 
This diagram shows a representation of various examples of mitotic defects that can lead to 
aneuploidy.  (A) A defective mitotic spindle which may include centrosome amplification can 
lead to chromosome mis-segregation or cytokinesis defects that give rise to aneuploid or 
tetraploid cells.  (B) Defective attachment of chromatids to the spindle may occur by loss or 
mutations in spindle assembly proteins and/or mitotic spindle checkpoint proteins producing 
daughter cells with loss or gain of chromosomes.  (C) Tetraploid cells can also arise from 
failure of the cell to complete cytokinesis.  Any of these defects or a combination could lead 





cells and/or cleavage furrow regression in live cells (114).  Overall, this increases mitotic defects 
and chromosome mis-segregation in future mitoses.  Currently, several lines of evidence suggest 
that tetraploidy is an important intermediate chromosomal state that plays a major role in the 
development of aneuploidy.  In fact, different models demonstrate that aneuploidy may develop 
through chromosomal loss from a tetraploid intermediate and that this could be monitored by 
the appearance of micronuclei in tetraploid cells (115).   
Aneuploidy and cancer 
 
 Although aneuploidy occurs frequently in malignant tumors its role in carcinogenesis is 
still controversial (109).  It is debated whether aneuploidy is an important mechanism driving 
tumorigenesis or a non-specific secondary state that occurs during the process of cancer 
formation.  There are several compelling lines of evidence that support the hypothesis that 
aneuploidy plays an active role in carcinogenesis.  First, there is tumor specific aneuploidy such 
as in the progression of colon adenoma to carcinoma (116).  Second, loss or gain of 
chromosomes in each generation of aneuploid cells is very high as compared to diploid cancer 
cell lines (117).  Third, mutations in specific mitotic spindle checkpoint genes are strongly 
associated with different cancers including colon, breast and leukemias (113).  Fourth, there are 
many pre-neoplastic lesions that show aneuploidy such as liver dysplasia and prostate 
intraepithelial neoplasias that subsequently progress to carcinoma (118, 119).  Taken together, 
these observations suggest that the development of aneuploidy may drive oncogenesis.  Still it is 
important to point out that there are a few diploid cancers in which aneuploidy cannot 
adequately explain the carcinogenesis process in these tumors.  
 Aneuploidy of cancer cells of certain types of tumors might be involved in the 
development of a more aggressive phenotype.  Examples of possible ways in which aneuploidy 
could be involved in cancer progression are by creating (109):  
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1. Loss of heterozygosity leading to decreased or abnormal function of a mutated tumor 
suppressor gene 
2. Gain of chromosomes or amplification of chrosmosomal regions causing the over-
expression of oncogenes that drive tumorigenesis.  
3. Destabilization of the structure of genes by DNA strand breaks that promote, deletion, 
amplification, and/or intra/interchromosomal rearrangements contributing to genomic 
instability.  
4. Disturbance of genes that affect the balance of the spindle checkpoint apparatus or 
other cell cycle regulators 
In summary, based on observations to date one can hypothesize that aneuploidy is one of 
the critical driving forces of carcinogenesis via a two-step mechanism in which cells become 
aneuploid, either by cytokinesis failure, mitotic spindle defects, or mutations in spindle 
checkpoint genes, creating a population of cells with unstable karyotypes and chromosomal 
instability.  Those aneuploid cells that remain and are maintained by subsequent cell division 
create a lineage of cells with much higher overall genomic instability that may drive 
tumorigenesis and/or the development of more aggressive phenotypes.  Thus, better 
understanding of aneuploidy in various cancers has important diagnostic, prognostic and 
therapeutic implications.   
Septin cytoskeleton interactions: Implications in mitosis and cytokinesis 
 
Since they were discovered in budding yeast, septins have been associated with cytoskeletal 
dynamics.  Temperature sensitive mutations in yeast septins CDC3, CDC10, CDC11 and CDC12 
were found to cause cell cycle arrest with major defects in budding morphology in the budding 
yeast Saccharomyces cerevisiae (1, 120, 121).  Perhaps most interesting was the characterization 
of septin mutants which play a central role in cell cycle delays by triggering the mislocalization of 
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inhibitory cyclin dependent kinases (122).  It was demonstrated that this mislocalization 
prevented the required degradation of inhibitors needed for cell cycle progression through 
G2/M, suggesting that septins helped regulate cell cycle progression through the association of 
mitosis-inducing protein kinases.  Other studies in Saccharomyces pombe revealed that septins 
play a crucial role in organizing the cytoskeleton for mitosis and cytokinesis, when septins were 
mutated cytokinesis failure was observed (122).  It was also found that septins have the ability 
to form microfilaments by interacting with cytoskeleton and filamentous proteins such as actin 
and myosin related proteins as well as the actomyosin ring in cytokinesis.  These findings 
demonstrate that cytoskeleton organization is tightly coupled to cell cycle progression and 
provides compelling evidence suggesting the possibility of a critical cytokinesis related cell cycle 
checkpoint.   
 The homologies between mammalian and yeast septins can shed light on the functional 
role of human septins as regulators of cytoskeletal dynamics, cytokinesis and possibly 
chromosome dynamics, which are all crucial for proper cell division and cell cycle progression.  
The complexity of mammalian septins, with 14 known members that encode several alternative 
transcripts, makes it quite challenging to understand their functional role as cytoskeletal 
proteins important in cell division and cell cycle regulation.  Despite this, several recent studies 
have elucidated the roles of mammalian septins in cytoskeletal dynamics, proper chromosome 
segregation, and completion of cytokinesis.   In contrast to yeast septins that localized primarily 
on the cortical sites of the mother-bud neck, mammalian septins localize to the plasma 
membrane and throughout the cytoplasm along with microtubules and actin filaments.   
A first indication that higher eukaryotic septins might interact with microtubules was 
the observation that Drosophila septins can bind to microtubules (MT) in vitro (123).  In 
mammalian cells, SEPT1 was found to localize to spindle poles at the centrosomes and 
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microtubules throughout mitosis, to the midbody at telophase, and to the contractile ring during 
cytokinesis.  SEPT1 also partially co-localized with Aurora B kinase, a mitotic protein important 
for chromosome segregation and cytokinesis (12).  
Two independent studies showed similar results where SEPT9 demonstrated cell-cycle 
dependent distribution and septins were implicated in microtubule dependent functions by 
their interaction with -tubulin.  Surka et al. found that in interphase cells, mammalian septin 
SEPT9 (MSF) co-localized with actin, microtubules and other septins.  In addition, they were able 
to determine that SEPT9_v1 (MSF-A) specifically localized with microtubules and this localization 
was disrupted by nocodazole treatment.  Interestingly, when SEPT9 was depleted by siRNA or 
microinjection of specific anti-MSF antibody, the accumulation of bi-nucleated cells and failure 
cytokinesis was observed (24).  Nagata et al. showed similar results in human mammary 
epithelial cells (HMECS) in which SEPT9_v1 was found to be localized at the mitotic spindle and 
microtubules at the midzone during mitosis.  They also were able to co-purify SEPT9_v1 with -
tubulin and identified the GTP-binding domain of SEPT9 to be required for this interaction. 
 This association of septins with microtubules suggested a possible role in mitosis.  In 
fact, a possible role of septins in chromosome attachment to spindle microtubules and in 
chromosome congression and segregation is suggested by reports delineating SEPT6 and SEPT2 
localization as a network of fibrillar structures at the mitotic midzone of epithelial cells (37).  
Surprisingly, SEPT2 was found to be required for the proper localization of centromere-
associated protein E (CENP-E) to the kinetochore for the proper attachment of chromosomes to 
spindle microtubules during mitosis.  MDCK cells depleted of SEPT2 by siRNA showed mis-
localization of CENP-E from the kinetochores and chromosomes fail to align properly and did not 
segregate correctly (37).  SEPT7 was also found to interact with CENP-E and regulated its 
distribution to the kinetochores.  When cells were depleted of SEPT7, CENP-E did not localize 
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appropriately to the kinetochores and the mitotic spindle checkpoint was activated due to 
misaligned chromosomes (47).   
 The mammalian septin heterotrimer Sept2:6:7 was found to bind to MAP4, a 
microtubule-binding protein. The heterotrimer was responsible for blocking the ability of MAP4 
to bind to microtubules in vitro.  The suppression of septin expression caused a striking increase 
in microtubule stability and an abnormal nuclear phenotype which was suppressed when MAP4 
was also depleted (22).  Together, these data identified a novel molecular function of septins in 
mammalian cells of modulating microtubule dynamics through the interaction with MAP4.   
 Most recently, it was demonstrated that SEPT9_v1 protein expression conferred 
resistance to microtubule-mediated HIF-1 inhibitors such as 2-methoxyestradiol and paclitaxel in 
various cancer cells (88).  Previously, it was determined that HIF-1 transcriptional activation 
depends on an intact microtubule-cytoskeleton network (124, 125) and that SEPT9_v1 regulates 
HIF-1 stabilization and transcriptional activity (72).  At the same time, SEPT9_v1 localized and 
interacted with microtubules (MT), therefore in this study it was concluded that cancer cells 
with high SEPT9_v1 expression were resistant to MT-dependent HIF-1 inhibitors specifically.   
Interestingly, no difference was found with MT-independent HIF-1 inhibitors such as YC-1 and 
17-AAG, that had previously been shown to inhibit HIF-1 without affecting MT (88).  
 Mammalian septins are also required for the late stages of cytokinesis.  For example, at 
least some septins were reported to be binding partners of Anillin, an actin-binding protein and 
a component of the cytokinetic ring, which recently was found to be over-expressed in diverse 
human tumors including breast cancer (126).   Additionally, SEPT2 acted as a scaffold for myosin 
II and its kinases to ensure full activation of myosin II, which is necessary for the final stages of 
cytokinesis in mammalian cells (127).  Also, SEPT2 and SEPT9 are required at the central spindle 
for the completion of cytokinesis, suggesting that septins play an important role coordinating 
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late cytokinesis events such as membrane targeting and/or fusion during abscission.  Apart from 
cell division and cytokinesis, septins’ interaction with microtubules might be involved in other 
cellular processes like microtubule–based vesicle transport in nervous transmission among 
others, which are beyond the scope of this study.   
 The multiple interactions that septins have with microtubules and other components of 
the cytoskeleton involved in mitotic events, whether by forming a regulating scaffold for mitotic 
proteins, and/or facilitating the interaction between microtubules and chromosomes, likely 
serve to regulate multiple steps of cell division, such as cytokinesis, spindle assembly and 
chromosome segregation.  Given this, I hypothesized that high SEPT9_v1 expression increases 
genomic instability through its association with cytoskeletal proteins relevant to chromosome 
segregation and cell division. Therefore, I wanted to investigate whether or not SEPT9_v1 
expression could impact tumorigenesis in mammary epithelial cells by promoting mitotic defects 
through its regulation of chromosome segregation and/or cytokinesis. 
Materials and Methods 
Cell lines 
 MCF10A and HCT116 were purchased from American Type Culture Collection (ATCC).  
HPV 4-12 was developed and provided by S.P Ethier (Karmanos Cancer Institute, Wayne State 
University, Detroit, MI).  MCF10A was maintained in F12/DMEM 1:1 media containing L-
glutamine, 15mM HEPES buffer and supplemented with 5% horse serum, 20 ng/ml of epidermal 
growth factor (EGF), 8 ug/ml of insulin, 500 ng/ml of hydrocortisone and 100 ng/ml of Cholera 
toxin (CT).  HPV4-12 cells were maintained in F12 Nutrient Mixture with 5% fetal bovine serum 
(FBS), 10ng/ml EGF, 8 ug/ml insulin, 1 ug/ml of hydrocortisone and 100 ng/ml of CT.  HCT116 





 HPV4-12 and MCF10A cells retrovirally transduced with empty vectors or SEPT9 were 
grown to 70% confluence.  Cells were treated with colcemid at 0.02 ug/ml for 18 hours to enrich 
for cells in metaphase.  Then, cells were trypsinized and collected by centrifugation at 1000 rpm 
for 5 min.  Cells were then washed with 1X PBS and incubated with a pre-warmed hypotonic 
solution (0.4 % KCL + 0.4 % sodium citrate) for 7 min at 37 °C with subsequent centrifugation.  
The resuspended pellet was fixed twice by dropwise addition of a 3:1 mixture of methanol and 
glacial acetic acid for 30 min and centrifugation between each fixation.  Fresh fixative was then 
added, and the resuspended cell pellets were dropped onto clean microscope slides.  Slides 
were air dried, stained in 0.54 mg/ml Giemsa solution, and destained in deionized water.  After 
air drying, chromosomes were visualized and counted using an Olympus BX60 model 
microscope with a 100 X oil objective.  Twenty-five metaphases were counted for aneuploidy, in 
triplicate, for each sample. 
Immunofluorescence  
 For immunofluorescence analysis, cells were grown on two-chambered slides and 
fixed with 4% paraformaldehyde for 40 min at room temperature.  Alternatively, cells were fixed 
10 min with cold methanol at -20 °C followed by 1 min with acetone at -20 °C.  Slides were then 
washed thrice in 1X PBS for 10 min, blocked for 1 h in blocking solution (5% dry milk, 1% BSA, 
0.025% Triton X-100 in 1X PBS) at room temperature, and incubated overnight at 4°C with 
polyclonal rabbit anti-SEPT9_v1 (1:50), monoclonal mouse anti--tubulin (1:100), polyclonal 
rabbit--tubulin (1:5,000), monoclonal anti- Flag (1:500) (Sigma-Aldrich Corp.) and/or polyclonal 
rabbit anti -Ki67 (1:50) (Abcam Inc.) primary antibodies diluted in blockinjg solution.  Phalloidin 
conjugated to Alexa Fluor 568 was used to identify filamentous actin (F-actin).  Alexa Fluor 488, 
Alexa Fluor 596 or Alexa Fluor 633 were used as secondary antibodies (Molecular Probes, 
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Invitrogen) at a 1:500 dilution in blocking solution for 1 h at room temperature.  Slides were 
preserved in ProLong Gold mountaing media with 4’,6-diamidino-2-phenylindole (DAPI) to stain 
the DNA.  Cells were visualized using an Olympus BX60 model microscope (100 x objectives).  
Transient transfection 
 SEPT9_v1 cDNA was subcloned into pCMV-3tag-1A (Stratagene) using Hind III and Sal 
I restriction sites, which encoded for SEPT9_v1 protein tagged with 3 Flag epitopes at the N 
terminus.   MCF10A and HCT116 cells were transiently transfected with pCMV-3tag-1A or pCMV-
3tag-1A-SEPT9_v1 plasmids using Fugene® HD transfection reagent following manufacturer’s 
instruction. Briefly, 18 ul of Fugene® HD reagent was mixed with 6 ug of plasmid in Opti-MEM 
reduced serum media and incubated for 15 minutes at room temperature.  The transfection 
complex was added dropwise to ~ 1.75 x 106 cells grown in 100 mm tissue culture plates.  Cells 
were collected for immunofluorescence, metaphase spreads and lysates for western blot 
analysis at different time points after transfection dictated by the doubling time of the cells.  
Flag-SEPT9_v1 expression, aneuploidy analysis and cell proliferation using Ki67 staining for 
immunofluorescence was determined for each time point in triplicate.   
Western blot 
 Western blot analysis was done using 50 ug of whole-cell lysates.  The following 
antibodies were used: monoclonal mouse anti-Flag at 1:1000 dilution, monoclonal mouse anti-
actin, peroxidase conjugated (Sigma-Aldrich, Inc.) at 1:10,000 dilution and/or mouse monoclonal 
anti-GAPDH (Abcam) at 1:10,000.  Also, a custom-made rabbit polyclonal anti-SEPT9_v1 
antibody at a working dilution of 1:4000; SAPK/JNK rabbit monoclonal antibody; anti-cyclin D1 
mouse monoclonal antibody; anti-phospho-cyclin D1 rabbit monoclonal antibody; and an anti-
phospho-c-Jun rabbit monoclonal antibody were used.  All antibodies were purchased from Cell 
Signaling Technology and used at working dilutions of 1:1000.  In addition, anti-cyclin B1 mouse 
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monoclonal, anti-cyclin E rabbit monoclonal and anti-JNK2 (D-2) HRP-linked antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and used at 1:200 dilution and 1:500 
respectively.  For secondary antibodies a goat anti-rabbit:HRP secondary antibody (1:000 
dilution), and a goat anti-mouse:HRP (1:1000 dilution) antibody were both purchased from Cell 
Signaling Technology.  All antibodies were diluted in 5% milk, 0.05% Tween 20 in 1X TBS.  The 
SuperSignal West Pico Chemiluminescent kit (Pierce Biotechnology) was used for detection 
before exposure to Kodak XAR-5 film.   
Immunoprecipitation 
 Cells were grown in 100mm dishes to 70% confluence before medium was removed, 
then the cells were washed twice with ice cold 1x PBS and incubated for five minutes at 4°C in 
M-PER lysis buffer (Pierce Biotechnology, Inc. Rockford, IL).  The cells were collected and lysates 
were cleared by centrifugation at 13 000 rpm for 30 minutes at 4°C.  Approximately 400 µg of 
solubilized lysate was used for each immunoprecipitation using the Protein G 
Immunoprecipitation kit (Sigma Aldrich, St. Louis, MO) and immunoprecipitations were 
performed according to manufacturer’s instructions.  The immunoprecipitated proteins were 
analyzed by SDS-PAGE and probed with the antibody described in the assay.    
GST pull downs 
 DH5 E. coli cells were transformed with plasmids for either pGEX-2T empty vector or 
pGEX-2T-SEPT9_v1-GST and were induced for 4 h at 25 °C with 1 mM IPTG. Then, 1.0 mg of E. 
coli whole cell lysates were incubated for 3 h at 4 °C with glutathione sepharose 4B bead slurry 
(Amersham, Piscataway N.J.). Following washes, 1 mg of whole cell lysates from HPV4-12 
Flag:JNK1 stably transduced cells was added and incubated overnight at 4 °C.  After washing 
thoroughly with NTEN200 buffer (20 mM Tris–HCl, 1mMEDTA, 0.5% NP40, 25 µg/ml PMSF, 200 
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mM NaCl), the beads were incubated for 15 min with 10 mM glutathione at room temperature. 
Samples were analyzed by Western blotting. 
Protein Stability Assay 
Cells were plated in six-well plates and grown to 70% confluence.  The cells were 
subjected to cycloheximide treatment as described (125).  Lysates were analyzed by Western 
blot at different timepoints.  Quantification of relative endogenous JNK1,2 expression was 
performed by densitometry using -Actin as the loading control (Alpha Innotech IS-1000 Digital 
Imaging System, version 2.00). 
UV treatment 
 Sub-confluent cultures of the cells were irradiated with UV as described and incubated 
for one hour to recover (128).  Whole cell extracts were isolated as previously described and 
used for Western blotting (20).  
Kinase Assay 
       In vitro:  Whole cell extracts used for the evaluation of JNK were prepared by following the 
manufacturer’s directions (SAPK/JNK Assay Kit (non-radioactive), Cell Signaling Technology 
Beverly, MA).  Briefly, cell extracts (250 µg of protein) were incubated with glutathione beads 
containing 1µg of GST-c-Jun (1-79) fusion protein, centrifuged, washed, and incubated in kinase 
buffer with 10 µM ATP for 30 minutes at 30 °C.  Phosphorylated substrate was detected by SDS-
PAGE and immunoblotting using phospho-specific c-Jun antibody.  Quantification of the JNK 
kinase activity relative to the parental and empty vector controls were performed by 
densitometric scanning (Alpha Innotech IS-1000 Digital Imaging System, version 2.00).  
       In vivo:  HPV4-12 human mammary epithelial cell lines, empty vector control (pLPCX), and 
SEPT9_v1 and SEPT9_v3 stable transductants were transiently transfected using FuGENE 6 
according to manufacturer’s instructions (Roche, Nutley, NJ) (20).  Cell were plated in six-well 
71 
 
culture plates and prepared following the manufacturer’s instructions for the c-Jun TransLucent 
in vivo Kinase Assay Kit (Panomics Inc., Redwood City, CA).  Briefly, the system is dependent 
upon the pTL-TAD expression vector, which contains the transcription activation domain (TAD) 
of cJun (amino acids 1-223), fused to the Gal4 DNA binding domain.  The TAD-Gal4 fusion 
protein is constitutively expressed in cells and binds to the Gal4 binding domain, upstream of 
the luciferase gene in the pTL-Luc reporter plasmid.  When TAD is phosphorylated by its specific 
kinase, JNK, it will activate transcription of luciferase.  The cells were co-transfected with 0.5 µg 
of the pTL-c-Jun or the Translucent Control Vector (pTL-BD, which only has the Gal4 DNA binding 
domain), 1.0 µg of the pTL-Luc reporter plasmid, and 25 ng of pRL-TK (a plasmid containing 
Renilla luciferase reporter vector).  Cells were lysed with lysis buffer from Promega Corporation.  
Quantification of the JNK kinase activity relative to controls was performed following the 
manufacturer’s instructions in the Dual-Luciferase Reporter Assay System, (Promega 
Corporation).  Luciferase activity was assessed using a 1420 multi-label counter luminometer 
from PerkimElmer Life and Analytical Sciences.    
JNK/c-Jun Transcriptome Activation Detection in vivo: Luciferase Assay        
Whole cell extracts were treated following the manufacturer’s instructions for the 
Pathway Profiling Luciferase System 3 kit for profiling cell proliferation and differentiation 
signaling pathways (Clontech Laboratories).  Briefly, HPV4-12 cells, the empty vectors controls 
(pLPCX), and SEPT9_v1 or SEPT9_v3 stable transductants were transiently transfected using 
FuGENE 6 (Roche) in a 6-well culture plate format.  One microgram of either the pTAL-Luc vector 
used as a negative control or the pAP1-Luc vector (containing the cis-acting enhancer AP-1 
element) and 25 ng of pRL-TK (a plasmid containing the Renilla Luciferase reporter vector) were 
used.  The values obtained for the negative control, pTAL-Luc, were subtracted from the 
experimental results to normalize the data.  Cells were lysed by adding lysis buffer from 
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Promega Corporation.  Quantification of the relative fold of induction with the AP-1 enhancer to 
the parental and empty vector controls was performed by following the manufacturer’s 
instructions in the Dual-Luciferase Reporter Assay System (Promega Corporation).  Luciferase 
activity was determined on a 1420 multi-label counter luminometer from PerkimElmer Life and 
Analytical Sciences.     
Real-time Quantitative PCR 
cDNA samples from IHMEC and BCCs were amplified in triplicate from the same starting 
material of total RNA following the manufacturer’s instructions (Omniscript RT kit, Qiagen).  
Samples were amplified using TaqMan MGB FAM dye-labeled probes from Applied Biosystems 
in an ABI7900HT model Real-Time PCR machine.  The following probes were used: 
Hs99999905_m1 (GAPDH) and Hs00277039_m1 (CCND1). 
Cell synchronization  
Cells were synchronized with a double thymidine block as described previously (129).  
Briefly, cells were incubated in medium containing 2 mM thymidine for 12 hours, released into 
normal medium for 8-10 hours, and then incubated for 12 hours in medium with 2 mM 
thymidine.  Samples were collected at regular intervals after releasing the cells from the 
thymidine block and the cell cycle distribution was detected by flow cytometry following 
staining with propidium iodide.  Whole cell lysates were collected at the same timepoints and 
analyzed by Western blotting to look at the SEPT9_v1 expression profile through the cell cycle.   
Results 
High SEPT9_v1 expression increases aneuploidy in mammary epithelial cells 
Due to the implication of septins, including SEPT9, in mitosis and cytokinesis, I assayed 
the cells with high ectopic SEPT9_v1 or SEPT9_v3 expression for aneuploidy, a characteristic of 
genomic instability in many cancers.  Ectopic expression of SEPT9_v1 increased the amount of 
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aneuploid cells to about ~50% as compared to ~5-15% in parental and empty vector controls 
(Fig. 3.2A) for both immortalized mammary epithelial cells (IHMECs) MCF10A and HPV 4-12.  
Similar results were observed for multiple polyclonal populations of MCF10A cells with high 
SEPT9_v1 expression (Fig 3.2B).  High ectopic SEPT9_v3-expressing MCF10A cells also showed 
increased aneuploidy to a lesser extent than SEPT9_v1, but the change was significant. 
Interestingly, high SEPT9_v1 expression gave rise to a striking bimodal distribution of cells with 
extra chromosomes.  One population showed generalized aneuploidy with few extra 
chromosomes, while the second population showed a gross number of extra chromosomes 
closer to a tetraploid status.  In contrast, the majority of SEPT9_v3 associated aneuploid cells 
were close to tetraploidy (Fig 3.2C).  This difference suggested that these two isoforms might 
impact genomic instability by at least two different mechanisms including mitotic spindle 
defects and/or incomplete cell division.   
SEPT9 isoforms have distinct cellular localizations and over-expression of SEPT9_v1, but not 
SEPT9_v3, disrupt tubulin filaments 
 To determine SEPT9_v1 and SEPT9_v3 localization in IHEMCs in relation to cytoskeletal 
proteins, IHEMCs over-expressing each variant were stained with either anti-SEPT9_v1 or anti-
SEPT9-X (to detect SEPT9_v3) antibodies for immunofluorescence. Endogenous SEPT9_v1 
localized to the cytoplasm in interphase cells with minimal nuclear staining (Figs. 3.3, panel b).  
However, ectopically expressed SEPT9_v1 showed this isoform was more abundant in both the 
nucleus and the cytoplasm, with an altered morphology of the cells (Fig. 3.3, panel n).  In 



































Fig 3.2: High SEPT9_v1 and SEPT9_v3 increases aneuploidy in IHMECs 
(A) Ectopic expression of SEPT9_v1 and SEPT9_v3 increases genomic instability in MCF10A 
and HPV 4-12 cells in that ~50% of the cells in the population are aneuploid.  (B) Multiple 
polyclonal populations of MCF10A cells over-expressing SEPT9_v1 showed similar results 
with ~45% of cells being aneuploid.  Columns, percentage of aneuploid cells from 25 
metaphases in each of three independent experiments; bars, SE. *p<0.001, ANOVA. (C) 
Graph showing that the majority of SEPT9_v3 cells (red line) are close to tetraploidy (81-96 
chromosomes) and showing binomial distribution of SEPT9_v1 (blue line) cells; one 
population of cells showed aneuploidy (49-70 chromosomes) and another population 
showed tetraploidy (71-96 chromosomes). 
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Fig 3.3:  Ectopic SEPT9_v1 and SEPT9_v3 co-localize with cytoskeletal proteins but with 
different outcomes 
Immunofluorescence studies were used to stain cells for DNA (DAPI; panels a, g, and m), 
SEPT9_v1 (panels b and n), SEPT9-X (panel h), phalloidin/F-Actin (panels c, i, and o), and 
alpha tubulin (panels d, j, and p).  Ectopic expression of the SEPT9_v1 isoform in HPV4-12 
cells caused the microtubule network to break down in interphase cells (panel p) compared 
to ectopic expression of the SEPT9_v3 isoform (panel j) or the parental cell line (panel d).  
The merged images of SEPT9_v1 and actin (panels e and q) show the limited co-localization 
of actin filaments with SEPT9_v1 and the merged image between SEPT9_v3 and actin (panel 
k) shows co-localization of SEPT9_v3 with actin rings in the transduced HPV4-12 cells during 
interphase.  The merged images of SEPT9_v1 and alpha tubulin show co-localization of 
SEPT9_v1 and microtubule filaments in the parental cell line (panel f) and with microtubules 
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SEPT9_v1 showed limited co-localization with filamentous actin and strong localization with 
alpha tubulin in interphase cells (Fig. 3.3, panels e, f, q, and r).  Interestingly, when SEPT9_v1 
was over-expressed, there was a dramatic disorganization of the tubulin filaments in 68% of 
interphase cells (Fig 3.3, panel p), compared to 0% in cells over-expressing SEPT9_v3 (Fig. 3.3 
panel j), and 11% of cells in the parental HPV4-12 line (p<0.001, ANOVA).  This was in strong 
agreement with the differences in the subcellular localization of the two variants. 
High SEPT9_v1 expression promotes mitotic spindle defects 
 SEPT9 transductants and empty vector control MCF10A cells were enriched in mitosis 
after a 10 hour release from a double thymidine block.  The cells were stained for anti- -tubulin 
(red), anti- -tubulin (green) and DAPI for DNA (Fig. 3.4).  SEPT9_v1 (Fig 3.4A and Fig. 3.4B 
bottom panel) promotes chromosome mis-segregation showed by misaligned chromosomes (f-
g), multipolar spindles (h), chromosome lagging (i) and centrosome amplification (k) in 25% of 
cells as compared to empty vector control (Fig 3.4A and Fig 3.4B top panel) (p<0.005).   
High SEPT9_v1 expression promotes cytokinesis failure 
 To assess whether over-expression of SEPT9_v1 can affect cell division, MCF10A-
SEPT9_v1, HPV 4-12-SEPT9_v1 and empty vector controls were stained with anti--tubulin (red) 
and DAPI (blue) for immunofluorescence.  SEPT9_v1 over-expression had a greater effect on cell 
division:  approximately 8-10% of SEPT9_v1 transductants were bi-nucleated as compared to 
empty vector control.  These results suggested that over-expression of the SEPT9_v1 transcript 
is somehow preventing proper cell division at the end of mitosis by disrupting cytoskeleton 










































Fig 3.4: High SEPT9_v1 expression increases mitotic spindle defects  
(A) Ectopic expression of SEPT9_v1 increases mitotic spindle defects in ~30% of MCF10A cells 
as depicted in the graph. Columns, percentage of cells with mitotic spindle defects in three 
independent experiments; bars, SDev. *p<0.005, Student t-test. (B) Immunofluorescence 
studies were used to stain cells for DNA (DAPI; blue), -tubulin (red) and -tubulin (green).  
SEPT9_v1 over-expression promotes mitotic spindle defects as compared to vector control: 
disorganization of the mitotic spindle (a vs f), chromatin outside of the metaphase plate (b vs 
g), multipolar spindles (c vs h), lagging chromosomes at the midbody (d vs i) and centrosome 






Fig 3.5: High SEPT9_v1 expression impacts cell division by increasing multinucleated cells 
(A) Immunofluorescence was used to stain cells for DNA (DAPI; blue) and -tubulin (red).  
Over-expression of SEPT9_v1 increases multinucleated giant cells.  (B) Graph showing that 
~8% of SEPT9_v1-cells become multinucleated as compared to the empty vector control. 





Fig 3.6:  Increased SEPT9_v1 expression showed Aurora A kinase amplification 
(A) MCF10A-SEPT9_v1 and vector control cells were synchronized in mitosis by a 10 hour 
release after a double thymidine block.  Immunofluorescence was used to stain for DNA 
(DAPI; blue), SEPT9_v1 (green) and Aurora A kinase (red).  SEPT9_v1 over-expression 
increased Aurora A kinase foci in mitotic cells (bottom panel) as compared to vector 
control (top panel). (B) SEPT9_v1 transductants show that ~30% of the cells have Aurora A 
kinase amplification. Columns, percentage of cells with >2 foci of three independent 
experiments; bars, SDev. *P<0.0001, Student t-test. 






































High SEPT9_v1 expression promotes increased incidence of micronuclei and nuclear 
fragmentation 
 While analyzing cells by immunofluorescence for mitotic spindle defects or evidence 
cytokinesis failure, novel phenotypes specific to SEPT9_v1 transductants when compared to 
empty vector controls were observed.  MCF10A-SEPT9_v1 transductants demonstrated 
approximately ~4 % of cells with nuclear fragmentation (Fig 3.7A) and ~6 % with micronuclei (Fig 
3.7B).   Even though these phenotypes were found at low frequency, the empty vector controls 
did not demonstrate either of these phenotypes.  The relevance of these phenotypes in term of 
genomic instability and cancer needs to be characterized further; however previous studies have 
associated the presence of micronuclei with loss of DNA material of one or both daughter cells 
during mitosis (115).  
SEPT9_v1 interacts with proteins important in mitosis and cell division 
 To begin examining the mechanism by which SEPT9_v1 promotes genomic instability in 
breast cancer cells, potential SEPT9_v1 interactions with components of the mitotic spindle, 
such as tubulins, and/or proteins involve in the spindle checkpoint, such as MAD2, and 
centrosome specific proteins, such as Aurora A, were tested.  Tubulins are key players of the 
mitotic machinery and cytoskeleton dynamics in mammalian cells, and MAD2 and Aurora A are 
key players in the organization of the spindles and proper chromosome segregation.  Therefore, 
we hypothesized that SEPT9_v1 over-expression affected the expression and/or localization of 
mitotic spindle proteins, which might impact proper cell division or chromosome segregation. 
 Previous studies showed an interaction between septins and tubulins; therefore, to 
explore further the interaction of SEPT9_v1 and -tubulin co-immunoprecipitation and 

















































Fig 3.7: SEPT9_v1 transductants showed nuclear atypia 
Immunofluorescence was used to stain cells for DNA (Dapi; blue) and -tubulin (red).  (A) 
SEPT9_v1 transductants showed nuclear fragmentation in ~4% of the cells as compared to 
the vector control.  (B) SEPT9_v1 increases the presence of micronuclei in ~6% of the cells as 
compared to the vector control.  Three hundred cells were counted per triplicate.  Columns, 








































































Fig 3.8: SEPT9_v1 interacts with components of the mitotic spindle  
(A) SEPT9_v1 co-immunoprecipitated with - tubulin. Whole cell lysates (left panel) from 
vector control (pLNCX2) and SEPT9_v1 transductants were used for immunoprecipitation.  
SEPT9_v1 (middle panel) and -tubulin (right panel) antibodies were used for 
immunoprecipitation and the samples were subsequently immunoblotted for SEPT9_v1 or-
tubulin.  (B) SEPT9_v1 co-immunoprecipitated with -tubulin (second panel), but not with -
actin (third panel) or MAD2 (fourth panel).    Whole cell lysates from vector control (pLNCX2) 
and SEPT9_v1 transductants were used for immunoprecipitation.  The SEPT9_v1 antibody 
was used for immunoprecipitation and the samples were immunoblotted for SEPT9_v1, -
tubulin, -actin and MAD2.  
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transductants and empty vector control cells were subjected to immunoprecipitation analyses 
with the SEPT9_v1 antibody.  Co-immunoprecipitation of -tubulin and SEPT9_v1 was 
confirmed in IHMECs, with a weaker band using empty vector lysates for immunoprecipitation 
and a stronger band with SEPT9_v1 transductant lysates (3.8A).   
 Immunoprecipitated proteins were then probed with anti--tubulin, anti-Aurora A, anti-
MAD2 and anti-CDC20 independently.  SEPT9_v1 did not interact with MAD2, Aurora A, CDC20 
or -Actin.   A signal corresponding to -tubulin was found in whole cell lysates of both vector 
and SEPT9_v1 transductants (Fig 3.8B).  These results indicated that SEPT9_v1 could interact 
with tubulins, suggesting a specific role of SEPT9 _v1 in mitotic spindle assembly during mitosis, 
but not necessarily with components of the mitotic spindle checkpoint.   
Transient expression of Flag-SEPT9_v1 construct was sufficient to increase both aneuploidy 
and cell proliferation 
 Previously, increased expression of SEPT9_v1 was found to accelerate growth kinetics of 
IHMECs by increasing cell proliferation and decreasing apoptotic response (Gonzalez et al. 
2007).  Therefore, I was interested in determining the relationship between cell proliferation 
and aneuploidy phenotypes.  With increasing genomic instability, there is a high frequency of 
loss and gain of chromosomes that can carry genes responsible for regulating cell cycle 
progression and cell proliferation.   To tease apart the connection between aneuploidy and cell 
proliferation, MCF10A and HCT116 cells were transiently transfected with a construct expressing 
Flag-SEPT9_v1 and an empty vector control.  SEPT9_v1 expression was assayed by Western blot 
at different time points post-transfection (Fig 3.9A).  The timepoints were chosen by the 
doubling time of each cell line.  At every time point, metaphases spreads were collected for 
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Fig 3.9: Transient transfection of SEPT9_v1 increases aneuploidy and cell proliferation 
(A) Western blot analysis showing transient expression of an empty vector control and a 
Flag-SEPT9_v1 construct in MCF10A (left) and HCT116 (right).  GAPDH was used as a loading 
control.  (B) Metaphase spreads were counted at each time point after transfection for both 
cell lines, MCF10A (left) and HCT116 (right).  MCF10A and HCT116 transfected with Flag-
SEPT9_v1 showed an increase in aneuploidy up to ~40% of cell lines one time point after 
transfection.  Columns, percentage of aneuploid cells from 25 metaphases in each of three 
independent experiments; bars, SDev. (C) Cell proliferation was assayed using ki67-positive 
cells.  MCF10A cells showed an increase in proliferation of ~ 60% one day post-transfection 
as compared to the empty vector control (left).  HCT116 did not show a significant increase 
in cell proliferation as compared to the vector control (right).  Columns, percentage of ki-67 
positive cells from 300 cells in each of three independent experiments; bars, SDev. 
-Flag 
-GAPDH  
MCF10A             HCT116 
MCF10A             HCT116 
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Western blot analysis showed that for MCF10A the expression of Flag-SEPT9_v1 was reduced 
overtime with no detectable signal on the empty vector control.  Surprisingly, SEPT9_v1 
transient expression increased aneuploidy to ~40% and cell proliferation to ~60% one day post-
transfection (approximately one doubling time) (Fig 3.9B-C; left panel).  Both phenotypes start 
decreasing three days after transfection, similar to the decrease of Flag-SEPT9_v1 expression 
over time as shown by the Western blot.  These data suggested that aneuploidy and cell 
proliferation might be independent of each other and that aneuploidy was not necessarily 
driving tumorigenesis by impacting cell proliferation.  HCT116 studies showed the same pattern; 
approximately 50% of HCT116-SEPT9_v1 cells became aneuploid 12 hours post-transfection 
(one doubling time) (Fig 3.9B; right panel).  Interestingly, HCT116 cells did not show a significant 
difference in proliferation between vector and SEPT9_v1 transfectants (Fig 3.9C), further 
supporting the hypothesis that SEPT9_v1 increases aneuploidy and cell proliferation kinetics via 
different molecular mechanisms.   
SEPT9_v1 impacts cell proliferation, independent of aneuploidy, through a specific c-Jun-N-
Terminal kinase (JNK) interaction 
 SEPT9_v1 expression could impact tumorigenesis in part by its association with signaling 
pathways controlling cell cycle progression and/or cell proliferation.  Previous studies showed 
that SEPT9_v1 stabilized the hypoxic inducible factor alpha (HIF-) and increased cell 
proliferation rates in prostate cancer cells (72).  JNK activation, a critical component of the 
proliferative response, was previously implicated in the induction of HIF-1 and cell cycle 
progression by modulating cyclin expression.  Given the impact of SEPT9_v1 and JNK1, 2 on cell 
proliferation, and the shared ability of SEPT9_v1 and JNK1,2 to regulate HIF-1, we hypothesized 
that increased SEPT9_v1 expression may exert its effects on proliferation via association with 






Fig 3.10: SEPT9_v1 co-immunoprecipitates with JNK1, 2 
(A) Co-immunoprecipitations with a JNK1,2 antibody using whole cell lysates from HPV4-12 
IHMEC cells (left side) and Hs578T breast cancer cells (right side) from both empty vector 
cells and SEPT9_v1 retroviral transductants.  Results show that SEPT9_v1 
immunoprecipitates with JNK1, 2 in both cell lines.  Bottom panels: Western blotting using 
whole cell lysates and the indicated antibodies indicate the amount of starting material 
(“input”) used for the immunoprecipitations. (B) A GST pull-down using a GST-SEPT9_v1 
fusion protein shows an interaction between SEPT9_v1 and ectopically expressed Flag-
tagged JNK. Top panel: Western blotting using a GST antibody shows the presence of the 
GST-SEPT9_v1 fusion protein. Lane number 3 indicates GST-SEPT9_v1 fusion protein 
expression in the bacterial whole cell extract (WCE) as starting material. Bottom panel: 
Western blotting using an anti-Flag antibody to detect Flag-JNK1 shows the interaction 
between GST-SEPT9_v1 and JNK (lane 4). Lane number 1 indicates the expression of Flag-JNK 
in whole cells extracts (WCE) from transfected HPV4-12 cells, indicating the amount of JNK in 
the starting material for the GST pull-down. 
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 To test the hypothesis that altered SEPT9_v1 expression directly affects the JNK 
signaling pathway, we first studied the potential interaction between JNK and SEPT9_v1 by 
immunoprecipitation and immunofluorescence experiments.  We used the immortalized human 
mammary epithelial cell line (IHMEC) HPV4-12, which develops tumorigenic properties after up-
regulation of SEPT9_v1, and the breast cancer cell line Hs578T, which has significantly less  
endogenous SEPT9_v1 expression than HPV4-12, as we were specifically interested in 
mechanisms that may be relevant to malignant progression in breast cancer cells (20).  
 Whole cell lysates from HPV4-12 and Hs578T parental cells and their respective 
retroviral transductants stably expressing SEPT9_v1 were subjected to immunoprecipitation 
experiments using an anti-JNK1,2 antibody that recognizes both JNK1 and JNK2.  
Immunoprecipitated proteins were probed with an anti-SEPT9_v1 antibody.  We found a strong 
specific signal corresponding to the SEPT9_v1 isoform in whole cell lysates from cells expressing 
exogenous and endogenous SEPT9_v1 immunoprecipitated with anti-JNK1, 2 antibodies (Fig 
3.10 A).  These results suggested that SEPT9_v1 could interact with JNK proteins. 
 To provide additional evidence of this interaction we performed GST pull-down 
experiments using a purified GST-SEPT9_v1 fusion protein and whole cell lysates from HPV4-12 
cells transiently transfected with a construct for Flag-tagged JNK2.  The results shown in Figure 
3.10B demonstrated that JNK1 and SEPT9_v1 also interact in vitro. 
SEPT9_v1 stabilizes JNK in mammary epithelial cells 
      To determine if SEPT9_v1 expression had any effect on JNK1,2 protein levels. As shown, 
increased SEPT9_v1 expression did not alter significantly alter the steady state JNK1,2 protein 
levels (Fig 3.10, input). Therefore, we hypothesized that SEPT9_v1 modified JNK1 and/or JNK2 
either post-transcriptionally or posttranslationally.  We studied the effects on JNK1,2 protein 
stability by using cycloheximide. Since cycloheximide inhibits new protein synthesis, JNK1,2 
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Fig 3.11: Up-regulation of SEPT9_v1 in HPV 4-12 immortalized human mammary epithelial 
cells, stabilizes JNK expression and increases JNK kinase activity in vitro 
(A) Left panel: SEPT9_v1 stabilizes JNK1,2 protein levels. Western blotting for JNK1,2 protein 
levels at various timepoints during cycloheximide treatment in cells without (left) or with 
(right) stably expressed exogenous SEPT9_v1. β Actin was used as loading control. Right 
panel: A graphical representation of the data from the left panel, as determined by 
densitometry, highlights how SEPT9_v1 over-expression stabilized JNK1,2 within the cells. 
Within less than 30 min of exposure to cycloheximide, JNK1, 2 (♦) protein levels in HPV4-
12+pLPCX cells were decreased by 50%. In cells transduced with SEPT9_v1, JNK1, 2 (▲) 
protein levels remained constant and did not decrease until 60 min of cycloheximide 
exposure (B) An in vitro kinase assay shows that SEPT9_v1 up-regulation increases JNK 
activity as indicated by increased levels of phosphorylated c-Jun in unstressed and UV-
treated cells. Left panel: Whole cell extracts (input) show the initial endogenous JNK1, 2 
levels in the cells used for the kinase assay. Right panel: Cell extracts (250 µg of protein), 
were incubated with glutathione beads containing 1 µg of GST-c-Jun (1–79) fusion protein. 
Phosphorylated substrate was detected by SDS–PAGE and immunoblotting using phospho-
specific c-Jun antibody. Quantification of the JNK1,2 kinase activity was performed by 
densitometric scanning showing that up-regulation of SEPT9_v1 caused a 7-fold increased 
induction of c-Jun phosphorylation in unstressed cells compared to parental and empty 








Fig 3.12: Up-regulation of SEPT9_v1 in HPV 4-12 immortalized human mammary epithelial 
cells increases JNK kinase activity in vivo 
(A) The in vivo JNK kinase assay was validated for JNK specificity by transiently transfecting 
HPV4-12 cells with a well-characterized JNK inducer, pMEKK1 or by inhibiting JNK activity 
with the chemical inhibitor, SP600125. JNK kinase activity was induced by more than 
threefold with the pMEKK1 activator and the JNK inhibitor, SP600125, inhibited JNK kinase 
activity by 12 fold in HPV4-12 cells.  (B) In vivo kinase assay shows SEPT9_v1 up-regulation 
increases JNK activity. Up-regulation of SEPT9_v1 in HPV4-12 and MCF10A IHMEC cells 
caused an induction of phosphorylated c-Jun-mediated reporter gene (Luciferase) expression 
primarily by the JNK pathway using the c-Jun Translucent in-vivo Kinase Assay Kit. The plot 
for this luciferase assay shows that SEPT9_v1 causes an increase of JNK1,2 kinase activity 
towards c-Jun by more than four-fold in HPV4-12 cells. SEPT9_v3 causes only a moderate 
increase in JNK1,2 kinase activity in vivo (ns: nonsignificant *p<0.001, **p<0.0001; Student's 
t-test).  (D) SEPT9_v1 over-expression increases the expression of phosphorylated c-Jun 
target genes (the JNK/c-Jun signaling transcriptome) that have an AP-1 enhancer element. 
Cells were transiently transfected with the pTAL-Luc vector used as a negative control or the 
pAP1-Luc vector containing the cis acting enhancer AP1 element and pRL-TK, a plasmid 
containing the Renilla Luciferase reporter. Compared to the empty vector control, up-
regulation of SEPT9_v1 doubled the expression of the reporter construct when compared to 
HPV4-12 parental and empty vector controls. SEPT9_v3 up-regulation had an insignificant 
effect when compared to the empty vector control. In MCF10A cells, compared to empty 
vector control SEPT9_v1 up-regulation doubled the expression of the reporter construct or c-
Jun activated transcription and SEPT9_v3 had a milder but significant effect (ns: non 
significant, *p<0.05, **p<0.01; Student's t-test). 
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levels over time would predominantly reflect the degradation process.  HPV 4-12 clones 
stably expressing the retrovirally transduced pLPCX empty vector or SEPT9_v1 constructs 
were exposed to cyclohexidimide across various time points and JNK protein levels were 
subsequently analyzed by Western blot.  Within 30 minutes of exposure to cycloheximide, 
JNK1,2 protein levels in control cells were decreased by 50% as analyzed by Western blot 
(Fig 3.11A).  However, Within in exogenously expressing SEPT9_v1 cells, JNK1,2 protein 
levels did not decrease to 50% levels until 60 minutes of cycloheximide exposure.  This 
data suggested that SEPT9_v1 is likely involved in cellular processes that regulate the 
stability and degradation of JNK1,2 proteins.  
SEPT9_v1 up-regulation increases JNK kinase activity in vivo and in vitro  
       To examine further the effects of SEPT9_v1 up-regulation on JNK1, 2 signaling in 
unstressed cells, we tested JNK1,2 kinase activity in HPV4-12 cells stably transduced with 
SEPT9_v1 or SEPT9_v3 isoforms, compared to the parental and empty vector controls.  
Strikingly, the ectopic expression of SEPT9_v1 caused an approximate seven-fold increase 
in c-Jun phosphorylation by JNK1,2 in unstressed cells (Fig 3.11B).  Interestingly, even 
though SEPT9_v3 was also able to interact with JNK1,2 similar to SEPT9_v1 (data not 
shown) over-expression of the SEPT9_v3 isoform did not enhance JNK1,2 kinase activity 
(Fig. 3.11B).  This indicates that SEPT9_v1’s extended unique amino terminus, which 
consists of 25 unique amino acids when compared to the otherwise identical SEPT9_v3 
isoform, is likely involved in the SEPT9 associated activation of JNK1,2.  To quantify and 
further explore these findings, we used an in vivo JNK kinase assay where c-Jun binding 
sites are located in the promoter upstream of a Luciferase reporter.  HPV4-12 cells stably 
expressing the empty vector, SEPT9_v1, or SEPT9_v3 isoforms were transiently co-
transfected with the reporter luciferase plasmid and the in vivo kinase vector pTAD-cJun, 
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 which contains a transcriptional activator specific for the JNK 
signaling pathway.  This in vivo kinase assay was validated by 
transiently transfecting HPV4-12 cells with pMEKK1, which 
induced the   
 
  
Fig 3.13: Increased SEPT9_v1 expression results in amplified expression of cyclin D1 and B1.   
(A) Western blot shows that asynchronous HPV4-12 cells exogenously expressing SEPT9_v1 
had higher levels of cyclin D1 expression and a 10-fold increase in phosphorylated cyclin D1 
when compared to the controls.  The top panel indicates the amount of phosphorylated c-
Jun present in the cells, as previously shown in Figure 3B, while the remaining panels are 
whole cell lysates.  β-Actin was used for a loading control.  (B) A graphical representation of 
data from real-time quantitative RT-PCR shows that CCND1 (cyclin D1) expression is 
approximately doubled in HPV4-12 cells exogenously expressing SEPT9_v1 when compared 
to controls.  Relative mRNA expression of CCND1 was determined against the GAPDH control 
(*p<0.05; Student’s t-test).  (C) SEPT9_v1 over-expression results in elevated Cyclin D1 and 
Cyclin B1 levels in synchronized cells.  Western blot analysis was performed for cyclin 
expression in whole cell lysates from cells synchronized at the G1/S boundary using a double 
thymidine block.  HPV4-12 parental, empty vector control cells and SEPT9_v1 stable 
transductants were analyzed for the expression profile of several cyclin proteins.  SEPT9_v1 
over-expressing cells had nearly double the amount of Cyclin D1 protein and a 2.5-fold 
increase in Cyclin B1 levels as determined by densitometry.  β-Actin expression was used as a 
loading control.   
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which contains a transcriptional activator specific for the JNK signaling pathway.  This in vivo 
kinase assay was validated by transiently transfecting HPV4-12 cells with pMEKK1, which 
induced the JNK kinase activity more than 3-fold, and also by treating the cells with a well 
characterized JNK inhibitor, SP600125, which inhibited JNK kinase activity by 12-fold (Fig 3.12A).  
Quantitative data obtained with this dual reporter Luciferase system are shown in Figure 3.12B.  
In one immortalized human mammary epithelial cell line, MCF10A cells, SEPT9_v3 did not 
significantly increase reporter expression compared to controls although SEPT9_v1 did.  Up-
regulation of SEPT9_v1 and SEPT9_v3 in HPV4-12 cells significantly activated the kinase activity, 
as determined by the endpoint of Luciferase expression, by more than 5-fold and 3-fold, 
respectively, when compared to the HPV 4-12 cells with empty vector control (p<0.001; 
Student’s t-test).   
 SEPT9_v1 Expression Amplifies JNK/c-Jun Signaling  
       The mechanism by which SEPT9_v1 mediates its tumorigenic properties via JNK1,2 
activation, leading to c-Jun induction, may include the transcriptional up-regulation of c-Jun 
target gene expression.  Transcriptional activity was measured by transiently co-transfecting 
cells with pRL-TK, expressing Renilla luciferase, and either a reporter plasmid containing the 
luciferase gene under a cis-acting enhancer AP-1 element (pAP1-Luc) or a negative control to 
determine the background signals associated with the culture medium and reporter activity 
(pTAL-Luc).  The difference between the two reporters was used to determine differences in 
transcription activity.  SEPT9_v3 up-regulation had an insignificant effect on transcriptional 
activity when compared to empty vector controls.  However, up-regulation of SEPT9_v1 
increased the reporter gene expression, or c-jun activated transcription, more than two fold 
when compared to empty vector controls (Fig 3.12C, p=0.05; Student’s t-test).  This data, 






suggests that the unique N-termini between the two SEPT9 isoforms have dif 
 
  
Fi  3.14: Up-reg lated expression of SEPT9_v1 contribute  to JNK1,2-mediated pro-
proliferative effects in mammary epithelial cells. 
(A) Cell cycle histograms generated by FACS analysis of parental HPV4-12 cells, the empty 
vector negative controls (pLPCX), and SEPT9_v1 transductants after releasing the cells from 
G1/S synchronization via double thymidine block.  (B) Quantification of the data in panel (A) 
represents the percentage of cells in each phase of the cell cycle for each time point for each 
of the cell lines.  SEPT9_v1 promotes cell cycle progression when it is up-regulated, 
compared to parental and vector control.  HPV4-12 cells exogenously expressing SEPT9_v1 
progressed to the S phase (5 hours after release), entered into G2, (7 hour post-release), and 
entered the next cycle (15 hours after release) faster than the controls.  (C) Up-regulation of 
SEPT9_v1 induced higher levels of phosphorylated c-Jun, cyclin D1 and cyclin B1 at earlier 
stages of the cells cycle.  Western blot analysis was used to determine the levels of 
SEPT9_v1, phosphorylated c-Jun, cyclin D1 and cyclin B1 at different time points after release 
from double thymidine synchronization for the empty vector controls and SEPT9_v1 
transductants of HPV4-12 cells.  Also note that endogenous SEPT9_v1 expression steadily 
increases following release from synchronization as the cells enter the G2 and M phases of 
the cell cycle.  The samples and time points studied here were collected at the same time as 
those used for subpanels (A) and (B).  β Actin and GAPDH were used as loading controls. 
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unique N-termini between the two SEPT9 isoforms have different abilities to regulate the JNK 
signaling pathway.  For this reason, we decided to focus our remaining studies on the effects of 
SEPT9_v1 on JNK signaling.  We decided to include SEPT9_v3 in subsequent assays as a 
comparison to the effects of SEPT9_v1 up-regulation in this pathway.    
Up-regulation of SEPT9_v1 Increases the Expression of Cyclin D1, a c-Jun Target Gene, at the 
Protein and mRNA Levels     
      The gene encoding cyclin D1 (CCND1) has emerged as an important target for the JNK/c-Jun 
pathway in driving cell proliferation (130, 131).  Ectopic expression of c-Jun induces expression 
of CCND1 through an AP-1 site in the promoter, which in turn is critical in driving G0 to G1 cell 
cycle progression   (132, 133).    
      We therefore investigated whether the enhanced transcriptional activity of the JNK1,2 
signaling pathway, as a result of SEPT9_v1 over-expression, increases cyclin D1 levels in human 
mammary epithelial cells.  Whole cell extracts of parental HPV4-12 cells, empty vector controls, 
and SEPT9_v1 over-expressing stable transductants were analyzed by Western blotting and 
probed with anti-cyclin D1, anti-phospho-cyclin D1 (Thr 286), and anti-cyclin E antibodies.  The 
same lysates used in the JNK Kinase assays and immunoprecipitation experiments were used for 
profiling the expression of various cyclin proteins to reproduce the testing conditions in 
unstressed cells.  Asynchronous SEPT9_v1 expressing cells showed higher levels of cyclin D1 
expression and a 10-fold increase in phosphorylated cyclin D1 when compared to the controls 
(Fig 3.13A).  As demonstrated in Fig 3.13, cells with high SEPT9_v1 expression have increased 
cyclin D1 levels as compared to controls, and phosphorylated cyclin D1 was also increased. 
Phosphorylation of cyclin D1 results in proteosomal degradation and a subsequent decline in its 
protein levels, which is necessary for the progression of the cell cycle from G1 to S.  Through its 
interaction with JNK proteins, high SEPT9_v1 expression may be affecting protein kinetics, by 
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having more cyclin D1 molecules available, there are also more molecules to  phosphorylate and 
target to the proteosome (134).   Further studies are necessary to determine if SEPT9_v1 is 
directly controlling the levels of cyclin D1 phosphorylation or affecting the expression of kinases 
responsible for the phosphorylation.  This finding agrees with the enhanced transcription from 
the luciferase reporter assay following SEPT9_v1 over-expression described in Figure 3.12C.  
Cyclin E expression was relatively unchanged in cells over-expressing SEPT9_v1.  However, the 
high endogenous expression of cyclin E we observed in this human mammary epithelial cell line 
is consistent with previously described data showing that high levels of cyclin E expression is a 
consequence of the immortalization process, which precludes further up-regulation of this cyclin 
or our ability detect any subtle changes in cyclin E levels (135).   
        Confirmation of SEPT9_v1 activating transcription of the downstream targets of the JNK/c-
Jun signaling pathway was achieved by determining the CCNDI mRNA relative expression 
compared to the GAPDH control, using quantitative RT-PCR.  We found nearly a 2-fold increase 
in CCNDI expression in HPV4-12 cells expressing the SEPT9_v1 construct (Fig 3.13B). 
SEPT9_v1 Up-regulation Correlates with Higher Cyclin Levels in the G1/S Phase of the Cell 
Cycle  
        Evidence to date indicates that up-regulation of cyclin D1 after the activating 
phosphorylation of c-Jun on residues Ser63 and Pro73 plays an important role in cell 
proliferation (128, 136).  Cyclin D1 serves as a key sensor and integrator of cellular signals in 
early to mid-G1 phase (136, 137).  We studied the consequences of SEPT9_v1 up-regulation in 
G1/S cells synchronized using a double thymidine block method.  Whole cell lysates of 
synchronized HPV4-12 parental, empty vector controls, SEPT9_v1 and SEPT9_v3 stable 
transductants were analyzed by Western blotting for the expression profile of several cyclin 
proteins.  No significant changes were noted when SEPT9_v3 was expressed.  Likewise, cyclin E 
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expression was the same in all of the cells regardless of the SEPT9 isoform expression or the cell 
stage as seen earlier in asynchronous cultures (Fig. 3.13A and C).  Cells exogenously expressing 
SEPT9_v1 had nearly double the amount of Cyclin D1 protein and a 2.5-fold increase in Cyclin B1 
levels (Fig 3.13C).  
Up-regulated Expression of SEPT9_v1 Contributes to JNK Pro-proliferative Effects in Mammary 
Epithelial Cells 
  We wanted to clarify the biological significance of the deregulation of SEPT9_v1 
expression towards JNK kinase activity during the cell cycle.  We hypothesized that increased 
SEPT9_v1 expression promoted cell cycle progression, possibly caused by the interaction with its 
binding partner, JNK1,2, thereby provoking the alteration in the JNK/c-Jun transcriptome.  First, 
we studied the cell cycle histogram by FACS analysis of parental HPV4-12, the empty vector 
negative controls (pLPCX), SEPT9_v1 and SEPT9_v3 transductants after releasing the cells from 
G1 synchronization.  We found a promotion of the cell cycle progression when SEPT9_v1 is up-
regulated, compared to parental and vector control (Fig 3.14A).  HPV 4-12 cells progressed to 
the S phase (5 hours after release), entered into G2, (7 hours post-release), and entered the 
next cycle (15 hours after release) faster than the controls.  A quantification of these data, as 
shown in Figures 3.14B, represents the percentage of cells in each phase of the cell cycle for 
each time point.   
 In order to investigate the potential physiological relevance of SEPT9_v1 up-regulation 
in mammary epithelial cells at different cell cycle phases, we determined the levels of SEPT9_v1, 
phosphorylated c-Jun, cyclin D1 and cyclin B1 at different time points after release from 
synchronization for the empty vector controls and SEPT9_v1 transductants of HPV4-12 and 
Hs578T cells.  Western blotting showed that up-regulation of SEPT9_v1 induced higher levels of 
phosphorylated c-Jun, Cyclin D1 and Cyclin B1 at earlier stages of the cells cycle (Fig 3.14C).  The 
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time points studied here correlated with the cell cycle histogram and the percentage of cells at 
each cell cycle stage mentioned above.  
 Together, these data suggests that when SEPT9_v1 expression is up-regulated, as seen 
in breast cancer cell lines and primary breast cancers, SEPT9_v1 could hyper-activate the JNK 
signaling pathway, causing up-regulated expression of the downstream target genes, such as 
cyclin D1 (131).  This would ultimately push the cells through the cell cycle at a faster rate. 
Discussion 
 We explored in further detail the roles of SEPT9_v1 in tumorigenesis by describing two 
independent mechanisms impacting genomic instability and cell proliferation.  First, SEPT9_v1 
was found to increase genomic instability in mammary epithelial cells by effects on chromosome 
segregation defects and cytokinesis failure.  In fact, when metaphase spreads of cells with high 
SEPT9_v1 were categorized by the number of extra chromosomes, a bimodal distribution was 
observed, with a population of cells with ploidy status close to tetraploidy and another 
population with more generalized aneuploidy.  This suggested the possibility of two types of 
mitotic errors promoted by high SEPT9_v1 expression, mitotic spindle defects and failure to 
complete cell division at cytokinesis.  A close look at mitotic cells showed that deregulation of 
SEPT9_v1 expression promotes mitotic spindle defects associated with chromosome mis-
segregation including disorganization of the chromatin in respect to the mitotic spindles, 
multipolar spindles, and chromosome lagging during telophase.  In addition, a small but 
significant population of SEPT9_v1 over-expressing cells became bi-nucleated demonstrating a 
failure of faithful division (cytokinesis) into two daughter cells.  Interestingly, over-expression of 
SEPT9_v3, an isoform that differs from SEPT9_v1 by 25 amino acids at the N terminus, also 
increased genomic instability in mammary epithelial cells, but the mechanisms seemed to be 
more specific to defects in cytokinesis, because the ploidy status of these cells were 
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predominantly tetraploid.  Different SEPT9 isoforms appear to have specific functional roles 
affecting different cellular processes by specific protein interactions, temporal-specific 
expression and/or cellular localization dictated possibly by the subtle differences in sequence.   
   Indeed, the cellular localization and protein interactions of these two SEPT9 isoforms 
are distinct.  SEPT9_v1 cellular localization was mainly cytoplasmic with partial localization of 
the nucleus in mammary epithelial cells.  SEPT9_v1 was found to co-localize with -tubulin 
filaments in contrast with SEPT9_v3 which mainly localized to the plasma membrane and co-
localized with F-actin filaments.  Mitotic cells from SEPT9_v3 did not show significant gross 
mitotic spindle defects and/or chromosome mis-segregation, supporting the view that SEPT9_v3 
impacts genomic instability by affecting cytokinesis, without major effects on the mitotic spindle 
machinery.  
 It was important to determine whether SEPT9_v1 affected general mitotic spindle 
assembly and function or interferes with proper regulation of the mitotic spindle checkpoint.  
Several candidates for protein interaction were assayed, and interactions with -tubulin and -
tubulin were observed by immunoprecipitation.  Interactions with components of the 
checkpoint were negative, suggesting that SEPT9_v1 might affect mitotic spindle dynamics 
and/or organization by interacting with tubulins which are major components of spindle 
microtubules and microtubule organizer center (MTOC), or centrosomes.  This is supported by 
previous studies that showed that SEPT9_v1 localized with microtubules at the midplane in 
metaphase during mitosis and in the midbody and cleavage furrow during cytokinesis (23, 24).  
Additional studies are needed to support these initial observations.    
 Previous studies have shown that knockdown of septins, including SEPT9 isoforms, 
resulted in cytokinesis defects and chromosome mis-segregation.  In this study we presented an 
over-expression model of SEPT9 showing similar phenotypes, which supported the idea that the 
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expression and localization of septins needs to be tightly regulated in order to perform their 
normal functional roles in epithelial cells.  When expression of septins is deregulated or the 
equilibrium between isoforms is altered, either by knockdown or over-expression, it could lead 
to the same phenotypes seen in this study.  In fact a widely accepted theory in septins’ research 
is that these proteins exert their functions by forming heterocomplexes and that the disruption 
of normal ratios of septins in the complex may change their functional dynamics in the cells.  
 Genomic instability can affect the overall equilibrium of cells between cell proliferation 
and apoptosis, cell cycle progression, and mitosis in general.  Trying to understand the cellular 
context in which high expression of SEPT9_v1 impacted genomic instability and high cell 
proliferation in mammary epithelial cells, analysis of the effects of ectopic expression of 
SEPT9_v1 overtime was performed.  The goal was to determine if there was a temporal 
relationship between the different phenotypes after SEPT9_v1 expression.  Specifically, I 
decided to explore the possibility that cell proliferation would increase after the establishment 
of aneuploidy or if these phenotypes could arise independently, which would have suggested 
that SEPT9_v1 is associated with different cellular mechanisms and signaling pathways.  As 
shown earlier, after transient expression of SEPT9_v1 both phenotypes arose simultaneously 
and as early as one doubling time after transfection.  This pattern was shown more clearly with 
the MCF10A cell line, but even though HCT116 showed a clear increase in aneuploidy, cell 
proliferation did not change as much during time, which actually supports the idea that these 
two phenotypes are affected by SEPT9_v1 expression via two different mechanisms. 
Given that SEPT9_v1 and JNK1, 2 impacted cell proliferation and they shared the ability 
to regulate HIF-1, which at the same time regulates cell proliferation and survival in response to 
oxygen levels, we hypothesized a crosstalk relevant to cell proliferation between these proteins.  
A potential interaction between SEPT9_v1 and JNK to try to understand better the role of 
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SEPT9_v1 in cell proliferation in mammary epithelial cells seemed important to explore.  In 
trying to elucidate the mechanism by which SEPT9_v1 increased cell proliferation, a novel 
connection with the JNK signaling pathway was found.  SEPT9_v1 interacted with c-Jun-N-
terminal kinase, stabilizing it and increasing its transcriptional activation of target Ap1 promoter 
genes such as cyclin D1 and cyclin B1 in unstressed cells.  The SEPT9_v1-JNK connection showed 
that SEPT9_v1 over-expression accelerated cell cycle progression and consequently cell 
proliferation.  Interestingly, retroviral expression of the SEPT9_v1 isoform consistently had 
stronger affects on JNK signaling and c-Jun transcription activation when compared to retroviral 
expression of the SEPT9_v3 isoform, a protein identical to SEPT9_v1 except for 25 amino acids 
at the N-terminus.  This was in agreement with previously discussed data that retroviral 
expression of the full-length SEPT9_v1 variant resulted in the striking development of oncogenic 
phenotypes when expressed in breast cells as compared to the retroviral expression of 
SEPT9_v3 (20).  As previously mentioned, only 25 N-terminal amino acids differentiate these two 
isoforms; this suggests that these residues are crucial for the contrasting regulation of JNK1,2 
signaling between these two isoforms.  This is not the first time that a difference in SEPT9 
isoforms has been noted.  For example SEPT9_v4 and SEPT9_v4* differ only in their 5’ 
untranslated regions, but only SEPT9_v4* is differentially expressed in cancers compared to 
normal tissue (76, 77).  More relevant to the isoforms discussed in this study was the finding 
that SEPT9_v3, but not SEPT9_v1, interacts with a Rho-guanine nucleotide exchange factor (GEF) 
along with actin stress fibers and inhibits Rho signaling activation (89, 90).   
   Our data correlated with previous reports in which the cyclin D1 gene, CCND1, has 
emerged as an important target of the JNK/c-Jun-AP1 pathway in driving proliferation (130, 
131).  This suggested that the up-regulation of SEPT9_v1 induced hyper-proliferation by a 
signaling mechanism involving JNK stabilization, but mediators or other components upstream 
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of SEPT9_v1 have yet to be identified.  We propose that the JNK/c-Jun/AP-1 pathway and its 
downstream target genes are relevant physiological targets of SEPT9_v1 as their up-regulation 
gave a proliferative advantage to the cells by making them cycle faster through the G1 phase of 
the cell cycle and altered the expression pattern of regulatory cyclin proteins, including cyclin D1 
and cyclin B1.   
Taken together, our data showed a novel association of SEPT9_v1 with the JNK1,2 
signaling pathway, an important signaling pathway that regulates cellular proliferation among 
other cellular roles.  This further supported the hypothesized role of SEPT9 in cell signaling 
pathways that regulate cellular proliferation as previously suggested by studies of SEPT9_v1 and 
its association with HIF-1 alpha (72).  A proposed model of the mechanism by which SEPT9_v1 
expression in breast cancer cells may impair cell cycle regulation, resulting in the increased 
transcription of key cyclins that drive progression through the cell cycle is shown in Figure 3.15.   
 Here it is demonstrated that deregulation of SEPT9 isoforms affects different cellular 
mechanisms.  The resulting cellular phenotypes, or the severity of them, may vary depending on 
which isoform is affected.  In this case, SEPT9_v1 and SEPT9_v3 both seem to increase genomic 
instability in mammary epithelial cells.  Interestingly, SEPT9_v1 affects proper function of the 
mitotic spindle and the completion of cytokinesis by interacting with some important 
components of the cytoskeleton, but SEPT9_v3 seems to largely control the cytokinesis event 
during mitosis.  In fact, cytoskeletal interactions between the two isoforms were somewhat 
different and specific.  In addition, it was found that, for at least two oncogenic phenotypes, cell 
proliferation and genomic instability due to high SEPT9_v1 expression, the results could be 
explained with two distinct mechanisms involving the JNK pathway and the cytoskeleton 
dynamics, respectively.  How SEPT9_v1 performs its diverse functions is still puzzling.  There is 
still the possibility that septins are scaffolding proteins involved in the recruitment of other 
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cytoskeletal proteins to their site of action and/or their potential role as signaling GTPases.  
Another key factor is SEPT9_v1 localization; there is evidence of cytoplasmic and nuclear 
localization raising the possibility that it shuttles in and out of the nucleus.  Further analysis of 
these observations will be important for elucidating the complex and distinct functions of 
SEPT9_v1 in breast tumorigenesis.   
 This study also demonstrated two intrinsic properties of SEPT9 isoforms.  First, different 
isoforms seems to have specific functions and deregulation of their expression gave rise to 
different phenotypes such as genomic instability and cell proliferation.  Second, the mechanism 
by which over-expression of SEPT9 isoforms, at least for SEPT9_v1 and SEPT9_v3, promoted the 
development of these phenotypes are discernable and probably dependent on cellular 
localization and cell cycle stage.  Future experiments analyzing the functional domains of 
SEPT9_v1 and spatial and temporal expression studies are essential to understanding the 
specific functional role of SEPT9_v1 in mammary tumorigenesis as a promoter of cancer 





Fig 3.15: Proposed model for the mechanism by which increased SEPT9_v1 expression 
results in increased cell proliferation, a hallmark of cancer cells 
SEPT9_v1 stabilizes JNK1,2 kinase, allowing the JNK kinases to activate c-Jun by 
phosphorylation.  c-Jun activity thus is not properly regulated and induces AP-1 mediated 
transcription of cyclin D1, and other AP-1 controlled target genes, to cause increased 
proliferation and “faster” movement through the cell cycle.  In an unidentified, or related, 
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 Septins are a highly conserved family of GTP binding cytoskeletal proteins implicated in 
multiple cellular functions including membrane transport, apoptosis, cell polarity, cell cycle 
regulation, cytokinesis, and oncogenesis.  This work describes the characterization of a novel 
interacting partner of the septin family, initially cloned from a human testis expression library 
following yeast two-hybrid isolation to identify SEPT9 binding partners.  Upon further genomic 
characterization and bioinformatics analyses, it was determined that this novel septin-
interacting partner was also a new member of the mammalian septin family, named SEPT14.  
SEPT14 maps to 7p11.2 in humans and includes a conserved GTPase domain and a carboxy-
terminus coil-coiled domain characteristic of other septins.  Three potential translational start 
methionines were identified by 5’ RACE-PCR encoding proteins of 432, 427 and 425-residue 
peptides, respectively.  SEPT14 shares closest homology to SEPT10, a human dendritic septin, 
and limited homology to SEPT9 isoforms.  SEPT14 co-localized with SEPT9 when co-expressed in 
cell lines and epitope-tagged forms of these proteins co-immunoprecipitated.  Moreover, 
SEPT14 was co-immunoprecipitated from rat testes using SEPT9 antibodies and yeast two-
hybrid analysis suggested SEPT14 interactions with nine additional septins.  Multi-tissue 
Northern blotting showed testis-specific expression of a single 5.0 kb SEPT14 transcript.  RT-PCR 
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analysis revealed that SEPT14 was not detectable in normal or cancerous ovarian, breast, 
prostate, bladder or kidney cell lines, and was only faintly detected in fetal liver, tonsil and 
thymus samples.  Interestingly, SEPT14 was expressed in testis but not testicular cancer cell lines 
by RT-PCR.  Additional expression and functional analyses are essential to understand the 





Unraveling the functional role of septins in mammalian cells will depend upon studying 
the formation of hetero-oligomers with members of their own family and other protein 
interactions.  In fact, recent studies showed for the first time that human septins form hexamers 
composed of two molecules of each mediated by both GTP-GDP and Nterm-Cterm interphases 
as shown by the SEPT2-SEPT6-SEPT7 complex (7).  These hexamers might be the structural 
conformation of septins while they exert their biological roles and by which they mediate 
dynamic interactions with other filamentous proteins.  In fact, it is known that animal septins, 
similar to yeast septins, can form polymeric actin-associated filaments and interact with other 
cytoskeletal and filamentous proteins such as myosin and tubulins, supporting their roles in 
cytokinesis, cell morphology, cell motility and polarity, and dynamic scaffolds(138).   
In humans, 13 septin genes have been characterized since 1997 (SEPT1-SEPT13) 
including SEPT9 which was mapped in our lab to a region of allelic imbalance in breast cancers 
on chromosome 17q25 (74).  In an effort to further understand SEPT9’s roles in normal cellular 
functions and oncogenesis, we sought to identify novel interacting partners.  Important to 
mention is that finding interacting proteins of septins has been challenging due to the 
complexity of their oligomers and their potential redundancy in mammalian cells.  One example 
that shows the intrinsic structural complexity and organization of mammalian septins was 
presented by Nagata et al. in which they found at least five septins, Sept2, Sept7, Sept8, Sept9b 
(SEPT9_v3), and Sept11, in septin complexes affinity-purified with an anti-Sept7 antibody-
conjugated column from rat embryonic fibroblast REF52 cells (139).  Importantly, 
immunofluorescence studies revealed co-localization of Sept7, Sept9b, and Sept11 along stress 
fibers and biochemical and immunoprecipitation analyses revealed that the three septins 
directly bind with each other through their N- or C-terminal divergent regions (139).  These 
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septins formed distinct and characteristic filament structures when transiently expressed in 
COS7 cells.  When only two of the three were co-expressed, changes in filament enlongation, 
bundling or disruption were observed.  Taken together, these results suggest that septin 
filament structures may be affected by interactions with other septins included in the complex 
(139).  In addition to this, we have to consider that the SEPT9 locus encodes for at least 7 
isofoms, which are expressed ubiquitiously in human cells.   
With this in mind, I describe herein the identification of a novel septin, SEPT14, by yeast 
two-hybrid analysis with SEPT9.  The characterization of its genomic organization, phylogenetic 
relationship to other human septins, expression profile, cellular localization and interaction with 
other septins is described in order to begin elucidating its function.   
Materials and Methods 
Plasmid construction   
 PCR products encoding full-length coding regions of MSF/SEPT9 isoforms were amplified 
from normal breast cDNA and TA subcloned into pCR-XL-TOPO (Invitrogen Corporation).  These 
TA-MSF/SEPT9 constructs were subsequently used as PCR templates with primers designed to 
add flanking 5’ NdeI and 3’ XmaI sites to the MSF/SEPT9 specific sequences.  Ligation of the 
NdeI-XmaI digested PCR product into yeast vectors included with the Matchmaker GAL4 Two-
Hybrid System 3 (BD Biosciences, San Diego, CA) produced an in-frame MSF/SEPT9 carboxy-
terminus fusion protein product with either the plasmid-encoded GAL4 binding domain or c-Myc 
sequences (pGBKT7).  All PCR products were resolved on 1.0% agarose gels, excised, and 
purified through QIAquick Spin Columns (Qiagen Inc., Valencia, CA) before subcloning, and all 
plasmids were sequenced at The University of Michigan Sequencing Core to confirm the 
absence of Taq polymerase induced errors before proceeding. 
In vitro transcription/translation  
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 SEPT14 cDNA starting at three different potential start site methionines was subcloned 
into the T7 promoter plasmid pCR-XL-TOPO by TA cloning following manufacturer’s instructions 
(Invitrogen Inc.).  Each plasmid SEPT14 –M1, -M2 and –M3 was used with the TNT® Quick 
Coupled Transcription/Translation System (Promega) following manufacturer’s instructions.  
Briefly, 0.5 ug of each plasmid was combined with 40ul TNT T7 Quick Master Mix, 1ul of 
Methionine 1mM, 1-2ul of Transcend™ Biotin-Lysyl-tRNA and nuclease-free water for a 50 ul 
reaction.  The reaction was incubated at 30 °C for 90 minutes.  SEPT14-M1 antisense plasmid 
was used as a negative control and a T7 promoter Luciferase plasmid was used as a positive 
control for the assay.  Then, samples were analyzed by SDS-PAGE using a 4-15% Tris HCL 
acrylamide gel.  Samples were transferred to a PVDF membrane using the Transblot SD Semidry 
blot system (BioRad) for 45 minutes.  Then, the membrane was incubated for 1 hour with 
TBS+0.5% Tween® 20 (TBST), followed by a one hour incubation with a 1:10,000 dilution of 
Streptavidin-HRP conjugated in TBST.  Then the membrane was washed 3 times with TBST and 3 
times with water.  To detect the products, 2.5 ml of Transcend™ Chemiluminescent Substrate A 
and 2.5ml of Substrate B were mixed and added to the PVDF membrane for one minute.  The 
blot was exposed to Kodak X-Omat AR X-ray film for different exposure times.  Finally, the film 
was developed in a Konika-Minolta SRX-101A developer.   
Site-directed mutagenesis  
 SEPT9-M1 and –M2 methionines were mutated to leucines using QuickChange® XL Site-
Directed Mutagenesis Kit (Stratagene®) following manufacturer’s instructions.  The following 
primers were used with the SEPT14-M1 plasmid to mutate M2 and M3 methionines: forward: 
5’–GGCAGAAAGAACACTGGCTCTGCCCACACAAATACC-3’ and reverse: 5’-
GGTATTTGTGTGGGCAGAGCCAGAGCCAGTGTTCTTTCTGCC-3’, and to mutate the –M3 
methionine in the SEPT14-M2 plasmid the primers used were forward: 5’-
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GGCAGAAAGAACAATGGCTCTGCCCACACAAATACC-3’ and reverse: 5’-
GGTATTTGTGTGGGCAGAGCCATTGTTCTTTCTGCC-3’.    Briefly, 10 ng of each plasmid was 
combined with 5 µl of 10X reaction buffer, 125 ng of each primer, 1 µl of dNTP, 3 µl of Quick 
Solution, and 1 µl of Pfu Turbo DNA polymerase (2.5 U/µl) provided by the kit.  The reactions 
were run in a thermocycler  95 °C for 1 min, (95 °C  for 50 sec, 60 °C for 50 sec, 68 °C for 3.5 min) 
x 18 cycles and 68 °C  for 7 minutes.  Then, 1 µl of Dpn I restriction enzyme (10 U/µl) was added 
to each reaction and incubated for 1 hour at 37 °C.  Finally, each reaction was transformed into 
XL10-Gold ultracompetent cells and screened for positive mutagenesis by DNA sequencing.  
SEPT9 Yeast two-hybrid screening 
 Standard methods and media were used as described in the Yeast Protocols Handbook 
(BD Biosciences, San Diego, CA).  pGBKT7 (TRP, KanR) constructs were transformed using lithium 
acetate into yeast strains AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4, gal80, 
LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-MEL1TATA-lacZ) (BD 
Biosciences).  Cultures were grown on SD-Met/-Ura, and transformants were selected on SD-
Trp.  Plasmid-derived protein expression was confirmed by Western analysis on total yeast 
lysate using fusion protein antibody c-Myc (BD Biosciences; pGBKT7 constructs).  Full-length 
coding region MSF-A/SEPT9_v1-pGBKT7 was mated with a commercially available 
pretransformed human testis pACT2 cDNA library (LEU, AmpR in Y187, BD Biosciences) in 2X 
YPDA overnight.  The presence of zygotes was confirmed microscopically before plating the 
culture on 150 mm high stringency SD-Ade/-His/-Leu/-Trp plates containing 20 g/mL X--gal.  
Blue colonies appearing after 7-14 days were used to inoculate SD-Ade/-His/-Leu/-Trp cultures 
from which plasmid DNA was isolated by lyticase/SDS lysis.  DNA was electroporated into KC8 
cells (BD Biosciences), and testis cDNA-pACT2 transformants were selected from MSF-
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A/SEPT9_v1-pGBKT7 transformants by ampicillin resistance.  DNA from subclones was purified 
using the Wizard Plus SV spin column (Promega Corporation) and sequenced. 
Chromosomal map and genomic organization 
 Human Genome Blast (http://www.ncbi.nlm.nih.gov/BLAST) was applied to determine 
the chromosomal mapping.  PCR against a human chromosomal mapping panel was used to 
confirm the mapping location.  The exon/intron structure was modeled based on the complete 
sequence of BAC 419m24.  
Phylogenetic analysis of the human septin family 
 Prior to this report, 13 human septins genes were reported.  The amino acid 
sequences from the following accession numbers were used to create a phylogenetic tree using 
ClustalW (http://www.ebi.ac.uk/clustalw/): NM_052838 (SEPT1), NM_001008491 (SEPT2), 
BC111779 (SEPT3), NM_080415 (SEPT4), Y11593 (SEPT5), AF403061 (SEPT6), NM_001011553 
(SEPT7), AF440762 (SEPT8), NM_006640 (SEPT9), AF146760 (SEPT10), NP_060713 (SEPT11), and 
NP_653206 (SEPT12).  The SEPT13 partial predicted amino acid sequence is available in Hall et 
al. 2005. 
Yeast two-hybrid with SEPT14 and septin family interactions 
  All plasmids and yeast strains were kindly provided by the lab of Roger Brent (140).  All 
yeast two hybrid methods were performed as previously described (140-142), and interactions 
were assessed by the ability of diploid yeast to grow on selective media and to activate the LacZ 
reporter.  Rat cDNAs for SEPT6 (GI 109512511) and SEPT11 (GI 109500352) were isolated from a 
rat brain cDNA library (Origene, Rockville, MD, USA).  The following sequences were cloned into 
yeast expression vectors using EcoRI and/or XhoI sites, and constructs were confirmed by 
sequencing:  human SEPT1 (GI 15082493); human SEPT2 (GI 56550108); rat SEPT3 (GI 9507084); 
human SEPT4 (GI 17986250); wildtype SEPT5 (28, 29); human SEPT7 (GI 19684120); human 
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SEPT8 (GI 1503987); human SEPT9_v1 (GI 34782782); human SEPT10 (GI 7688656); and rat 
SEPT12_v2 (GI 66911992).   SEPT9_v1 also was subcloned into a pcDNA-Flag vector, analogous 
to that described elsewhere (Surka et al, 2002).  pEGFPC1-SEPT14 was constructed by 
subcloning from PCR-XL-TOPO. 
Northern analyses 
 Multi-tissue polyA+ Northern membranes (BD Biosciences Clontech) were 
hybridized as previously described (74) using the 3a-S1 and 3a-S2 SEPT14 PCR products as a 
probe. 
PCR   
 Reactions to amplify products for subcloning in TA and yeast two-hybrid vectors were 
performed using the Expand High Fidelity PCR System (Roche Molecular Biochemicals, 
Indianapolis, IN) per manufacturer’s instructions.  Reactions for 5’ RACE were performed using 
the GeneRacer Kit (Invitrogen Corporation) with the Expand Long Template PCR System (Roche 
Molecular Biochemicals, Indianapolis, IN) and testis total RNA (BD Biosciences).  All other PCR 
reactions were performed using Taq polymerase (Promega Corporation) as previously described 
(74).   
 To optimize semi-quantitative multiplex PCR, reactions using normal breast cDNA with 
actin (143) and septin primers initially at 0.8 µM each were sampled every two cycles from 
cycles 15-25.  Products were analyzed on a 3% agarose gel to determine optimal cycle number 
for linear amplification of both bands.  If necessary, reactions using the optimal cycle number 
were repeated adjusting actin or septin primer concentrations (0.1 to 3.2 µM) to generate 
products of equal intensity.  Tissue-specific cDNA was generated from total RNA as previously 
described (144) or was commercially available (Human Immune Multitissue cDNA panel; BD 
Biosciences, San Diego, CA).  
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 To generate products for TA subcloning, primer pairs MSF5-F and 311-F3 (1727 bp), 
311atg-F2 and 311-F3 (1783 bp), and 311seq-P2 and 311-F3   (1312 bp) were used.  To add NdeI 
and XmaI sites to PCR products for yeast vector subcloning, primer pairs MSFY2HNdeI-F and 
MSFxY2HxmaI-R (1715 bp), MSFaY2HNdeI-F and MSFxY2HXmaI-R (1779 bp), and MSFbY2HNdeI-
F and MSFxY2HXmaI-R (1287 bp) were used.  To amplify additional 5’ sequences of SEPT14 by 
RACE, primers RACE1 and RACE2 were paired with commercially provided GeneRacer 5’ and 5’ 
nested primers respectively.  To determine the chromosomal location of SEPT14 on a human 
chromosomal mapping panel (Coriell Institute for Medical Research panel 2/version 3) (145), 
primers 3a-F1 and 3a-R1 (142 bp) were used.  To generate a SEPT14 hybridization product for 
Northern analysis, primers 3a-S1 and 3a-S2 (1077 bp) were used.  To co-amplify septins with 
actin for semi-quantitative PCR, primer pairs MSF-F and 311-RACE4 (503 bp), 311atg-F2 and 
311sljseq-R (129 bp), 311e3-R and 311-10R (1139 bp), and 3a-S3 and 3a-R1 (288 bp) were used.  
Immunostaining and image acquisition 
 Cells were permeablized in 0.1% Triton X-100 in blocking solution (3% milk powder in 
PBS) for 2 minutes prior to staining.  Cells were fixed, processed and imaged as previously 
described (Surka et al., 2002).  Briefly, anti-SEPT9 polyclonal antibodies were used at a dilution 
of 1:2000, as previously described (Surka et al, 2002) and DNA was visualized with bisbenzimide 
(Sigma-Aldrich Canada Ltd) at a concentration of 5 g/mL for 10 minutes.  Rhodamine-
conjugated secondary antibodies (Jackson ImmunoResearch Labs) were used as previously 
described (Surka et al., 2002).  Imaging was done using a Quorum Spinning Disk Confocal 
Microscope and a Leica DMIRE2 inverted fluorescence microscope equipped with a Hamamatsu 
Back-Thinned EM-CCD camera and spinning disk confocal scan head, equipped with 4 separate 
diode-pumped solid state laser lines (Spectral Applied Research: 405nm, 491nm, 561nm, 
652nm), an ASI motorized XY stage, an Improvision Piezo Focus Drive and a 1.5X magnification 
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lens (Spectral Applied Research).  The equipment was driven by Volocity acquisition software 
and powered by an Apple Power Mac G5.  Representative optical slices (captured at a Z-spacing 
of 0.2m) are shown. 
Co-immunoprecipitation studies 
  Sixty millimeter dishes of CHO cells (approximately 80% confluency) were cotransfected 
for 24 hours with Flag-SEPT9_v1 and GFP-SEPT14, using Fugene transfection reagent (Hoffman-
La Roche Limited,).  Upon lysis in 40 mM Tris, pH 8.0, 100 mM NaCl, 1% TritonX-100 and 
standard protease inhibitors, lysates were incubated with rotation for one hour at 4C and 
clarified by high-speed centrifugation.  Two micrograms of anti-FlagM2 monoclonal antibody 
(Sigma-Aldrich Canada, Ltd.) was used for immunoprecipitation, and controls were conducted 
with purified mouse IgG.  Following the addition of antibodies, protein G-agarose was added 
(Invitrogen Canada Inc.), and samples were rotated for several more hours at 4C.  After 
extensive washing, samples were resolved by SDS-PAGE and transferred to PVDF membrane 
(Millipore Corp.), and Western blotting was performed using a standard protocol.  Affinity-
purified anti-GFP polyclonal antibody (Invitrogen Canada Inc.) was used at a dilution of 1:1000; 
anti-Flag monoclonal antibody (Sigma-Aldrich Canada, Ltd.) was used at a dilution of 1:1000, and 
HRP-conjugated secondary antibodies (BioRad Laboratories Ltd.) were used at a dilution of 
1:5000.  The signal was detected by ECL Western blotting Detection Reagent (GE Healthcare) 
and exposure to autoradiography film. 
Mass Spectrometry 
 Immunoprecipitation was performed as described above, except 20 g of anti-SEPT9 
antibody was used; this antibody is described elsewhere (24).  Rabbit IgG was used as a control.  
Briefly, one rat testicle (Harlan Laboratories, Indianapolis, IN, USA) was homogenized using a 
mortar and pestle, under liquid nitrogen; then resuspended and lysed in 40mM Tris, pH 8.0, 
115 
 
100mM NaCl, 1% TritonX-100, and standard protease inhibitors in a dounce mechanical 
homogenizer.  After rotation for one hour at 4C, followed by clarification by high-speed 
centrifugation, antibodies were added and rotation was continued.  After approximately 4 
hours, protein A-agarose beads were added (Invitrogen Inc.) and immunoprecipitation was 
conducted overnight.  Following extensive washing in the above buffer, immunoprecipitated 
proteins were resolved by SDS-PAGE and bands of interest were excised.  After standard trypsin 
digestion, bands were subjected to MALDI-TOF analysis.  Unique peptide hits of greater than 
95% accuracy were compared against public databases allowing for identification of 
corresponding proteins.  Mass spectrometry was conducted by the Hospital for Sick Children 
Advanced Protein Technology Centre (Toronto, ON, Canada). 
Identification of rat SEPT14 
 BLAST analysis was used to determine the sequence of the rat SEPT14 cDNA, using 
human SEPT14 ORF, human SEPT14 gene structure, and EST clones as templates.  Alignments 











Identification and sequence analysis of human SEPT14 
 To begin to elucidate the functions of the members of the SEPT9 (MSF) subfamily of 
septins in normal cellular processes, we searched for interacting proteins.  SEPT9_v1 (MSF-A) 
was chosen to initiate the analysis as this alternative transcript is ubiquitously expressed (74).  
We chose to screen against a testis-specific expression library, reasoning that this tissue exhibits 
a comprehensive transcript expression profile.  Using a yeast two-hybrid GAL4 DNA interacting 
and binding domain coupled system, the development of blue diploid yeast colonies on high 
stringency SD-Ade/-His/-Leu/-Trp/+X--gal culture plates indicated the capture of a potential 
SEPT9_v1 (MSF-A) interacting partner.  From one such colony, a testis library-derived, ampicillin 
resistant plasmid was isolated.  BLAST sequence analysis determined that the 1658 bp insert 
encoded a partial sequence for an apparently novel septin that included the signature GTPase 
domain.  Retransformation of this plasmid into the yeast Y187 haploid strain and subsequent 
mating with the original SEPT9_v1 (MSF-A)-expressing AH109 haploid strain produced blue 
diploid colonies under identical high stringency growth conditions, verifying this clone.  In 
addition, mating of the recovered novel septin construct with GAL4 binding domain constructs 
expressing full-length SEPT9_v3 (MSF) or the SEPT9_v4 (MSF-B) isoforms also produced blue 
diploid yeast colonies under similar growth conditions (Fig. 4.1).  Following the HUGO approved 
septin nomenclature system (81), we designated this novel septin SEPT14.   
 In addition to a GTPase domain, the captured SEPT14 insert encoded in-frame amino 
acids ending in a predicted stop codon followed by a consensus polyadenylation signal and a 





Exon Acceptor Donor Exon (bp) Intron (Kb) 
1 5’ UTR... ...ccctgggaaagtaagttatt 68 0.677 
2 aaatttccagctcttttagt... ...TGGAGATACAgttaagtata 68 15.306 
3 tttatttaagCAAAAAGAAA... ...CTCTGTGTGGgtaagtgtca 120 1.799 
4 tctattacagGGGAGACTGG... ...AAGAAGCCAGgtgagtgttt 195 1.395 
5 ttttttttagCTACCAACCA... ...TGACAGTAAGgtatgtttgg 186 8.356 
6 ttcttcatagGTGAATATTA... ...CTCAGTTAGTgtaagtttca 161 15.202 
7 tgttttctagGGGCTGTTAC... ...GTTTTGCAAGgtaaaaatga 96 11.869 
8 tttttactagTGGAAAATGA... ...AGCCAGTTAGgtgagtaaaa 168 1.7 
9 ttctctttagTTTTCAAGAA... ...TGAAAAAGAGgttagtactg 132 9.166 




aConsensus ag/gt splice dinucleotides are in bold.  Nucleotides in upper case flank coding exonic regions; 
nucleotides in lower case flank untranslated or intronic regions. 
 
  











 To complete the amino terminus coding sequence of SEPT14, RACE using a testis cDNA 
library was utilized to isolate additional 5’ sequences that included a potential translational start 
methionine.  Overlapping amplification products were assembled that added an additional 176 
bp.  Three potential translational start methionines (M1, M2, and M3) were found within 30 
nucleotides of each other and downstream of a stop codon (Fig. 4.2).  Proteins of 432 
residues/50.0 kDa, 427 residues/49.4 kDa, and 425 residues/49.2 kDa were predicted originating 
from M1, M2, and M3 respectively (Fig. 4.2).  Methionines M1 and M2 were preceded by more 
precise Kozak consensus sequences compared to M3, although all three were able to direct 
protein synthesis in vitro from constructs (Fig. 4.3).   
SEPT14 was most similar to SEPT10 (67% identity/78% conservation), a septin on 
chromosome 8q11 (81), and showed only limited amino acid homology to MSF-A/SEPT9_v1 
(39% identity, 61% conservation; Fig. 4.2).  In addition to a GTPase domain, in silico modeling 
predicted a carboxy-terminus coiled-coiled domain, characteristic of Group II septins (19).  A 




Fig 4.1:  SEPT14 interacts with SEPT9 isoforms in a yeast-two hybrid assay  
 Formation of blue color by diploids grown on selective plates containing IPTG indicates a 
protein-protein interaction between full-length SEPT14 and SEPT9 _v1, _v3, and _v4.  
Mating pairs are indicated with the top haploid strain representing the yeast binding-
domain GAL4 pGBKT7 construct or empty vector (pBD), and the bottom haploid strain 
representing the SEPT14 construct. 
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SEPT14  ------------------------------------------MAER-------------- 4 
SEPT10  ---------------------------MASSEVARHLLFQSHMATK-------------- 19 
SEPT9   TDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQE 240 
                                                                         
SEPT14  -TMAMPTQIPADGDTQKENNIRCLTTI---------GHFGFECLPNQLVSRSIRQGFTFN 54 
SEPT10 -TTCMSSQGSDDEQIKREN-IRSLTMS---------GHVGFESLPDQLVNRSIQQGFCFN 68 
SEPT9 ATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFN 300 
                  
SEPT14 ILCVGETGIGKSTLIDTLFNTNLKDN-----KSSHFYSNVGLQIQTYELQESNVQLKLTV 109 
SEPT10 ILCVGETGIGKSTLIDTLFNTNFEDY-----ESSHFCPNVKLKAQTYELQESNVQLKLTI 123 
SEPT9 IMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTV 360 
                
SEPT14 VETVGYGDQIDKEASYQPIVDYIDAQFEAYLQEELKIKRSLFEYHDSRVHVCLYFISPTG 169 
SEPT10 VNTVGFGDQINKEESYQPIVDYIDAQFEAYLQEELKIKRSLFTYHDSRIHVCLYFISPTG 183 
SEPT9 IDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINR-KKRIPDTRVHCCLYFIPATG 419 
                 
SEPT14 HSLKSLDLLTMKNLDSKVNIIPLIAKADTISKNDLQTFKNKIMSELISNGIQIYQLP--T 227 
SEPT10 HSLKTLDLLTMKNLDSKVNIIPVIAKADTVSKTELQKFKIKLMSELVSNGVQIYQFP--T 241 
SEPT9 HSLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFD 479 
                       
SEPT14 DEETAAQANSSVSGLLPFAVVGSTDEVKVGKRMVRGRHYPWGVLQVENENHCDFVKLRDM 287 
SEPT10 DDDTIAKVNAAMNGQLPFAVVGSMDEVKVGNKMVKARQYPWGVVQVENENHCDFVKLREM 301 
SEPT9 EDSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDL 539 
                
SEPT14 LLCTNMENLKEKTHTQHYECYRYQKLQKMGFTDVGPNNQPVSFQEIFEAKRQEFYDQCQR 347 
SEPT10 LICTNMEDLREQTHTRHYELYRRCKLEEMGFTDVGPENKPVSVQETYEAKRHEFHGERQR 361 
SEPT9 LIRTHMQNIKDITSSIHFEAYRVKRLNEG------------------------------- 568 
                       
SEPT14 EEEELKQRFMQRVKEKEATFKEAEKELQDKFEHLKMIQQEEIRKLEEEKKQLEGEIIDFY 407 
SEPT10 KEEEMKQMFVQRVKEKEAILKEAERELQAKFEHLKRLHQEERMKLEEKRRLLEEEIIAFS 421 




Fig 4.2:  Alignment of human SEPT14 with SEPT10 and SEPT9   
Amino acids identical to SEPT10 are shown with a gray background.  The nine amino acids 
that are boxed in predict a GTP-binding site motif (AG)-X(4)-G-K-(ST), and sequences within a 
coiled-coil domain are shown in bold.  Arrows indicate predicted start site methionines (M1, 
































































































Fig 4.3:  SEPT14 protein synthesis in vitro from three independent SEPT14 T7 plasmids 
with putative ORFs starting at methionines M1, M2 or M3 respectively 
(A) SDS-Page showing protein synthesis of SEPT14-M1, -M2 or -M3 constructs made in 
(pCR-XL-TOPO) using the T7 TNT Transcription/Translation Assay.  The SEPT14-M2 
construct has a premature stop codon, producing a smaller band (~37 kDa) than –M1 and 
–M3 (~50 kDa).  All three constructs were able to synthesize a peptide around 37-50 kDa. 
(B)  M1 and M2 methionines were mutated to leucine by site-directed mutagenesis to try 
to discriminate which methionine is the translation start site. Construct SEPT14 –M1 
(M1L) and –M2 (M6L) were able to synthesize a peptide with sizes 37-50 kDa similar to 
wild type constructs.    
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To determine the interaction specificity of SEPT14, haploid yeast containing human 
SEPT14 in the lexA bait vector were crossed with haploid yeast expressing each of the other 
mammalian septins (except SEPT13) in the prey vector, and interaction strength was determined 
by the degree of LacZ activation in the diploid yeast.  Interestingly, SEPT14 interacted with all 
septins except those that are members of its family, namely SEPT6, 8, 10, and itself (Fig. 4.5). 
BLAST analysis mapped SEPT14 to BAC RP11-419m24 (Genbank Accession No. 
AC092647) and chromosomal locus 7p11.2; PCR against a human chromosomal mapping panel 
confirmed localization to chromosome 7 (data not shown).  The exon/intron structure of SEPT14 
was modeled based on the complete sequence of 419m24 (Table 4.1).  The gene spanned at 
least 65 kb, and all exon/intron boundaries followed the consensus GT/AG rule (146).  Exon-
specific primers were designed in flanking intronic sequences to confirm exon sizes. 
Tissue expression pattern of human SEPT14 
Multi-tissue Northern blot analysis showed only testis-specific expression of a single 
approximately 5.0 kb SEPT14 transcript (Fig. 4.6A).  Recognizing the sensitivity limitations of 
Northern blotting, expression of SEPT14 and SEPT9 alternative transcripts were further analyzed 
in multiple tissues by RT-PCR.  Expression of SEPT9_v1(MSF-A), originally used to pull out 
SEPT14, as well as SEPT9_v3 (MSF) and SEPT9_v4* (MSF-B), also shown to interact by yeast two-
hybrid, were detected in testis cDNA along with SEPT14 (Fig. 4.6B).  SEPT14 expression profile 
was assayed by RT-PCR using cDNA from multiple fetal and adult tissues.  SEPT14 was not 
expressed in fetal brain or fetal liver, two tissues generally known to have a broad expression 
profile, or in either of the normal or cancerous tissues of the breast, ovaries, prostate, bladder 
and kidney (Fig. 4.6B-C).  In addition, testing for expression of SEPT14 in organs of the immune 







PRD PB GBDSEPT 9 
Proline-rich base Polybasic GTP binding Coiled-coil
PB GBD CCSEPT 1, 2, 5, 6, 7, 11, 13 and SEPT14 
PRD PB GBD CCSEPT 4 and 8
PB GBDSEPT 3 and 12
Fig 4.4:  Phylogenetic tree of the human septin family.  
 (A) A dendrogram tree illustrates the phylogenetic relationship of SEPT14 with the other 
13 human septin family members after ClustalW analysis (B) An Illustration showing the 




Fig 4.5:  Yeast two-hybrid analysis indicates that SEPT14 interacts with other septin family 
members 
Yeast mating intersections show SEPT14 interacts with 10 other septin family members.  S. 
cerevisiae expressed human SEPT14 as bait and all other respective septins as prey.  
Intensity of blue color indicates strength of interaction as determined by the degree of LacZ 
activation.  SEPT14 is capable of interacting with all septins except members of its own 
subgroup: SEPT6, 8, 10 and itself. 
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partners of MLL (65, 106), was negative (Fig 4.6D).  Interestingly, even though SEPT14 was found 
to be expressed in normal testis cDNA by Northern blot and semi-quantitative RT-PCR, three 
testicular cancer cell lines were negative for SEPT14 expression by RT-PCR. (Fig. 4.6E). 
To confirm SEPT14 and SEPT9 interact in a mammalian system, GFP-tagged SEPT14 and 
FLAG-tagged SEPT9_v4 were transiently transfected into CHO cells and after 24 hours the cells 
were fixed and processed for immunostaining.  Only cells expressing both proteins at very low 
levels were imaged to eliminate artifacts of overexpression.  In all cases, SEPT9 and SEPT14 were 
found to co-localize to stress fibers (Fig. 4.7).  This is not surprising given that other septins, 
including SEPT9 variants, localize to these structures (24, 147). 
To determine if the co-localized proteins interacted in the cells, lysates were prepared 
from transiently transfected CHO cells for immunoprecipitation.  Monoclonal anti-FLAG or 
control mouse IgG antibodies were added to the lysates and immunoprecipitated on protein G-
agarose beads.  The immunoprecipitate was separated by SDS-PAGE and then blotted for the 
presence of GFP, fused to SEPT14.  As shown in Figure 4.8, SEPT9 was capable of 
immunoprecipitating SEPT14, indicating that these proteins interact within mammalian cells.  
The presence of GFP-tagged SEPT14 in anti-FLAG immunoprecipitated lysates further confirmed 
the protein-protein interaction observed in the co-localization studies (Fig. 4.8A). 
Since SEPT14 is not normally expressed in CHO cells (data not shown), we attempted to 
show that SEPT14 and SEPT9 interact in a more physiologically relevant context.  As indicated 
above, SEPT14 expression is highest in the testes, and SEPT9 is expressed in testes as well 
(Kalikin et al. 2000; Surka et al, 2002), raising the possibility that these two proteins may interact 
in that tissue.  Lysates were prepared from rat testes and SEPT9 was immunoprecipitated using 

























































































































































































































































Fig 4.6: Characterization of SEPT14 expresssion by Northern blot and RT-PCR 
  (A-B) SEPT14 expression by Northern blot (A) and semiquantitative duplex RT-PCR (sdRT-PCR) 
(B) is only detected in testis.  Septin specific bands are indicated by product size; the other 
band is a 626bp -actin product used as an internal control.  (C) Relative expression of SEPT14 
(288 bp) in breast (a), ovarian (b), prostate (c) and bladder (d) cancer cell lines by sdRTPCR 
was performed.  Testis cDNA was used as a positive control for expression.  (D) Expression 
profile of SEPT9-X transcripts and SEPT14 by standard RT-PCR using commercially available 
normalized immune tissue-derived cDNAs was performed. SEPT14 expression was barely 
detected or negative as compared to SEPT9 expression.  (E) SEPT14 expression was absent in 






Fig 4.7:  Over-expressed Flag-SEPT9 and GFP-SEPT14 colocalize to stress fibers in CHO cells. 
 CHO cells were transiently transfected with GFP-SEPT14 and Flag-SEPT9, fixed, and stained 
for GFP (green), Flag (red) and Dapi (blue).  Cells expressing low levels of both proteins were 






















Coomassie staining revealed the presence of several bands in the SEPT9 
immunoprecipitate that were absent from the control IgG lane (Fig. 4.8B).  These bands 
were isolated, subjected to tryptic digestion and analyzed by MALDI-TOF mass 
spectrometry.  The lower unique band (asterisk) contained several peptides specific for rat 
SEPT2, while the upper band (<) contained peptides for rat SEPT7, SEPT9 and SEPT14.  The 
peptides identified for rat SEPT14 are shown highlighted on the sequence of rat SEPT14, 
which is shown in alignment with human SEPT14 (Fig. 4.8C).   
Discussion 
Septins have been characterized as proteins relevant in multiple cellular functions 
including cell division, membrane dynamics, cell signaling, cell cycle regulation, and 
apoptosis.  Importantly they have been implicated in neurodevelopment and oncogenesis 
making them highly relevant to human disease.  These biological functions of septins are 
intrinsically related in part to their ability to assemble into polymers, which serve as 
diffusion barriers in the cell membrane and form scaffolds for interacting proteins at 
specific intracellular locations(7, 138).  Therefore, identifying new septin family members 
and novel interacting proteins is crucial to elucidating their cellular functions and their 
role in human diseases.   
SEPT14 was identified by yeast-two hybrid as a novel septin family member and 
interacting protein of SEPT9 isoforms (SEPT9_v1-SEPT9_v4).  The gene described here has 
previously been annotated in NCBI (Accession Number: NM_207366), but our findings 
describe additional 5’ sequences that encode a highly conserved GTP-binding domain near 
the N-terminus in addition to the coiled-coil domain at the C-terminus, characteristic of 
the septin family.  SEPT14 shares closest homology to SEPT10, a human dendritic septin on 
chromosome 8q11 (148), and shows limited homology with SEPT9 isoforms.  
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  A.  
B.     C. 
Fig 4.8:  Coimmunoprecipitation of SEPT9 and SEPT14 
(A) Co-immunoprecipitation of SEPT9 and SEPT14 following transfection.  CHO cells were 
transiently transfected with GFP-SEPT14 and Flag-SEPT9, lysed, and subjected to 
immunoprecipitation with anti-Flag antibody.  Twenty percent of the immunoprecipitated 
material was electrophoresed beside 5% of the initial cell lysate.  Lane 2 shows that GFP-
SEPT14 is able to co-immunoprecipitate with Flag-SEPT9, whereas this is not observed with 
non-specific rabbit IgG (lane 3).  Lane 4 shows the expression of the Flag-SEPT9.  (B)  Co-
immunoprecipitation of endogenous SEPT9 and SEPT14 from rat testis.  
Immunoprecipitation with anti-SEPT9 (second lane) from testis lysate revealed several 
bands on Coomassie stained SDS-PAGE gels not seen in control immunoprecipitate (<,*), C.  
Alignment of human and rat SEPT14 generated using ClustalW.  Digestion and MALDI-TOF 
mass spectrometry of the region at approximately 50kDa (arrow) yielded several peptides 
unique to rat SEPT14 as well as peptides to SEPT7 and SEPT9, while a 42 kDa band 
contained peptides to SEPT2 (not shown).  Peptides identified by MALDI-TOF are 
highlighted in light grey.  An “*” means that the residues or nucleotides in that column are 
identical in all sequences in the alignment, a “:” indicates that conserved substitutions have 
been observed and a "." means that semi-conserved substitutions are identified. 
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 Unlike SEPT9, which is ubiquitously expressed, SEPT14 is specifically expressed in the 
normal testis, with a transcript size of approximately 5.0 kb.  Thus, SEPT14 may not play a role in 
the pathobiology of breast and ovarian tumorigenesis for which SEPT9 has been implicated (74, 
77, 78, 80, 94). However, interestingly, SEPT14 was not expressed in testis teratoma cell lines by 
RT-PCR leading us to speculate that SEPT14 expression may be relevant in testis-specific cellular 
functions such as proper development and spermatogenesis and that SEPT14 expression may be 
associated with specific cell types within the testes. 
 In support of this, SEPT4 and other septins are expressed in post-meiotic male germ 
cells and associated with sperm terminal differentiation (149).  Importantly, Sept4 knockout 
mice lack a functional annulus structure and are sterile due to defective morphology and 
motility of the sperm flagellum.  In addition, annulus ring disorganization has been noted in 
asthenospermia syndrome in humans.  This has led to the suggestion that acortical organization 
based on circular assembly of the septin cytoskeleton is essential for the structural and 
mechanical integrity of mammalian spermatozoa (43).  Finally, expression profiles of several 
other septins show differential expression in testis cancer tissues compared to normal controls 
(21, 83).  To confirm this, further characterization of SEPT14 expression and functional analysis 
of its role in testis is fundamental.   
 Interestingly, SEPT14 can interact with nine other septins in addition to SEPT9, but does 
not strongly interact with SEPT8 or SEPT10, the septins within its branch on the phylogenetic 
tree.  Moreover, SEPT14 co-localizes with SEPT9 in CHO cells and can co-immunoprecipitate with 
SEPT9 both following ectopic expression and from testes tissue.  In testes, SEPT14 co-
immunoprecipitated with SEPT2, 7, and 9.  Septins form heterologous filaments, with each 
septin usually present in stoichiometric ratios, and studies by Versele and Thorner (2005), 
suggest a specific organization of the septins within yeast septin complexes (Versele and 
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Thorner, 2005).  Based on available interaction data and limited sequence similarity, it was 
speculated that mammalian septins might assemble in similar ways with a member of each of 
the four major families taking each position in the complex.  In support of this hypothesis, 
SEPT2, 7, 9 and 14 represent four different septin subgroups, suggesting that this is likely to be 
the septin subunit complex found in the testes. 
 In summary, we have identified and characterized SEPT14, a novel protein that interacts 
with several members of the human and rat septin family.  Interestingly, the expression of this 
new septin appears to be unique to the testes, suggesting a role in the normal development and 
function of the testis and/or as a key player in the process of spermatogenesis.  Further detailed 
studies of SEPT14 along with its interacting septin partners and related proteins may provide 
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 Breast cancer is a complex disease affecting millions of women and men worldwide.  In 
the United States alone breast cancer accounts for 1 in 4 cancer diagnoses in women, excluding 
skin cancers.  According to the American Cancer Society, a woman living in the US has a 12.3% (1 
in 8) lifetime risk of developing breast cancer.  Despite recent advances in the prevention, 
diagnosis and management of breast cancer, there are still gaps and limitations of current 
research into the pathophysiology, detection, treatment and prevention of this disease.  Gaps in 
our knowledge still exist in the molecular genetics, mechanisms of initiation and progression, 
targeted therapies, prognostic markers and prevention of breast cancer (150). It is imperative 
that these gaps are closed to improve patients’ treatment and outcomes. 
 Multiple genes of different penetrance are known to be involved in the predisposition to 
breast cancer (93).  We still need to identify additional variants, effects, and interactions of low 
penetrance genes.  This will help determine the relevance of somatic events to prognosis, 
response to therapy, development of new targeted therapies, and better genetic risk 
estimation.  Understanding signaling pathways involved in breast architecture, apoptotic 
processes in mammary epithelial cells and the importance of the stroma, cell adhesion and 
extracellular matrix are crucial to identifying pre-invasive changes and their implications for 
patient-tailored therapies (150).  Elucidating the complexity of additional molecular pathways 
133 
 
involved in the progression from DCIS to invasive disease including the processes of 
angiogenesis, metastasis, dormancy, reactivation of distant micrometastasis, and the influence 
of the tumor microenvironment, is also crucial (150).  This understanding would facilitate the 
process of predicting therapeutic response with growth inhibitors, improve the selection of 
patients with ductal in situ carcinoma for adjuvant and endocrine therapies, and contribute to 
the development of new agents to target breast cancer progression (150).  Finally, expanding 
our knowledge in biomarkers and compensatory signaling pathways responsible for drug 
resistance is an important challenge to conquer in order to improve prognostic indices, and the 
individualization, response and duration of therapy (150). 
 The efforts to identify additional high-penetrance susceptibility genes, such as BRCA1 
and BRCA2, still continues, but as important is the identification and characterization of low 
penetrance genes and/or biomarkers with smaller effects that modulate cancer initiation, 
progression, chemotherapeutic response, aggressiveness and/or recurrence.  Members of the 
human septin family are potential candidates for genes modulating cancer phenotypes.  Several 
studies showed differential expression of these genes in various cancers including breast cancer.  
One of these, SEPT9, has become of great interest in the oncogenesis of many cancers.  The 
effect of SEPT9 expression and its mechanism and relevance to breast cancer is still not well 
understood.   
SEPT9_v1 expression is associated with breast cancer progression 
 SEPT9 was positionally cloned from a region of allelic imbalance in breast cancers (74).  
Subsequently, seven alternative transcripts were identified and their expression was assayed in 
a panel of breast cancer cell lines (BCCs) (20).  SEPT9_v1 was preferentially over-expressed in 
60% of BCCs as compared to immortalized human mammary epithelial cells (IHMECs).  In 
addition, high SEPT9_v1 cytoplasmic staining was observed in tumor tissue as compared to 
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controls in 25 matched-control breast cancer samples (20).  To tease out the role of SEPT9_v1 in 
mammary tumorigenesis, over-expression models in IHMECs were developed.  Surprisingly, 
ectopic high SEPT9_v1 expression by retroviral transduction led to the development of several 
pro-oncogenic phenotypes, all characteristic of tumorigenesis (20).  High SEPT9_v1 expression 
increased growth kinetics by accelerating cell proliferation and decreasing apoptotic response; 
both phenotypes are required for tumor growth (20).  Another phenotype that confirmed the 
effect of SEPT9_v1 on cell proliferation was the increased mitotic index of SEPT9_v1- cells (20).  
SEPT9_v1 has been associated with increasing proliferative rates in prostate cancer and other 
septins, such as SEPT4/ARTS, have been implicated in mitochondria-mediated apoptosis (25, 26, 
72). 
 Invasive disease and metastasis processes are still not completely understood.  
SEPT9_v1 expression seems to enhance motility and invasiveness in IHMECs, which is suggestive 
of a role in cancer progression to a more aggressive phenotype (20).  Septins have been 
associated with cellular motility and polarity; both mechanisms are important for cancer cells to 
acquire the ability to invade and metastasize to other sites.  Identifying novel interacting 
partners, especially with proteins involved in apical/basal polarity, cellular matrix, basement 
membrane, and pathways involved in invasion are crucial to understanding how deregulated 
SEPT9_v1 expression might lead to these phenotypes.  In fact, SEPT9_v1-cells showed a change 
in morphology reminiscent of an epithelial to mesenchymal transition confirmed by an 
association of SEPT9_v1 with vimentin and the fact that cells showed increased vimentin 
staining, a phenotype tightly associated with cellular motility and invasion (20).  Another 
possibility is the association of septins with cytoskeletal architecture and signaling, which is also 
important in cancer.   
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 Another phenotype promoted by SEPT9_v1 was focus formation, indicating an effect on 
contact-contact growth inhibition, at least in Hs5787t, a breast cancer cell line with no 
endogenous SEPT9_v1 expression.  This suggests that SEPT9_v1 acts in combination with other 
oncogenic mutations present in breast cancer cell lines to promote an oncogenic 
transformation.  The future identification of possible genetic interactions of septins with breast 
cancer genes of major impact, for example HER2/neu, BRCA1 and/or BRCA2, will be relevant to 
identify the type of tumors in which SEPT9_v1 expression might affect the oncogenic process.  
For example, bioinformatics data annotated in GEO profiles at NCBI showed that SEPT9_v1 
expression is up-regulated when BRCA1 is ablated by siRNA in MCF10A cell line studies.  
Hormone receptor-negative tumors are mainly associated with BRCA1 mutations (102, 105, 151, 
152).  Therefore, it was intriguing that high expression of SEPT9_v1 was found to be correlated 
with estrogen and progesterone receptor positive tumors.  These potential correlations 
between SEPT9_v1 expression and either BRCA1 status and/or hormone receptor status showed 
the importantce to further study the role of SEPT9_v1 as a breast cancer biomarker for 
prognosis, clinical course of the disease and therapy.  Looking at the expression of SEPT9_v1 
protein on a BRCA1 and BRCA2 mutant tumor microarray will be extremely useful to confirm the 
possible association between BRCA status and SEPT9_v1 expression.  In addition, the analysis 
showed that high SEPT9_v1 expression is correlated with grade 2 tumors and not with lymph 
node involvement.  This may appear puzzling, given the fact that according to our cell culture 
model, SEPT9_v1 is associated with cancer progression and aggressiveness, but not necessarily 
with cancer initiation.  One possibility is that SEPT9_v1 may drive or potentiate the development 
of invasive cancers but then might get lost during tumor progression to metastasis as a 
consequence of the increased in genomic instability or by a different mechanism that needs to 
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be determined.  Still, further studies with more patient samples are imperative to confirm these 
correlations with SEPT9_v1 expression.      
 The observed oncogenic effects discussed seem to be specific for the SEPT9_v1 isoform; 
over-expression of SEPT9_v3 and SEPT9_v4 in IHMECs did not have as significant impact on 
oncogenic phenotypes.  SEPT9_v3 expression had an opposite effect compared to SEPT9_v1 
expression as proliferative rates of SEPT9_v3 transductants were significantly reduced.  
SEPT9_v1 differs from SEPT9_v3 only in the first 25 amino acids; this difference in protein 
structure might account for the different effects of these two isoforms in cells.  These 25 amino 
acids might be important for distinct cellular localization and/or protein interactions relevant to 
specific roles of these two isoforms, as otherwise these two proteins are highly conserved in 
their central domains.  For example, expression of SEPT9_v3, but not SEPT9_v1, inhibits the 
activation of Rho signaling pathway via its interaction with SA-RhoGEF in Hela and Cos7 cells (89, 
90).  This interaction could explain a different role for SEPT9_v3, especially because studies have 
showed that Rho proteins can activate the JNK signaling pathway (153).  This connection 
between SEPT9_v3, Rho signaling, and JNK signaling could explain why SEPT9_v3 decreases cell 
proliferation in mammary epithelial cells.  We can hypothesize that SEPT9_v3 inhibits Rho 
signaling pathway and this prevents the activation of the JNK signaling and its downstream 
genes involved in cell proliferation.  This is in contrast to SEPT9_v1, which we have 
demonstrated up-regulates JNK signaling (154).  SEPT9_v3 may also decrease cell proliferation 
by increasing the number of tetraploid cells, which may lower the mitotic index and increase 
apoptosis.  Based on our data, one can argue that SEPT9_v1 also increases tetraploid cells, but 
the frequency is much lower than in SEPT9_v3 cells, so the downstream overall effect could be 
different.  Future studies to elucidate the difference between SEPT9 isoforms and the potential 
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interactions between these will be important to understand the role of SEPT9 locus in 
tumorigenesis. 
 
SEPT9_v1 expression regulates genomic stability 
 Genomic instability is common in many epithelial cancers.  Septins have been implicated 
in cell division since the 1970’s and are associated with filamentous proteins such as actin and 
myosin (1, 120, 121).  Septins localize to the actomyosin ring and, when mutated, these proteins 
prevent cytokinesis (1, 24, 120, 121).  To determine if the up-regulation of SEPT9 isoforms 
affects cell division and/or genomic stability, the ploidy status of SEPT9 transductants was 
assayed.  When both SEPT9_v1 and SEPT9_v3 were independently over-expressed in IHMECs, an 
increase in the incidence of aneuploidy was shown.  Interestingly, the degree of aneuploidy 
differs between the two isoforms; SEPT9_v1 cells showed a bimodal distribution with a 
generalized aneuploidy as well as an increase in the number of tetraploid cells.  In contrast, the 
majority of SEPT9_v3-cells analyzed were tetraploid.  It seems that SEPT9_v3 increases 
aneuploidy primarily by promoting cytokinesis failure which leads to tetraploidy.  Conversely, 
SEPT9_v1 seems to promote both mitotic spindle defects and cytokinesis failure, two 
mechanisms by which SEPT9_v1 increases genomic instability (108, 109, 155).  This seems to be 
mediated by SEPT9_v1’s interaction with the cytoskeleton and microtubule proteins, including 
key components of the mitotic spindle such as -tubulin and -tubulin.  Interactions between 
SEPT9_v1 and other proteins important in the mitotic spindle checkpoint were not found, but 
other possible interactions and pathways need to be addressed, for example CENP-E, BUBR1, 
CDC20 and others.  In addition, the effects of SEPT9_v1 expression on the activation of mitotic 
spindle checkpoint merits further study. 
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 Increased genomic instability in cells could drive the development of other pro-
oncogenic phenotypes due to the loss of tumor suppressors or gain of oncogenes.  Analyzing the 
expression of SEPT9_v1 at different timepoints after transient transfection demonstrated that 
both aneuploidy and increased cell proliferation arise at the same time.  More importantly, it 
suggested that these phenotypes are not an artifact of over-expression or multiple passages of 
cells in tissue culture.  It also suggested that both phenotypes can arise independently and that 
there may be distinct mechanisms controlling both phenotypes.  Further analyses will help 
differentiate the critical molecular pathways that give rise to SEPT9_v1-associated genomic 
instability and increased cell proliferation.  
Novel SEPT9_v1 association with JNK signaling is relevant to cell proliferation 
 We found that up-regulation of SEPT9_v1 expression throughout the cell cycle, 
particularly in the G1 phase, significantly alters cell cycle progression via the JNK signaling 
pathway.  We demonstrated a novel interaction between SEPT9_v1 and JNK1,2 kinases, which 
controls the activation of the transcription factor c-Jun by phosphorylation thereby resulting in 
the transcription of target cell cycle genes, such as CCND1 (cyclin D1), with AP-1 sites in their 
promoters.  Through its interaction with (and stabilization of) JNK1,2, SEPT9_v1 causes cells to 
progress at a faster rate through the cell cycle due to the increased expression of cyclin proteins, 
particularly cyclin D1 and cyclin B1, which are responsible for progression through the cell cycle.  
These findings shed new light on possible mechanisms by which SEPT9_v1 alters cellular 
proliferation and contributes to malignant progression in breast cancers. 
Identification and characterization of SEPT14, a novel interacting partner 
 As cytoskeletal proteins, septins may interact with different proteins or form scaffolds 
to recruit proteins to specific compartments of the cell.  Identifying interacting partners of 
septins has proven to be challenging due to the formation of complex heteroligomers with 
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themselves and other septin family members.  The initial approach used in this study to try to 
identify novel interacting partners of SEPT9 isoforms was a highly stringent yeast-two hybrid 
assay using a human testis cDNA library as bait.  A new septin, subsequently named SEPT14, was 
the only candidate captured by this method.  One can speculate that the reason for this is the 
high stringency used in this method or possibly the disruption of structural conformation or 
protein complexes necessary for other protein interactions.  SEPT14 was identified and 
characterized as a novel protein that interacts with several members of the human and rat 
septin family.  Interestingly, the expression of this new septin appears to be unique to the 
testes, suggesting a role in the normal development and function of the testis and/or as a key 
player in the process of spermatogenesis.  However, we can’t exclude the possibility of very low 
levels of expression in other tissues and/or expression at different stages in development.  We 
also analyzed the expression of SEPT14 in different cancer cell lines and did not find any 
expression.  Further detailed studies of SEPT14, along with its interacting septin partners and 
related proteins may provide additional insight into its functional role in mammalian 
development and possibly testicular cancer. 
SEPT9_v1 model of mammary tumorigenesis 
 This study showed that high expression of SEPT9_v1 in mammary epithelial cells impacts 
breast tumorigenesis through different mechanisms.  The cellular processes affected, such as 
cell proliferation and genomic stability, are usually deregulated during cancer progression of 
different tumors.  How the altered expression of SEPT9_v1 affects many of these processes is 
still puzzling.  Septins form complex filaments with two molecules of each individual septin 
which tend to localize along cytoskeletal components such as microtubules and actin stress 
fibers (7).  The importance of the formation of these complexes is being studied at present, but 
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we cannot discard the possibility that these proteins can also have distinct functions 
independent of the formation of these highly ordered filaments.    
  SEPT9_v1 interacts with several proteins such as tubulins and JNK.  The dynamics of 
these associations might dictate the effect of SEPT9_v1 in normal and cancer cells.  One 
hypothesis states that septins are cytoskeletal proteins acting as scaffolds mediating the 
localization of other proteins in specific sites of the cell and/or the interaction between specific 
proteins (18).  Another possibility is that septins act as signaling GTPases modulating specific 
signaling pathways.  SEPT9_v1 has proven to have a role as cytoskeletal protein important in cell 
division by interacting with tubulins.  High expression impacts alpha-tubulin filaments and 
mitotic spindle function which might be indicative of a structural function of SEPT9_v1 in the cell 
cytoskeleton.  High SEPT9_v1 expression might be inhibiting microtubule dynamics by either 
affecting their assembly or disassembly, which would prevent the proper function of the mitotic 
spindle during mitosis, causing chromosome mis-segregation.  SEPT9_v1 also increases the 
frequency of cytokinesis failure.  To understand this, future studies to determine SEPT9_v1 
protein interactions with components of the cytokinesis machinery, cleavage furrow, and 
midbody are essential to see if altered expression of SEPT9_v1 affects their localization and/or 
expression.  For example, it has been shown anillin, an organizer of the cytokinesis machinery, 
interacts with septins and that SEPT9_v1 is localized to the midbody and cleavage furrow during 
completion of telophase and cytokinesis.  Additional studies to explore the functional 
consequences of this interaction are needed. 
 Changes in morphology, such as the epithelial to mesenchymal transition, increased 
cellular motility and invasiveness also support the hypothesis of SEPT9_v1 as a structural protein 
as cytoskeleton dynamics are crucial for the regulation of these phenotypes.  This might not be 
the only way SEPT9_v1 functions in the cell.  By identifying the interaction of SEPT9_v1 with the 
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JNK signaling pathway, in which it stabilized the JNK protein products and increased JNK kinase 
activity as well as transcriptional activation, we showed that SEPT9_v1 could actively regulate 
JNK.  In fact, this interaction is dependent on the GTPase domain, which might be involved in the 
activation of this pathway.  We cannot discard, however, the possibility that SEPT9_v1 might be 
sequestering JNK and preventing its degradation, which could lead to overall enhanced activity 
of the JNK pathway and its downstream targets that might be indicative of the scaffolding 
properties of SEPT9_v1.   
 One important observation is that our preliminary data suggests that SEPT9_v1 contains 
a bipartite nuclear localization signal located within the first 25 amino acids.  SEPT9_v1 was also 
found to be localized to the nucleus, in addition to the cytoplasm in breast cancer cell lines and 
cells retrovirally expressing high levels of SEPT9_v1.  The role of nuclear SEPT9_v1 remains to be 
determined, but one can hypothesize that it might be important in the transport of other 
proteins to the nucleus or it may exert its own specific cellular function.  The first aspect to tease 
out is to determine if SEPT9_v1 normally shuttles between the cytoplasm and the nucleus and 
then examine how this affects the phenotypes described here.  Another hypothesis is that when 
SEPT9_v1 is highly expressed in cells it might be sequestered in the nucleus preventing its 
function as a cytoskeletal component, or, at the same time, promoting the mis-localization of its 
interacting proteins.  This might explain how the high expression of SEPT9_v1 can give rise to 
similar phenotypes as SEPT9 knockdown experiments described in other studies (20, 23, 24, 37).  
Nuclear localization of SEPT9_v1 could be similar to not having the protein available in the 
cytoplasm during essential cellular processes.    
 Our model for oncogenic SEPT9_v1 in mammary epithelial cells demonstrates that, by 
some unknown mechanism, SEPT9_v1 becomes amplified and over-expressed during cancer 




Fig 5.1: SEPT9_v1 working model of mammary tumorigenesis 
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essential cellular processes as dictated by SEPT9_v1 specific interactions.  During mitosis, we 
have demonstrated that SEPT9_v1 affects mitotic spindle formation by impacting microtubule 
organization, assembly, or disassembly, which increases genomic instability, a hallmark 
characteristic of many cancers.  We have also shown that SEPT9_v1 increases proliferation rates 
by modulating the JNK signaling pathway important in cell cycle progression.  Together, these 
SEPT9_v1 associated cellular processes drive malignant progression in mammary epithelial cells 
(Fig 5.2).  
Future Directions 
 This study answered many questions and provided several novel insights about the 
cellular roles of septins in general and, more specifically, about the multiple roles of SEPT9_v1 in 
mammary tumorigenesis.  However, many other aspects of SEPT9 biology still need to be 
elucidated.  The SEPT9 expression model used here was determined by highly expressing SEPT9 
isoforms under the CMV promoter.  The threshold where the expression level is not 
transforming was not determined given that all the lines produced for our studies had 
comparable protein expression to breast cancer cell lines with high endogenous SEPT9.  To 
explore expression levels more comprehensively, development and analysis of an inducible 
system will be ideal to control SEPT9_v1 expression levels and to determine how expression is 
important to promote transformation.  Another approach will be to select and expand 
monoclonal stable cell lines with different expression levels of SEPT9_v1 and examine them for 
the development of pro-oncogenic phenotypes.  The data acquired from these experiments will 
complement the knockdown of SEPT9 by RNAi experiments described in Chapter 2 to get a more 
complete profile of SEPT9_v1 expression and its ability to transform cells.  We described that 
high expression of SEPT9_v1 promotes pro-oncogenic phenotypes, but the breadth of molecular 
mechanisms responsible for these changes remains elusive.  To study this, a cDNA microarray 
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analysis should be performed after transient transfection of SEPT9_v1 to help determine if there 
are changes in downstream messages that will give us a clue as to the specific molecular 
mechanism of SEPT9_v1 transformation.  In addition, ongoing correlation studies using tissue 
microarrays may be helpful in identifying important gene associations.  
 Analysis of deletion constructs encompassing the different conserved domains are 
crucial to understanding further the role of each domain in the development of pro-oncogenic 
phenotypes.  A deletion construct of the GTPase domain will be especially useful to study the 
aneuploidy and mitotic spindle defect phenotypes.  The GTPase domain has proven essential for 
the interaction of SEPT9_v1 and microtubules (23, 24), therefore expression of a GTPase 
deletion construct should provide insights into the relevant functional dynamics of this 
interaction.  For example, expression of the GTPase deletion construct might abrogate the 
mitotic spindle defects and chromosome mis-segregation by inhibiting SEPT9_v1’s interaction 
with tubulins.  In addition, co-expression of this construct with full length SEPT9_v1 will be 
important to see if the GTPase deletion acts as a dominant negative by inhibiting the interaction 
of full length SEPT9_v1 with tubulin or by decreasing or enhancing aneuploidy and mitotic 
spindle defects.  
 The difference between SEPT9_v1 and SEPT9_v3 effects on several cellular processes 
and in oncogenesis might be associated with their difference in protein sequence, specifically 
with the distinct 25 amino acids at the N-terminus of SEPT9_v1.  A deletion construct of these 25 
amino acids will be useful to determine its relevance to the acquisition of the different 
oncogenic phenotypes in cells with high SEPT9_v1 expression.  Novel protein interactions 
mediated by these 25 amino acids will be of extreme importance to understand better the 
differences between these two isoforms, their relationships with different functional 
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mechanisms, and to understand why SEPT9_v1 acts as an oncogene while SEPT9_v3 does not 
seem to have similar properties.   
 Further discovery of novel protein interactions relevant to the distinct functional roles 
of SEPT9_v1 in mammary epithelial cells is crucial to further understand its role in oncogenesis.  
The potential interactions of SEPT9_v1 with other components of the mitotic spindle and the 
mitotic spindle checkpoint will be addressed by immunoprecipitation analyses.  Some of the 
candidates that will be tested are CENP-E, BUBR1, CDC20, and Aurora A.  In addition it will be 
useful to include proteins important to cytokinesis, given the role of SEPT9_v1 in this process.  
Due to the possible complexity of these interactions, multiple methods may be used, including 
GST pull downs, yeast-two hybrid analysis, and if necessary, analysis of interactions in live cells 
using fluorescent resonance energy transfer (FRET). 
 Finally, tumorigenicity studies in SCID mice are ongoing.  Human mammary epithelial 
cells (MCF10A) expressing SEPT9_v1 constructs have been injected into mammary fat pads of 
female SCID mice to monitor tumor formation.  Results from these experiments will be crucial to 
determine if high expression of SEPT9_v1 is sufficient to induce transformation of cells and, 
therefore, the development of tumorigenesis in an in vivo model.  If over-expression of 
SEPT9_v1 is not sufficient to promote tumor development, a cancer cell line, Hs578t, with high 
ectopic SEPT9_v1 expression will be used for analysis.  This approach will help determine if, 
instead of promoting the initiation of tumorigenesis, SEPT9_v1 is a modulator of cancer 
aggressiveness by promoting the development of tumors earlier than vector controls or by 
increasing the metastatic potential of the tumors.  It will also help determine what other 
molecular factors are needed to work in concert with SEPT9_v1 expression to drive 
tumorigenesis.   
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  Transgenic mouse models expressing SEPT9_v1 and a SEPT9_v1 knockout mouse will be 
essential to further analyze multiple aspects of the biological roles of SEPT9_v1.  A SEPT9_v1 
transgene, under the control of a specific mammary promoter (e.g. MMTV), will be essential to 
pinpoint the biological role of SEPT9_v1 in the initiation and/or progression of mammary 
tumorigenesis.  This animal model will be also important to determine if SEPT9_v1 expression is 
important for proper mammary gland development.  This aspect is important because cancer 
development and progression are intrinsically dependent on the tumor microenvironment as 
well as changes in tissue development and remodeling.  In addition, crosses between SEPT9_v1 
transgenic mice and other mouse model of oncogenes (e.g. Her2/neu, BRCA1) will be important 
to study potential associations of SEPT9_v1 with pathways and genes known to be important in 
breast cancer.  The knockout mouse will shed additonal light on the various functional roles in 
which SEPT9_v1 is important.  It is already known that a conventional knockout of SEPT9 is 
embryonic lethal at E9 with increased apoptosis (Füchtbauer, E-M., personal communication), so 
the use of a conditional or inducible system will be needed to analyze this.  
Summary 
 This study has characterized the relevance of SEPT9_v1 as a modulator of mammary 
tumorigenesis.  We showed that SEPT9_v1 is a multi-functional protein that impacts cell 
proliferation and genomic instability (20, 154).  SEPT9_v1 is associated with these phenotypes 
by interacting with cytoskeletal proteins and its association with the JNK signaling pathway 
(Figure 5.1) (154).  These data in combination with other published studies, highlight SEPT9_v1 
as a potential prognostic tool and/or biomarker for breast cancer therapy options, given the 
preliminary correlation with hormone negative-receptor tumors and an interaction with 
microtubules.  These data open new and important directions of exploration in the area of 
breast cancer research.  The discovery and characterization of new proteins, such as SEPT9_v1, 
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that may be important in the oncogenesis process is crucial to advance this field.  The 
pathogenesis of breast cancer is complex and the identification of new molecular pathways and 
interactions leading to better diagnosis, prognosis and treatment for patients is the goal of 











Fig 5.2: The impact of SEPT9 on different molecular pathways and cellular processes 
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